---
document_datetime: 2023-09-21 19:46:37
document_pages: 88
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/lonsurf-h-c-003897-ii-0012-epar-assessment-report-variation_en.pdf
document_name: lonsurf-h-c-003897-ii-0012-epar-assessment-report-variation_en.pdf
version: success
processing_time: 101.26732
conversion_datetime: 2025-12-22 09:11:36.493678
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2019 EMA/479870/2019 Committee for Medicinal Products for Human Use (CHMP)

## CHMP extension of indication variation assessment report

Invented name: Lonsurf

International non-proprietary name: trifluridine / tipiracil

Procedure No. EMEA/H/C/003897/II/0012

Marketing authorisation holder (MAH): Les Laboratoires Servier

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                           |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                   | 8                                                                                                         |
| 2.1. Introduction                                                                                                          | ........................................................................................................8 |
| 2.2. Non-clinical aspects............................................................................................      | 11                                                                                                        |
| 2.2.1. Ecotoxicity/environmental risk assessment.........................................................                  | 11                                                                                                        |
| 2.2.2. Conclusion on the non-clinical aspects                                                                              | ............................................................... 11                                        |
| 2.3. Clinical aspects ..................................................................................................   | 12                                                                                                        |
| 2.3.1. Introduction....................................................................................................    | 12                                                                                                        |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 12           |
| 2.3.3. Pharmacodynamics..........................................................................................          | 12                                                                                                        |
| 2.3.4. Conclusions on clinical pharmacology.................................................................               | 13                                                                                                        |
| 2.4. Clinical efficacy ..................................................................................................  | 13                                                                                                        |
| 2.4.1. Dose response study(ies)                                                                                            | ................................................................................. 13                      |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 13  |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 47                                                                                                        |
| 2.4.4. Conclusions on the clinical efficacy ....................................................................           | 50                                                                                                        |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 51   |
| 2.5.1. Discussion on clinical safety..............................................................................         | 74                                                                                                        |
| 2.5.2. Conclusions on clinical safety ............................................................................         | 78                                                                                                        |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 78  |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 78                |
| 2.7. Update of the Product information........................................................................             | 82                                                                                                        |
| 2.7.1. User consultation ............................................................................................      | 82                                                                                                        |
| 3. Benefit-Risk Balance                                                                                                    | ............................................................................. 82                          |
| 3.1. Therapeutic Context ...........................................................................................       | 82                                                                                                        |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 82               |
| 3.1.2. Available therapies and unmet medical need.......................................................                   | 82                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................      | 83                                                                                                        |
| 3.2. Favourable effects..............................................................................................      | 83                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 83                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................       | 84                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects                                                              | ......................................... 84                                                              |
| 3.6. Effects Table......................................................................................................   | 85                                                                                                        |
| 3.7. Benefit-risk assessment and discussion.................................................................               | 86                                                                                                        |
| 3.7.1. Importance of favourable and unfavourable effects..............................................                     | 86                                                                                                        |
| 3.7.2. Balance of benefits and risks                                                                                       | ............................................................................ 86                           |
| 3.7.3. Additional considerations on the benefit-risk balance                                                               | ........................................... 86                                                            |
| 3.8. Conclusions.......................................................................................................    | 86                                                                                                        |
| 4. Recommendations.................................................................................                        | 87                                                                                                        |
| 5. EPAR changes                                                                                                            | ....................................................................................... 87                |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Term   | Definition                                                 |
|--------|------------------------------------------------------------|
| 5-FU   | 5-fluorouracil                                             |
| ADR(s) | adverse drug reaction(s)                                   |
| AE(s)  | adverse event(s)                                           |
| ALT    | alanine aminotransferase                                   |
| ANC    | absolute neutrophil count                                  |
| AST    | aspartate aminotransferase                                 |
| AT     | as-treated                                                 |
| BID    | twice per day                                              |
| BSA    | body surface area                                          |
| BSC    | best supportive care                                       |
| CHMP   | committee for medicinal products for human use             |
| CI     | confidence interval                                        |
| CT     | consolidated term                                          |
| CPH    | Cox proportional hazards                                   |
| CR     | complete response                                          |
| CrCl   | creatinine clearance                                       |
| CSR    | clinical study report                                      |
| CT     | computed tomography                                        |
| DCR    | disease control rate                                       |
| DMC    | data monitoring committee                                  |
| dMMR   | deficient mismatch repair                                  |
| DNA    | deoxyribonucleic acid                                      |
| DoR    | duration of response                                       |
| ECOG   | Eastern cooperative oncology group                         |
| EEA    | European economic area                                     |
| EMA    | European medicines agency                                  |
| EORTC  | European organisation for research and treatment of cancer |
| ESMO   | European society for medical oncology                      |
| EU     | European union                                             |
| EURDs  | EU reference dates                                         |
| FTD    | trifluridine                                               |
| GC     | gastric cancer                                             |
| G-CSF  | granulocyte-colony stimulating factor                      |
| GCP    | good clinical practice                                     |
| GEJ    | gastro-esophageal junction                                 |
| GVP    | good pharmacovigilance practices                           |
| HCl    | hydrochloride                                              |

<div style=\"page-break-after: always\"></div>

| Term      | Definition                                                               |
|-----------|--------------------------------------------------------------------------|
| HER2      | human epidermal growth factor receptor 2                                 |
| HER2+     | HER2-positive                                                            |
| HER2-     | HER2-negative                                                            |
| HR        | hazard ratio                                                             |
| HR QoL    | health-related quality of life                                           |
| IA        | interim analysis                                                         |
| ICH       | international conference on harmonisation                                |
| ILD       | interstitial lung disease                                                |
| ITT       | intention-to-treat                                                       |
| IU        | International Units                                                      |
| IXRS      | interactive voice/web response system                                    |
| MA        | marketing authorization                                                  |
| MAH       | marketing authorization holder                                           |
| mCRC      | metastatic colorectal cancer                                             |
| mDoR      | median duration of response                                              |
| MedDRA    | medical dictionary for regulatory activities                             |
| mGC       | metastatic gastric cancer                                                |
| mOS       | median overall survival                                                  |
| mPFS      | median progression-free survival                                         |
| MSI-H     | microsatellite instability high                                          |
| NA        | not available                                                            |
| NCI CTCAE | national cancer institute common terminology criteria for adverse events |
| NCCN      | national comprehensive cancer network                                    |
| ORR       | objective response rate                                                  |
| OS        | overall survival                                                         |
| PDCO      | paediatric committee of the European medicines agency                    |
| PDT       | post-discontinuation anti-cancer therapy                                 |
| PD-1      | programmed cell death 1                                                  |
| PD-L1+    | tumours positive for PD-1 ligand                                         |
| PEC       | predicted environmental concentration                                    |
| PFS       | progression-free survival                                                |
| PK        | pharmacokinetic(s)                                                       |
| PO        | per os , i.e. orally                                                     |
| PR        | partial response                                                         |
| PS        | performance status                                                       |
| PSUR      | periodic safety update report                                            |
| PT        | preferred term                                                           |
| QLQ       | QoL questionnaire                                                        |
| QLQ-C30   | quality of life questionnaire - core 30                                  |
| QoL       | quality of life                                                          |

<div style=\"page-break-after: always\"></div>

| Term     | Definition                                         |
|----------|----------------------------------------------------|
| RCT      | randomised controlled trials                       |
| RECIST   | response evaluation criteria in solid tumours      |
| RECOURSE | refractory colorectal cancer study                 |
| RMP      | risk management plan                               |
| ROW      | rest of world                                      |
| SAE(s)   | serious adverse event(s)                           |
| SAP      | statistical analysis plan                          |
| SCE      | summary of clinical efficacy                       |
| SCS      | summary of clinical safety                         |
| SD       | stable disease                                     |
| SOC(s)   | system organ class(es)                             |
| TAGS     | TAS-102 gastric study, i.e. the main/pivotal study |
| TEAE(s)  | treatment-emergent adverse event(s)                |
| TPase    | thymidine phosphorylase                            |
| TPI      | tipiracil hydrochloride                            |
| TR       | tumour response                                    |
| ULN      | upper limit of normal                              |
| US(A)    | United States (of America)                         |
| WBC      | white blood cell                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Les Laboratoires Servier submitted to the European Medicines Agency on 11 October 2018 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, platinum-, and either a taxaneor irinotecan-based chemotherapy for Lonsurf; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. An RMP has also been submitted and updated in accordance with Template Rev 2.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) CW/0001/2015 adopted on 23 July 2015 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The applicant did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Paula Boudewina van Hennik

Co-Rapporteur:

Jorge Camarero Jiménez

| Timetable                                                  | Actual dates     |
|------------------------------------------------------------|------------------|
| Submission date                                            | 11 October 2018  |
| Start of procedure:                                        | 3 November 2018  |
| CHMP Rapporteur Assessment Report                          | 20 December 2018 |
| CHMP Co-Rapporteur Assessment Report                       | 20 December 2018 |
| PRAC Rapporteur Assessment Report                          | 3 January 2019   |
| PRAC members comments                                      | 9 January 2019   |
| Updated PRAC Rapporteur Assessment Report                  | 10 January 2019  |
| PRAC Outcome                                               | 17 January 2019  |
| CHMP members comments                                      | 21 December 2019 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report       | 24 January 2019  |
| Request for supplementary information (RSI)                | 31 January 2019  |
| CHMP Rapporteur Assessment Report                          | 28 May 2019      |
| PRAC Rapporteur Assessment Report                          | 3 June 2019      |
| PRAC members comments                                      | 5 June 2019      |
| Updated PRAC Rapporteur Assessment Report                  | n/a              |
| PRAC Outcome                                               | 14 June 2019     |
| CHMP members comments                                      | 17 June 2019     |
| Updated CHMP Rapporteur Assessment Report                  | 21 June 2019     |
| 2 nd Request for Supplementary Information                 | 27 June 2019     |
| PRAC Rapporteur's updated assessment report circulated on: | 09 July2019      |
| PRAC members comments                                      | 15 July2019      |
| Updated PRAC Rapporteur Assessment Report                  | n/a              |
| CHMP members comments                                      | 15 July 2019     |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report       | n/a              |
| CHMP opinion:                                              | 25 July 2019     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## Lonsurf (trifluridine/tipiracil)

Lonsurf  (trifluridine/tipiracil,  also  named  TAS-102  or  S95005)  is  comprised  of  trifluridine  (FTD;  an antineoplastic  thymidine-based  nucleoside  analogue),  and  tipiracil  hydrochloride  (TPI;  a  thymidine phosphorylase  (TPase)  inhibitor),  at  a  molar  ratio  1:  0.5.  Following  uptake  into  cancer  cells,  FTD  is phosphorylated by thymidine kinase. Subsequently, this compound is further metabolised in the cells to a deoxyribonucleic acid DNA substrate. This substrate is incorporated directly into DNA, thereby interfering with DNA function to prevent cell proliferation. However, FTD is rapidly degraded by TPase and readily metabolised by a first-pass effect following oral administration, hence the inclusion of the TPase inhibitor, TPI. In non-clinical studies, TAS-102 demonstrated antitumour activity against both 5-fluorouracil (5-FU) sensitive and resistant colorectal cancer cell lines. The cytotoxic activity of TAS-102 against several human tumour xenografts correlated highly with the amount of FTD incorporated into DNA, suggesting this as the primary mechanism of action.

In  the  European  Union  (EU),  Lonsurf  is  approved  for  the  treatment  of  adult  patients  with  metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatinand irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents. The recommended starting dose of Lonsurf is 35 mg/m 2 /dose administered orally twice daily (BID) on days 1 to 5 and days 8 to 12 of each 28-day cycle, which is to be continued as long as benefit is observed or until unacceptable toxicity occurs.

Lonsurf has been administered, alone or in combination with other agents, to at least 4,000 patients in clinical trials, and to more than 64,000 patients worldwide (of which 16,173 in Europe) as a marketed product.

## Indication applied for in current procedure

The MAH initially applied for the following new indication:

## Gastric cancer

Lonsurf  is  indicated  for  the  treatment  of  adult  patients  with  metastatic  gastric  cancer  including adenocarcinoma  of  the  gastroesophageal  junction,  who  have  been  previously  treated  with,  or  are  not considered candidates for, available therapies including fluoropyrimidine-, platinum-, and either a taxaneor irinotecan-based chemotherapy.

The following indications have been agreed:

## Colorectal cancer

Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including  fluoropyrimidine-,  oxaliplatin-  and  irinotecan-based  chemotherapies,  anti-VEGF  agents,  and anti-EGFR agents.

## Gastric cancer

Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease (see section 5.1).

<div style=\"page-break-after: always\"></div>

At the time of submission Lonsurf was not approved for the treatment of gastric cancer in any region (during the procedure it has received approval in the USA on the 22 February 2019).

The proposed posology for the treatment of gastric cancer is the same as for the currently approved mCRC indication, i.e. 35 mg/m 2  administered BID per os (PO) on days 1 to 5 and days 8 to 12 of each 28-day cycle, which is to be continued as long as benefit is observed or until unacceptable toxicity occurs.

The addition of monotherapy for both indications is introduced for clarity and consistency with the regulatory approach in the field after discussion at the oncology working party which approved that product used as monotherapy in clinical practice should always specify this in the indication.

## Gastric cancer

Gastric cancer (GC; also referred to as stomach cancer), is the fifth most common and third most deadly cancer in the world. In 2018, there were over 1 million (1,033,701) new cases of GC and 782,685 deaths from GC reported globally. Of these, 133,133 cases and 102,167 deaths occurred in the EU. The geographic distribution of GC, is varied across the globe, with the highest burden of disease seen in Eastern and Western Asia, Central and Eastern Europe, and South America (Globocan 2018; accessed on 21 November 2018).

Gastro-oesophageal  junction  (GEJ)  cancer  anatomically  straddles  the  distal  oesophagus  and  proximal stomach. Due to its location and given that, like GC, the majority of GEJ tumours are adenocarcinomas, GEJ cancer is frequently grouped together with GC in the advanced setting and treated the same way. For simplicity, when hereafter the term 'GC' is used, this includes both gastric as well as GEJ cancer, unless stated otherwise.

Surgical  resection  is  available  as  a  potentially  curative  option  for  patients  diagnosed  with  early  stage disease,  although  the  majority  of  patients  will  ultimately  relapse  following  resection  (Smyth,  2016). Approximately half of patients will have advanced disease, not eligible for resection, at diagnosis (Ajani, 2016).

Advanced and/or metastatic gastric cancer (i.e. stage IV) remains among the deadliest solid tumours, with 5-year overall survival (OS) below 5%; even with optimal treatment, median survival remains less than 1 year (Yang, 2011; Digklia, 2016; Koizumi, 2008). Patients with inoperable advanced and/or metastatic disease should be considered for chemotherapy, which has shown improved survival and quality of life compared with best supportive care alone (Smyth, 2016).

The  most  common  therapeutic  approach  in first-line  systemic  treatment for  these  patients  is  doublet chemotherapy,  most  commonly  employing  a  fluoropyrimidine  and  a  platinum  derivative  (Ajani,  2016; Smyth, 2016). Evidence suggests that significant benefit may derive from the addition of a third agent (for example, docetaxel), provided the patient is able to tolerate such treatment (Okines, 2009). For patients with  human  epidermal  growth  factor  receptor  2-positive  (HER2+)  tumours  (approximately  20%  [van Cutsem, 2015]), the addition of trastuzumab is recommended (Smyth, 2016).

For  patients  who  progress  following  first-line  chemotherapy, second-line treatment has  been  shown  to further prolong survival and improve quality of life for many patients. Selection of treatment is dependent upon prior therapy and performance status (PS) at baseline. The European Society for Medical Oncology (ESMO) guidelines currently provide a number of possible approaches that may include the anti-vascular endothelial  growth  factor  receptor  monoclonal  antibody  ramucirumab  and/or  paclitaxel,  irinotecan,  or docetaxel (Smyth, 2016).

After  failure  of  second-line  therapies ,  there  are  neither  approved  nor  standard  third-line  treatments. Nevertheless, patients with good PS (≤1) and with good organ function could be offered the option to receive systemic  chemotherapy  without  proof  of  OS  benefit.  Indeed,  even  though  currently  not  supported  by randomized data, third-line chemotherapy is increasingly administered to patients failing previous lines and maintaining  an  acceptable  PS,  particularly  in  Asian  countries  (Salati,  2017).  Then  again,  the  ESMO

<div style=\"page-break-after: always\"></div>

guidelines note on this matter that second-line treatment options may be used sequentially in second- and third- line, but with caution that 'there is no clear evidence for a benefit beyond second-line treatment' (Smyth, 2016).

As said, no study has yet identified a preferred or consistently effective third- (or later-) line option for all patients, although apatinib and nivolumab have shown success for different subsets of patients (Li, 2016; Kang, 2017). The major concern for the results of these product is the lack of generalisability to a European population since both medicinal products' studies enrolled only Asian patients, who are recognised to have different tumour biology and clinical outcome compared to the European population. Apatinib and nivolumab are not registered in the EU for this indication. Very recently, the results of the JAVELIN Gastric 300 study of avelumab versus (vs.) physician's choice of paclitaxel or irinotecan as third-line treatment in metastatic gastric cancer (mGC) were published. The study did not meet its primary objective of superiority in OS (Bang, 2018).

Considering the above, best supportive care (BSC) is deemed an acceptable option for the target population.

Table  1 provides  an  overview  of  the  main  randomised  controlled  trials  (RCT)  in  second-  and  later-line treatment of mGC. From the rather poor efficacy outcomes in this table, it is clear that new therapeutic approaches are urgently needed in this setting.

Table 1. Post-second-line treatment of metastatic gastric cancer - Overview of randomised controlled trials

| Citation Trial Type (Phase)       | Trial Description                                                                   | Efficacy Outcomes                                                             |
|-----------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Kang, 2012 RCT (Phase 3) N=202    | Docetaxel or irinotecan plus BSC vs. BSC alone (South Korea) ≥2 nd line             | mOS 5.3 vs. 3.8 months (p=0.007) mPFS: NR ORR: 9.5% vs. NR                    |
| Shitara, 2018 RCT (Phase 3) N=395 | KEYNOTE-061: Pembrolizumab vs. paclitaxel ≥2 nd line                                | OS: 9.1 vs. 8.3 months (NS) PFS: 1.5 vs. 4.1months                            |
| Li, 2016 RCT (Phase 3) N=267      | Apatinib vs. placebo (China) 3 rd line                                              | mOS: 6.5 vs. 4.7 months (p=0.0156) mPFS: 2.6 vs. 1.8 months ORR: 2.8% vs. 0%  |
| Kang, 2017 RCT (Phase 3) N=493    | ATTRACTION-2: nivolumab vs. placebo (Japan, South Korea, Taiwan only) ≥3 rd line    | mOS: 5.3 vs. 4.1 months (p<0.0001) mPFS: 1.6 vs. 1.5 months ORR: 11.2% vs. 0% |
| Bang, 2018 RCT (Phase 3) N=371    | JAVELIN Gastric 300; Avelumab vs. chemotherapy (paclitaxel or irinotecan) 3 rd line | mOS: 4.6 vs. 5.0 months (NS) mPFS: 1.4 vs. 2.7 months ORR: 2.2% vs. 4.3%      |

Abbreviations:  BSC  =  best  supportive  care;  N = number  of  patients  in  trial;  NS  =  not  Statistically  significant; ORR = objective response rate; mOS = median overall survival; mPFS = median progression-free survival

(Cont'd)

## TAS-102 in treatment-refractory metastatic gastric cancer

The efficacy of TAS-102 against tumours insensitive to 5-FU has been demonstrated, both in vitro and in vivo, using a variety of human gastric carcinoma models (Matsuoka, 2018; Suzuki, 2017).

TAS-102 has previously been evaluated in the treatment of patients with GC in two separate clinical studies.

The first was study TAS-102-9806, an open-label, single-arm (Taiho-sponsored) study conducted in the US, in which patients with mGC who had progressed on 1 prior therapy received TAS-102 monotherapy 25

<div style=\"page-break-after: always\"></div>

mg/m 2  BID (thus a lower dose than the approved dose of 35 mg/m 2  BID in colorectal cancer). The study design was the 2-stage Simon design and there was no tumour response among the first 18 patients in stage 1;  accordingly,  this  study  was  terminated  early  and  did  not  proceed  to  stage  2.  Safety  findings  were consistent with the safety profile of TAS-102 established in earlier pivotal mCRC clinical studies (Mayer, 2015, i.e. page 25-6 of RECOURSE protocol in Supplementary Material).

The second study, EPOC1201 (Bando, 2016), was an investigator-initiated Phase 2 study conducted in Japan, evaluating the efficacy and safety of TAS-102 (35 mg/m 2 BID) in 29 patients with treatment-refractory mGC who had previously received 1 or 2 previous chemotherapy regimens containing fluoropyrimidines, platinum agents, and taxanes or irinotecan. In this study, the objective response rate (ORR) was 3.4% (95% confidence interval [CI], 0.1, 17.8), the disease control rate (DCR) was 65.5% (95% CI,  45.7,  82.1);  the  median  progression-free  survival  (PFS)  was  2.9  months  (95%  CI,  1.1,  5.3)  by investigator assessment, and median OS (mOS) was 8.7 months (95% CI, 5.7, 14.9). In this population of pre-treated patients, TAS-102 had an acceptable toxicity profile. Common Grade 3 or 4 adverse events (AEs) included neutropenia (69.0%), leukopenia (41.4%), anaemia (20.7%) and anorexia (10.3%). No treatment-related deaths were observed.

The results of study EPOC1201, which included DCR, mOS, and median PFS (mPFS) comparable to or better than those achieved in other studies of post-second-line treatment approaches to mGC (Table 1), provided the  rationale  for  the  pivotal  study  that  forms  the  basis  of  this  application,  i.e.  the  randomized, placebo-controlled, phase 3 TAS-102 gastric study (TAS-102-302, TAGS). Of note, the results of TAGS have very recently been published (Shitara, 2018).

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

In light of the extension of the indication for Lonsurf, an environmental risk assessment was submitted by the MAH.

In the new proposed indication considering the worst case situation for the daily dose calculation and the revised prevalence of Gastric cancer, the PECSURFACEWATER (μg/L) for trifluridine and tipiracil, HCl can be calculated as follow for gastric cancer:

PECSURFACEWATER for trifluridine = 57.14x1000x0.0000259 / 200x10 = 0.00074 µg/L PECSURFACEWATER for tipiracil, HCl = 23.39x1000x0.0000259 / 200x10   = 0.00030 µg/L

Calculation taking into consideration both indications, metastatic colorectal cancer and gastric cancer, for Lonsurf provides a PECSURFACEWATER of:

PECSURFACEWATER (μg/L) for trifluridine = 0.0029 + 0.00074 = 0.0036 μg/L PECSURFACEWATER (μg/L) for tipiracil, HCl = 0.0012 + 0.00030 = 0.0015 μg/L

Based on the calculation above a Phase II assessment is not necessary.

## 2.2.2. Conclusion on the non-clinical aspects

Trifluridine-tipiracil HCl is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trial (Table 2) was performed in accordance with GCP as claimed by the applicant.

The MAH has provided a statement to the effect that clinical trial conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 2. Tabular overview of clinical study

| Study ID           | Description                                                                                                                                                                                                                                                                                                                                                                                     | Treatment                                                                                            | Number of patients                                        | Endpoints                                                                                                                               |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| TAS-102-302 (TAGS) | Randomized, double-blind, placebo-controlled, phase 3 study in patients with mGC who have received ≥2 prior regimens (including fluoropyrimidine, platinum, and either a taxane- and/or irinotecan-containing regimen; patients whose tumours are known to be HER2+ were required to have received prior anti-HER2 therapy if available) and were refractory to or failing those chemotherapies | TAS-102 35 mg/m 2 PO BID on days 1 to 5 and days 8 to 12 of each 28-day cycle + BSC or placebo + BSC | N=507 patients (ITT population) TAS-102: 337 Placebo: 170 | Primary : • OS Key secondary : • PFS, safety and tolerability Other secondary : • ORR, DCR, time to deterioration of ECOG PS to ≥2, QoL |

Abbreviations: BID = twice daily; BSC = best supportive care; mGC = metastatic gastric cancer; DCR = disease control rate; ECOG: Eastern cooperative oncology group; HER2+: human epidermal growth factor receptor 2-positive; ITT = intent to treat; ORR = overall response rate; OS = overall survival; PS: performance status; PFS = progression free survival; PO = by mouth; QoL: Quality of life

## 2.3.2. Pharmacokinetics

No  pharmacokinetic  (PK)  assessments  were  conducted  during  study  TAS-102-302  (TAGS).  Further, drug-drug and drug-disease (non-cancer) interactions were not evaluated in this study.

The proposed TAS-102 starting dose in adult patients with mGC is 35 mg/m 2  administered orally twice daily (BID) on days 1 to 5 and days 8 to 12 of each 28-day cycle, which is to be continued as long as benefit is observed or until unacceptable toxicity occurs. This posology is identical to that previously accepted for treatment of adult patients with mCRC. No specific comparison of the PK of FTD and/or TPI between mGC and mCRC patient types was provided in this variation. However, in the initial application for the mCRC indication, TAS-102 was dosed to patients with various solid tumours. No differences in PK of FTD and/or TPI were noted between the different patient populations at that time (Lonsurf mCRC EPAR).

## 2.3.3. Pharmacodynamics

Not applicable, as no new data were provided in this application.

<div style=\"page-break-after: always\"></div>

## 2.3.4. Conclusions on clinical pharmacology

There are no indications that FTD and/or TPI Pharmacology in mGC patients is different to that in mCRC patients.

## 2.4. Clinical efficacy

The only study included in this application, is the pivotal study (TAGS).

## 2.4.1. Dose response study(ies)

No dose response studies were included in this application. The applicant has given a justification for the proposed posology as follows:

TAS-102 (35 mg/m2/dose) was administered orally BID, within 1 hour after completion of morning and evening meals, for 5 days each week with 2 days rest for 2 weeks, followed by a 14-day rest. This treatment cycle was repeated every 4 weeks. The safety and tolerability of this TAS-102 regimen was previously demonstrated in the randomized, double-blind, phase 3 study (RECOURSE; TPU-TAS-102-301), in which TAS-102 was shown to significantly improve OS compared to placebo in patients with mCRC, who had previously been treated with, or were not candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy,  an  anti-VEGF  biological  therapy,  and  an  anti-epidermal  growth  factor  receptor  (EGFR) therapy (Mayer, 2015; Lonsurf mCRC EPAR). In an investigator-sponsored, phase 2 study conducted in Japan (Bando, 2016), this TAS-102 regimen was also well-tolerated in patients (n = 29) with mGC who had failed prior standard therapies.

In addition, a lower dose of 25 mg/m 2  BID was investigated as second-line treatment in the other phase 2 study TAS-012-9806 in US patients with mGC. As there was no tumour response among the patients in stage 1 of the 2-stage Simon study design, this study was terminated early (Mayer 2015).

## 2.4.2. Main study

## Title of Study

TAGS (TAS-102-302): Randomized, Double-Blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Gastric Cancer Refractory to Standard Treatments

## Methods

TAGS was a multinational, randomized, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of TAS-102 plus Best Supportive Care (BSC) vs. placebo plus BSC in patients with mGC refractory to standard treatments, i.e. patients who had received ≥2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy. A schematic of the study design is provided in Figure 1.

<div style=\"page-break-after: always\"></div>

## Figure 1. Study design TAGS

<!-- image -->

Abbreviations:  BID  =  twice  daily;  ECOG  =  Eastern  cooperative  oncology  group;  PD  =  progressive  disease;  PS  = performance status; ROW = rest of world

Eligible patients who met all of the inclusion and none of the exclusion criteria (see below in section Study participants ) were centrally randomized (in a 2:1 ratio) to receive either TAS-102 35 mg/m 2  BID per os (PO) plus BSC (experimental arm) or placebo plus BSC (control arm).

Computed tomography (CT) scans were performed at baseline (i.e. within 28 days prior to day 1 of cycle 1) and every 8 weeks thereafter until disease progression. On-site tumour assessments were performed by the investigator/local radiologist. Tumour assessments were analysed using response evaluation criteria in solid tumours (RECIST) criteria (version 1.1, 2009). Patient reported quality of life assessments (EORTC QLQ-C30 and QLQ-STO22) were performed prior to study treatment administration in each cycle.

For patients who discontinued treatment for reasons other than radiologic disease progression (e.g., due to intolerable side effects), every effort was made to perform an end of treatment tumour assessment prior to the start of new anti-cancer therapy. These patients continued to be followed for tumour response every 8 weeks until radiologic disease progression (or death) or initiation of new anti-cancer therapy (whichever occurred first). After discontinuation of study treatment, all patients were followed for survival every 4 weeks until death or until the target number of events (deaths) was met, unless a patient had withdrawn consent to participate in the study.

After the final analysis for the primary endpoint of OS, the study was to be unblinded, and patients from the placebo arm were to be offered the option to cross over to open-label TAS-102.

A  data  monitoring  committee  (DMC)  was  established  for  this  study  to  provide  additional,  independent oversight that could enhance safety of study participants and the study conduct. The DMC comprised of clinicians and a statistician, all independent from the sponsor and investigative sites and selected as to avoid conflict of interest.

<div style=\"page-break-after: always\"></div>

## Study participants

The study was conducted at 110 centres in 17 countries: Italy, USA, Turkey, France, Japan, Portugal, UK, Israel,  Spain,  Russian  Federation,  Czech  Republic,  Germany,  Poland,  Belarus,  Belgium,  Ireland,  and Romania.

Key inclusion criteria were:

1. Adult patients (≥18 years of age), with Eastern cooperative oncology group (ECOG) PS 0 or 1, and who were able to take medications orally.
2. Histologically confirmed, non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction as defined by the American Joint Committee on Cancer (AJCC) staging classification (7th ed., 2010). Documentation of histology of the tumour (primary or metastasis) was required prior to enrolment. Gastroesophageal junction involvement was documented by endoscopic, radiologic, surgical, or pathology report.
3. Patients had previously received ≥2 prior regimens (≥1 cycle per regimen) for advanced disease and patients were refractory to or unable to tolerate their most recent prior therapy:
- a. Prior regimen(s) were required to have included a fluoropyrimidine-, platinum-, and either a taxane- and/or irinotecan-containing regimen; patients whose tumours were HER2+ were required to have received prior anti-HER2 therapy if available.
- b. Patients  had  progressed  based  on  imaging  during  or  within  3  months  of  the  last administration of their most recent prior regimen.
- c. Patients  who  had  withdrawn  from  their  most  recent  prior  regimen  due  to  unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease were also eligible to enter the study.
- d. Patients who  received (both preoperative neoadjuvant chemotherapy  as  well as) postoperative adjuvant chemotherapy or chemo-radiotherapy, and had recurrence during or within 6 months of completion of the adjuvant chemotherapy were allowed to count this therapy as 1 prior regimen for advanced disease (only if the same regimen was administered both pre- and postoperatively).
4. Measurable or non-measurable disease as defined by RECIST 1.1 criteria.
5. Adequate organ function as defined by the following criteria:
- a. Absolute neutrophil count (ANC) ≥1,500/mm 3  (i.e., ≥1.5 × 10 9 /L by International Units [IU]).
- b. Platelet count ≥100,000/mm 3  (IU: ≥100 × 10 9 /L).
- c. Haemoglobin value of ≥9.0 g/dL.
- d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 × upper limit of normal (ULN); if liver function abnormalities were due to underlying liver metastasis, AST and ALT ≤5 × ULN.
- e. Total serum bilirubin of ≤1.5 × ULN.
- f. Serum creatinine ≤1.5 mg/dL.

Key exclusion criteria were:

<div style=\"page-break-after: always\"></div>

1. Previous treatment with TAS-102 and/or known or assumed hypersensitivity to TAS-102 or any of its ingredients.
2. Any serious illness or medical condition(s) including, but not limited to the following:
- a. Other concurrently active malignancies excluding malignancies that were disease-free for more than 5 years or carcinoma-in-situ deemed cured by adequate treatment.
- b. Known brain metastasis or leptomeningeal metastasis.
- c. Active infection.
- d. Intestinal  obstruction,  pulmonary  fibrosis,  renal  failure,  liver  failure,  or  cerebrovascular disorder.
- e. Uncontrolled diabetes.
- f. Myocardial  infarction  within  12  months  prior  to  randomization,  severe/unstable  angina, symptomatic congestive heart failure New York Heart Association class III or IV.
- g. Gastrointestinal haemorrhage (Grade ≥3) within 2 weeks prior to randomization.
- h. Known  human  immunodeficiency  virus  (HIV)  or  acquired  immunodeficiency  syndrome (AIDS)-related illness, or chronic or acute hepatitis B or hepatitis C.
- i. Patients  with  autoimmune  disorders  or  history  of  organ  transplantation  who  required immunosuppressive therapy.
3. Any of the following within the specified time frame prior to randomization:
- a. Major surgery within prior 4 weeks.
- b. Any anti-cancer therapy within prior 3 weeks.
- c. Extended field radiation within prior 4 weeks or limited field radiation within prior 2 weeks.
- d. Any investigational drug/device received within prior 4 weeks.
3. Any unresolved toxicity NCI CTCAE Grade ≥2, attributed to any prior therapies (excluding anaemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity).
4. For women: pregnancy or lactation.

## Treatments

A treatment cycle was defined for all patients as 28 days. On days 1 through 5 and days 8 through 12 of each cycle, each patient received one of the following treatments (based on the treatment group to which they were randomised). In addition, all patients received BSC.

-  Interventional arm: TAS-102 35 mg/m 2  BID PO, within 1 hour after completion of morning and evening meals;
-  Control arm: placebo.

TAS-102 contains FTD and TPI as active ingredients with a molar ratio of 1:0.5, and is formulated as an immediate-release film-coated tablet, which is supplied in 2 strengths (expressed as FTD content):

- -The '15 mg' white, round tablet contains 15 mg FTD and 6.14 mg TPI (i.e. 7.065 mg TPI HCl) as active ingredients;

<div style=\"page-break-after: always\"></div>

- -The '20 mg' pale-red, round tablet contains 20 mg FTD and 8.19 mg TPI (i.e. 9.42 mg TPI HCl) as active ingredients.

Placebo tablets had a similar composition to the TAS-102 tablets, except for the active ingredients.

The study drug tablet calculation is presented in Table 3, which shows the number of tablets that are needed per calculated body surface area (BSA).

Table 3. Study drug tablet calculation

| TAS-102 dose (twice daily)   | Body surface area (m 2 )   | Dose in mg (twice daily)   | Total daily dose (mg)   | Tablets per dose (twice daily)   | Tablets per dose (twice daily)   |
|------------------------------|----------------------------|----------------------------|-------------------------|----------------------------------|----------------------------------|
|                              |                            |                            |                         | 15 mg                            | 20 mg                            |
| 35 mg/m 2                    | <1.07                      | 35                         | 70                      | 1                                | 1                                |
| 35 mg/m 2                    | 1.07 - 1.22                | 40                         | 80                      | 0                                | 2                                |
| 35 mg/m 2                    | 1.23 - 1.37                | 45                         | 90                      | 3                                | 0                                |
| 35 mg/m 2                    | 1.38 - 1.52                | 50                         | 100                     | 2                                | 1                                |
| 35 mg/m 2                    | 1.53 - 1.68                | 55                         | 110                     | 1                                | 2                                |
| 35 mg/m 2                    | 1.69 - 1.83                | 60                         | 120                     | 0                                | 3                                |
| 35 mg/m 2                    | 1.84 - 1.98                | 65                         | 130                     | 3                                | 1                                |
| 35 mg/m 2                    | 1.99 - 2.14                | 70                         | 140                     | 2                                | 2                                |
| 35 mg/m 2                    | 2.15 - 2.29                | 75                         | 150                     | 1                                | 3                                |
| 35 mg/m 2                    | ≥2.30                      | 80                         | 160                     | 0                                | 4                                |

Study treatment was started within three calendar days after the date of randomization and continued until one of the discontinuation criteria was met or until completion of the primary endpoint, whichever occurred first. The discontinuation criteria included:

- -RECIST-defined disease progression;
- -Clinical progression;
- -An  irreversible, treatment-related, Grade  4, clinically relevant, non-hematologic  event  or (otherwise) unacceptable AE(s), or change in underlying condition such that the patient can no longer tolerate therapy;
- -Patient request; and
- -Physician's decision.

After the final analysis for OS and unblinding of the study, patients from the placebo arm were to be offered the option to cross over to open-label TAS-102, and patients already receiving TAS-102 were also switched to open-label TAS-102.

## Objectives

## Primary objective

The primary objective of this study was to evaluate OS for TAS-102 vs. placebo.

The null and alternate hypotheses are read as follows:

<div style=\"page-break-after: always\"></div>

- -H0: active treatment does not have a differential effect on the primary assessment of mortality risk (OS hazard ratio [HR]). The null hypothesis presumes that no statistically significant difference in OS between two groups of patients (investigational drug and placebo-controlled) is observed in the study.
- -HA: active treatment does have a differential effect on the primary assessment of mortality risk (OS HR). The alternate hypothesis presumes that there is a statistically significant difference in OS between two groups of patients (investigational drug and placebo-controlled).

## Key secondary objectives

The key secondary objectives were:

- -Progression-free survival (PFS) based on investigator assessment of radiologic images
- -Safety and tolerability

## Other secondary objectives

Other secondary objectives were:

- -Overall response rate (ORR)
- -Disease control rate (DCR)
- -Time to deterioration of ECOG PS to a score ≥2
- -Quality of life (QoL) as evaluated by the European organization for research and treatment of cancer (EORTC) quality of life questionnaire-core 30 (QLQ-C30) and the QLQ-STO22, which is a module specific to patients with gastric cancer

## Outcomes/endpoints

## Primary endpoint

OS was the primary endpoint of this study, defined as the time from the date of randomization to the date of death due to any cause for the ITT population. In the absence of confirmation of death or for patients alive as of the OS cut-off date, the survival time was censored at the date of last study follow-up or the cut-off date, whichever was earlier. The cut-off date for OS was to be defined by the date of the 384 th  death. Patients having a documented survival status (alive or dead) after this date were censored at the cut-off date.

## Key secondary endpoints

PFS was defined as the time from the date of randomization until the first date of investigator-assessed radiological  disease  progression  or  death  due  to  any  cause.  Patients  who  were  alive  with  no  disease progression as of the analysis cut-off date were censored at the date of the last tumour assessment. Patients who received non-study cancer treatment before disease progression were censored at the date of the last evaluable tumour assessment before the non-study cancer treatment was initiated.

Standard safety and  tolerability monitoring  was  performed  and  AEs  were  Graded  using  NCI  CTCAE version 4.03.

## Other secondary endpoints

The assessment of ORR was based on investigator review of radiologic images and following RECIST criteria (version 1.1, 2009). ORR was defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR). The assessment of ORR was restricted to the tumour response (TR)

<div style=\"page-break-after: always\"></div>

population, i.e. patients with measurable disease (at least 1 target lesion) at baseline and with at least 1 post-baseline evaluation. At the analysis stage, the best overall response was assigned for each patient as the best response recorded from the start of treatment through the treatment period (excluded assessments during follow-up). If applicable, responses recorded after radiologic disease progression or after initiation of non-study antitumor therapy were excluded. A best response assignment of stable disease (SD) required that SD be maintained for at least 6 weeks from the start of treatment.

DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. The assessment of DCR paralleled that of ORR.

The time to deterioration to ECOG PS ≥2 was defined as the time from randomization until the first date on which an ECOG PS ≥2 was observed. Of note, ECOG PS 2 entails that a patient is ambulant and capable of all self-care but unable to carry out any work activities. Patients not reaching an ECOG PS score of ≥2 were censored at the last recorded ECOG assessment.

QoL  was  assessed  using  the  EORTC  QLQ-C30  and  QLQ-STO22.  The  core  questionnaire,  the  QLQ-C30, incorporates 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status scale, and a number of single items assessing additional  symptoms  commonly  reported  by  cancer  patients  (dyspnoea,  loss  of  appetite,  insomnia, constipation  and  diarrhoea)  and  perceived  financial  impact  of  the  disease.  The  gastric  cancer  module (QLQ-STO22) is meant  for use  among gastric  cancer  patients  varying  in  disease  stage  and  treatment modality. This 22-item instrument is used alongside the 30-item QLQ-C30 core questionnaire, resulting in a total of 52 items. The time to deterioration of QoL was defined as the time from randomization until the first date on which a deterioration of QoL by ≥5 points in global health status was observed.

## Sample size

The study was designed to detect with 90% power a hazard ratio for death of 0.70 (30% risk reduction) in the TAS-102 arm compared with the placebo arm with an overall 1-sided type 1 error of 0.025. A variable accrual period of 18 months and a 5%/year loss to survival follow-up rate was assumed. Using a treatment allocation of 2:1 (TAS-102:placebo) of 500 patients, 384 deaths were targeted for the final OS analysis.

Based on these design operating characteristics and assuming a median survival time of approximately 5 months in the control arm, the primary analysis target events milestone would be reached approximately 8 months after the last patient was randomized in the study. The mOS in the control arm was estimated based on the observed mOS of 3.8 months in the placebo arm of the phase 3 ramucirumab (REGARD) study in the second-line treatment of GC (Fuchs, 2013), and the observed mOS of 4.3 months in the placebo arm of the phase 3 everolimus (GRANITE) study in the second- and third-line treatment of GC (Ohtsu, 2013). The estimate was further increased to 5 months to account for the higher control median projected in the Japanese population.

One interim analysis (IA) for efficacy and futility was planned for the study after approximately half of the total target events are observed (192 deaths), see section Statistical methods below.

## Randomisation

Once patient confirmation of eligibility and the criteria for randomization were met, patients were centrally randomized in a 2:1 ratio to TAS-102 plus BSC or placebo plus BSC via an interactive voice/web response system (IXRS) based on a dynamic allocation method (biased coin).

Patients were stratified by the following criteria:

- -Region (rest of world [ROW] vs. Japan)

<div style=\"page-break-after: always\"></div>

- -ECOG PS (0 vs. 1)
- -Prior treatment with ramucirumab (yes vs. no)

## Blinding (masking)

This was a double-blind study. TAS-102 tablets of each strength, 15 mg or 20 mg, and the corresponding placebo  tablets,  respectively,  were  identical  in  appearance  and  were  packaged  in  identical  containers. During the conduct of the study, the treatment assignment was unknown to all patients, investigators, and ancillary study personnel at each study site, and to employees of the sponsor, except for pre-specified personnel involved in pharmacovigilance reporting activities and clinical trial material management. Among the contract research organizations who assisted in the conduct of the study, treatment assignment was unknown except for personnel involved in drug labelling and distribution, IXRS activities, pharmacovigilance reporting activities, and provision of data for periodic DMC review.

The final analysis was to be performed after the target number of events was reached, i.e. 384 deaths. After the final analysis, the study was to be unblinded. If the primary endpoint of the study was met and efficacy as well as safety supported a favourable benefit/risk ratio for TAS-102, patients currently or previously treated with placebo who continued to meet study eligibility criteria were to be offered the option to cross over to open-label TAS-102. Patients receiving TAS-102 were also switched to open-label TAS-102.

## Statistical methods

## Analysis populations

The ' intent-to-treat (ITT) population ' comprised all randomized patients, regardless of whether or not study drug was administered. This population was the primary population for the analysis of the efficacy data. All analyses using this population were based on the treatment assigned.

The  ' as-treated  (AT)  population '  was  defined  as  all  patients  who  received  at  least  one  dose  of  study medication. This population was used in the assessment and reporting of safety data. The 'as-treated population' was equivalent to 'safety population'. This population was used for safety analyses. All analyses using this population were based on the treatment actually received.

The ' tumour response (TR) population ' included all patients in the ITT population that met both of the two following criteria:

- -measurable disease (at least one target lesion) at baseline; and
- -at least one post-baseline evaluation or early disease progression/cancer-related death occurred before first evaluation on treatment (post-baseline) took place.

All analyses using this population were based on the treatment assigned.

## Primary endpoint OS analyses

OS in the ITT population was compared between the 2 treatment groups (ITT population) using the stratified log-rank test. One- and 2-sided p-values were presented. The study would be declared to have met its primary objective if the 1-sided p-value was less than 0.0215. The estimate of the HR and corresponding 95% CI  were  provided  using  a  Cox  proportional  hazards  (CPH)  model  including  treatment  and  the  3 stratifications factors in the model. Survival for each arm was summarized using Kaplan Meier curves and further characterized in terms of the median and survival probability at 3, 6, 9 and 12 months, along with the corresponding 2-sided 95% CI for the estimates. The stratification factors were populated as per the IXRS assignment.

<div style=\"page-break-after: always\"></div>

Subgroup  analyses  were  conducted  for  each  of  the  stratification  factors  (as  per  IXRS)  and  additional subgroups were utilized for the supportive analysis of the primary and key secondary endpoint. Summary statistics,  HR  and  associated  95%  CI  were  presented  for  each  subgroup.  Only  2-sided  p-value  were calculated and presented in the tables by the subgroups.

Supportive analyses for OS, conducted in the ITT population (unless otherwise noted), included:

The unstratified log-rank test and a CPH model (only treatment effect included in the model);

1. Multivariate  analysis  using  the  CPH  model,  including  the  3  stratification  factors  and  potential prognostic/predictive factors: age (&lt;65, ≥65 years), race (white, Asian, other), gender, number of prior  regimens  (2,  3+),  prior  therapy,  previous  gastrectomy,  GEJ  involvement,  presence  of peritoneal  metastases,  presence  of  liver  metastases,  number  of  metastatic  sites  (1-2,  3+), measurable disease, histology subtype (diffuse, intestinal), and HER2 status;

Factors included in the model were assessed for co-linearity and a stepwise selection process was applied to identify a final subset of prognostic/predictive factors in the model. Once the subset was established, treatment was added to the final model to assess its effect in the presence of the identified covariates;

An exploratory analysis of treatment by factor interactions using the CPH model was conducted, using the factors identified in the final model above;

2. Subgroup analyses  were  also  conducted  for  each  of  the  stratification  factors  and  the  potential prognostic/predictive factors identified above. The HR and associated 95% CI were presented for each subgroup;
3. The primary efficacy analysis, as outlined above, were also run excluding any patients who did not have documented refractory mGC, as defined above in inclusion criteria #2 and #3 in section Study participants ;
4. Additional sensitivity analyses defined in the statistical analysis plan (SAP):
4. o The primary efficacy analysis that excluded/adjusted for all major protocol violations;
5. o Stratified  test  analysis  using  the  CRF  designation  instead  of  IVRS,  assuming  there  are differences;
6. o OS analysis using as-treated (AT) population;
7. o Analysis  described  above  in  Section  10.4.1  was  also  run  excluding  high  accrual  (&gt;25 patients) sites;
8. o Analysis described above was also run using date of all collected events (death) and survival status as of 30-April-2018.

One IA for efficacy and futility was planned for the study after approximately half of the total target events were observed (192 deaths). The Lan-DeMets alpha-spending approach was used with O'Brien-Fleming stopping boundaries to guide the efficacy evaluation at the interim and final OS analysis. This approach accounted for multiple testing and preserved the overall 1-sided study significance level of 0.025. A fixed HR boundary was used to assess futility (non-binding). Stop due to futility would have been recommended if observed HR would have been ≥0.95 when conditional power would have been less than 2%. Stopping the study for efficacy would have been recommended if calculated 1-sided p-value would have been less than 0.0015. The corresponding HR for such significant results would have been less than approximately 0.63, associated with a mOS improvement from 5 to 7.9 months. The exact boundaries were derived based on the actual number of events used for the IA.

<div style=\"page-break-after: always\"></div>

For the final analysis of the primary efficacy endpoint the result was considered as significant if 1-sided p-value was less than 0.0245 (this was subject to change based on the information/number of events at the IA). The corresponding HR for such significant result was less than approximately 0.808 associated with a mOS improvement from 5 to 8 months).

## Key secondary endpoint PFS analyses

Since PFS was the only key secondary endpoint for regulatory registration purposes, no further multiplicity adjustments were made. Assuming that OS demonstrated significance at the 1-sided 0.025 level, PFS could subsequently be tested at the 2-sided 0.05 level.

PFS analyses largely followed the methodology specified above for OS. In line with FDA guidance additional sensitivity analyses were conducted on the ITT population. Subgroup analysis followed the logic applied to the primary endpoint investigation. The list of other planned examinations reads as follows:

- -Analysis that included clinical progression as a PFS event in addition to the presence of radiological evidence of progression.
- -Analysis  including  clinical  progression  as  a  PFS  event  that  also  counted  initiation  of  non-study antitumor  therapy  as  an  event  date  rather  than  as  date  used  to  censor  subsequent  response assessment.
- -Analysis that included all deaths and response assessments (without censoring missed visits) and counted as an event any one of the following list: radiological evidence of progression, clinical progression, initiation of non-study antitumor therapy, and death through the date of cut-off for survival.
- -Analysis described above was also run excluding high accrual (&gt;25 patients) sites.
- -Analysis  of  time  to  first,  second  and  third  radiological  tumour  assessments  from  the  date  of randomization (Kaplan-Meier curves of times was depicted and the corresponding supporting tables were created; log-rank test were applied for examination and comparison of the two groups).

The PFS censoring rules are shown below in Table 4.

<div style=\"page-break-after: always\"></div>

Table 4. PFS censoring rules

<!-- image -->

| Situation                                                                                                            | End Date                                                                                     | Censored   | Assignment in PFS table                                                                                               |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------|
| Documented radiological PD                                                                                           | Date of the first assessment of the series of the tests that determined PD                   | No         |                                                                                                                       |
| Death during the study before PD                                                                                     | Date of death                                                                                | No         |                                                                                                                       |
| Treatment discontinuation for other than radiologic PD or death with no post- baseline tumor assessments             | Date of randomization                                                                        | Yes        | Discontinued Follow Up                                                                                                |
| Treatment discontinuation for other than radiologic PD or death with post- baseline tumor assessments                | Date of last adequate tumor assessment prior to initiation of non-study anti-tumor treatment | Yes        | Discontinued Follow Up                                                                                                |
| Subjects still followed without radiologic PD as of cut-off date                                                     | Date of last adequate tumor assessment prior to cut-off date                                 | Yes        | Ongoing                                                                                                               |
| Non-study anti-tumor treatment initiated before radiologic PD                                                        | Date of last adequate tumor assessment prior to initiation of non-study anti-tumor treatment | Yes        | Initiated anti-tumor therapy                                                                                          |
| Non-study anti-tumor treatment initiated on date of radiologic PD                                                    | Date of radiologic PD (= date of initiation of non-study anti- tumor treatment)              | No         |                                                                                                                       |
| Death or radiologic PD after a missed tumor assessment                                                               | Date of last adequate tumor assessment prior to missed tumor assessment                      | Yes        | Missed Visit                                                                                                          |
| Death or radiologic PD after 91 days period since first dose (no post-baseline tumor assessments during this period) | Date of randomization                                                                        | Yes        | Missed Visit                                                                                                          |
| Only NE tumor assessments after CR, PR. or SD                                                                        | Date of last adequate tumor assessment prior to NE tumor assessments                         | Yes        | Missed Visit                                                                                                          |
| Ongoing patients with no post-baseline tumor                                                                         | Date of randomization                                                                        | Yes        | Ongoing                                                                                                               |
| assessments                                                                                                          |                                                                                              |            |                                                                                                                       |
| No baseline tumor assessment                                                                                         | Date of randomization                                                                        | Yes        | Depends on the discontinuation status and post-baseline tumor scan status - anyone of the 4 categories can take place |

## Other secondary efficacy endpoint analyses

All other secondary endpoints comparisons were made at the 2-sided 0.05 significance level.

The treatment comparison for ORR and DCR were based on the TR population using Fisher's exact test. Treatment estimates and differences were presented along with the associated 95% CIs.

<div style=\"page-break-after: always\"></div>

The time to deterioration of ECOG PS to a score ≥2 was analysed using methodology described above for OS. A sensitivity analysis was performed using only on therapy ECOG assessments for analysis, i.e. excluding deaths during the survival follow-up period (when ECOG was not measured).

The time to deterioration of QoL by ≥5 points in global health status was assessed using the EORTC QLQ-C30 and QLQ-STO22. Scales was scored according to the EORTC scoring manual. Descriptive statistics, for both scales, for the summary scores, as well as the subscale scores were provided for each assessed time point. In  addition,  change  in  QoL  scores  at  representative  time  points  (i.e.  prior  to  cycle  2,3,  and  4)  were determined for the summary, all domains and single items by subtracting each patient's score from their corresponding baseline score. In addition, time to QoL deterioration was evaluated for each arm using Kaplan-Meier  estimates  and  compared  using  the  log-rank  test  (and  Cox  proportional  hazards  models adjusting for the baseline value of the EORTC QLQ-C30 and QLQ-STO22 score, country and primary tumour type). Patients with no deterioration in EORTC QLQ-C30 and QLQ-STO22 scores were censored at the end of study, cut-off date or death date. A sensitivity analysis was similar to the aforementioned main analysis, but it was conducted using a decrease of ≥10 points to define deterioration in QoL.

## Changes in the planned analyses

The original statistical analysis plan (SAP) version 1.05 was approved on 06-Jul-2016. Prior to database lock (and  all  statistical  analyses),  the  SAP  was  amended  once;  version  2.0  was  issued  on  27-Apr-2018. Substantial changes to the SAP are summarized below in Table 5.

<div style=\"page-break-after: always\"></div>

Table 5. Summary of substantial changes to the statistical analysis plan

| Section                           | Key Changes                                                                                                                                                                                                                                                                                                                                  |
|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 8.1                       | Reference date for age calculation was changed from randomization date to the date the informed consent was signed                                                                                                                                                                                                                           |
| Sections 8.7, 8.8, and Appendix H | Definitions for cycle windows and handling of multiple assessments were further detailed and documented.                                                                                                                                                                                                                                     |
| Section 8.9                       | Time-adjusted incidence rate calculations were revised from 1 year to 100 years.                                                                                                                                                                                                                                                             |
| Section 8.12                      | Creatinine clearance levels for the severe renal function impairment group were added to the definition.                                                                                                                                                                                                                                     |
| Section 8.13                      | Imputation rules for partial birth dates, missing end of exposure dates, and start of antitumor therapy dates were added.                                                                                                                                                                                                                    |
| Section 9.2                       | Definitions of CSR reportable protocol deviations were added to the existing Major Protocol Deviations.                                                                                                                                                                                                                                      |
| Section 9.5.1, 9.6.1              | Details of how prior cancer medical history and prior anti-cancer therapies are summarized were updated.                                                                                                                                                                                                                                     |
| Section 9.5                       | Medical history was summarized for the AT population instead of the ITT population                                                                                                                                                                                                                                                           |
| Section 10.2                      | List of subgroups for the efficacy analyses (OS and PFS) was fevised to remove primary tumor site subgroup and add prior immunotherapy subgroup (PD1/PDL1).                                                                                                                                                                                  |
| Section 10.4.2.3                  | Additional sensitivity analyses were added including one excluding high-accrual (> 25 patients) sites.                                                                                                                                                                                                                                       |
| Section 11.2.1, 11.2.2,11.6.4     | Subgroups for the key safety analyses (treatment-emergent adverse events and clinical laboratory data) were defined and the list of treatment-emergent adverse event summaries was updated.                                                                                                                                                  |
| Section 12                        | The efficacy bound (p-value) for the final analyses was derived based on the actual event count used for the interim analysis.                                                                                                                                                                                                               |
| Appendices                        | Appendices were added: Appendix C: Progression-ffree survival censoring rules Appendix D: Standard laboratory ranges were updated Appendix G: Date for the clinical cut-off was established and rnules for submission database were added. Appendix H: Data Handling Guidance that further details data handling rules for safety endpoints. |

Abbreviations: AT = as-treated (population); CSR = clinical study report; ITT = intent-to-treat (population); OS = overall survival; PFS = progression-free survival

## Results

## Recruitment and participant flow

Between 24-Feb-2016 and 05-Jan-2018, 507 patients were enrolled and randomly assigned (2:1) to the TAS-102 group (N=337) and the placebo group (N=170). The target number of events, i.e. 384 deaths, was reached on 27-Mar-2018, which is thus the OS data cut-off date. There occurred 11 additional deaths (TAS-102: 9; placebo: 2) in  the  time  period  between  these  two  dates,.  The  cut-off  date  for  all  other (non-OS) clinical data was 31-Mar-2018. Median duration of survival follow-up was 10.7 months (TAS-102: 10.6 months; placebo: 10.7 months).

<div style=\"page-break-after: always\"></div>

A total of  625  patients  provided  signed  informed  consent  for  participation  in  the  study.  Of  these,  118 (18.9%) were screened but not randomized primarily (111/118 = 94%) due to screen failures. Of the 507 patients randomized (ITT population), 337 were assigned to TAS-102 and 170 were assigned to placebo.

Four patients (2 patients in each treatment group) did not receive study treatment. In the TAS-102 group, 1 patient died (before having received treatment) and 1 had a protocol violation; both patients in the placebo group withdrew consent (before having received treatment). The patient flow is depicted below in Figure 2 (alternatively see Figure 1 of Shitara, 2018).

Figure 2. Patient flow

<!-- image -->

Abbreviations: AT = as-treated (population); BSC = best supportive care; ITT = intent-to-treat (population)

## Conduct of the study

## Protocol amendments

The original study protocol was issued on 30-Jun-2015. Substantial changes to the protocol (including e.g. the addition of QoL to the [other] secondary endpoints) are described in order of issuance in Table 6.

<div style=\"page-break-after: always\"></div>

Table 6. Summary of substantial changes in the protocol

| Amendment No.                                                   | Date                    | Key Changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------------------------------------------------------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Original                                                        | 30 Jum 2015             | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Version 0.1 Rest of World                                       | 16 Jul 2015             | Administrative; change in Medical Monitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Version 1.0 Japan                                               | 10 Jul 2015             | Added Appendix E: Supplemental Requirements for Japan Only Added Appendix F: Summary of Changes to Protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Version 1.1 Japan                                               | 16 Jul 2015             | Administrative; change in Medical Monitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Version 1.0 Rest of World Version 2.0 Japan                     | 19 Feb 2016 22 Feb 2016 | Added Quality of Life to secondary endpoints Revised footmote in the Study Schedule and throughout the docuument to peis juawean Aps pue 'uoyezimopuer pouad Suneas jo Suun gue Revised footnote in the Study Schedule to clarify timing of Eastem Cooperative Oncology Group (ECOG) perfonmance status score collection. Revised suuvival follow-up to exclude patients who have withdrawm consent from the study uless they request discontinuation of study treatment but agree to survival follow-up (this was not considered withdrawal of consent). Revised inclusion/exclusion criteria definition of contraception to comply with Health Authority Request. Minor clanification was made to inclusion criterion #3d to allow patients who received postoperative adjuvant chemotherapy or chemoradiotherapy to continue the adjuvant therapy. Clarified resumption criteria for patients with decreases in neutrophils Clarified Quality of Life assessments were to be performed prior to dose administration in each cycle. Clarified reference points of Quality of Life assessments from Weeks to Cycles. Added definition of serious adverse reaction, and reporting requirements for serious adverse events, serious adverse reactions and suspected umexpected serious adverse reactions (SUSARs) per Health Authority request. Clarified reporting requirements for medication errors and SUSARs. |
| Version 1.0 Germany                                             | 22 Feb 2016             | The same changes were made as for Version 1.0 Rest of World amendment. In addition the following change was made: Added new assessment: 12-lead electrocardiogram (ECG) was to be performed within 28 days prior to randomization.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Version 2.0 Rest of World Version 2.0 Germany Version 3.0 Japan | 05 May 2016             | Clarified that steroids at doses  20 mg of prednisone equivalent per day for ≤ 2 weeks are permitted duing the study. Added dose intemuption/resumption guidelines for febrile neutropenia per Health Authority Request. Revised terminology pertaining to related adverse events: “related\" was changed to \"reasonably possible”\" and \"not related\" was changed to \"not reasonably possible.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Version 4.0 Japan                                               | 23 Apr 2018             | Appendix E: Supplemental requirements for Japan Only The study period was changed from Jum 2018 to Dec 2018 to extend the planned study duration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Protocol deviations

A CSR reportable protocol deviation was related to inclusion/exclusion criteria, conduct of the trial, patient management or patient assessments that impact the safety of the patients or jeopardize the quality of the study data. In addition, among all CSR reportable protocol deviations, a set of 'major protocol deviations' was defined as a means to measure adherence to key aspects of the protocol using pre-specified sensitivity analyses.

<div style=\"page-break-after: always\"></div>

The occurrence of any major protocol deviation was similar between the treatment arms (TAS-102: 2.7%; placebo:  2.4%),  see  Table  7.  The  patient  in  the  placebo  arm  who  had  received  'Other  concurrent chemotherapy … while receiving study treatment' had received ramucirumab.

Overall, 60 (17.8%) patients in the TAS-102 group and 14 (8.2%) patients in the placebo group had CSR reportable (non-major) deviations . Thirty-nine patients (11.6%) in the TAS-102 treatment group and 4 patients (2.4%) in the placebo group received the wrong treatment or incorrect dose, thus 43 patients overall. Of note, 'wrong treatment' did not mean that a patient received TAS-102 instead of placebo or the other way round. Of these 43 patients, in 31 patients (in 2 of whom the event occurred twice), the dose of study medication was not held even though the ANC was below 1.5 x 10 9 /L prior to dosing. In 6 patients (in one of whom it occurred 4 times), the patient took the wrong dose. In 4 patients, the height or weight was recorded incorrectly leading to a wrong BSA calculation. In 2 patients the wrong kit was given and in 2 patients the kits were not returned. Of note, for 2 patients, more than 1 reason than the RD3 category was assessed.

Table 7 . Summary of protocol deviations

|                                                                                                                         | Number (%) of Patients   | Number (%) of Patients   | Number (%) of Patients   |
|-------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------|
| Deviation                                                                                                               | TAS-102 (N=337) n (%)    | Placebo (N=170) n (%)    | Total (N=507) n (%)      |
| Major CSR Reportable Deviations                                                                                         |                          |                          |                          |
| Any criteria                                                                                                            | 9 (2.7)                  | 4 (2.4)                  | 13 (2.6)                 |
| MRD1 - No histological confirmation of gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction | 0                        | 0                        | 0                        |
| MRD2 - No metastatic disease                                                                                            | 0                        | 0                        | 0                        |
| MRD3 - No measurable or non-measurable disease per RECIST v1.1                                                          | 0                        | 0                        | 0                        |
| MRD4 - Received fewer than 2 prior regimens                                                                             | 7 (2.1)                  | 1 (0.6)                  | 8 (1.6)                  |
| MRD5 - Prior anticancer therapy within 3 weeks prior to study treatment administration                                  | 2 (0.6)                  | 2 (1.2)                  | 4 (0.8)                  |
| MRD6 - Previously received TAS-102                                                                                      | 0                        | 0                        | 0                        |
| MRD7 -- Received incorrect treatment (ie, randomized to 1 arm but received the other treatment)                         | 0                        | 0                        | 0                        |
| MRD8 - Other concurrent chemotherapy or radiotherapy administered while receiving study treatment                       | 0                        | 1 (0.6)                  | 1 (0.2)                  |
| CSR Reportable Deviations                                                                                               |                          |                          |                          |
| Any criteria                                                                                                            | 60 (17.8)                | 14 (8.2)                 | 74 (14.6)                |
| RD1 -- Did not meet entry criteria                                                                                      | 13 (3.9)                 | 6 (3.5)                  | 19 (3.7)                 |
| RD2 -- Developed withdrawal criteria but were not withdrawn                                                             | 4 (1.2)                  | 1 (0.6)                  | 5 (1.0)                  |
| RD3 - Received the wrong treatment or incorrect dose                                                                    | 39 (11.6)                | 4 (2.4)                  | 43 (8.5)                 |
| RD4 - Received an excluded medication                                                                                   | 2 (0.6)                  | 1 (0.6)                  | 3 (0.6)                  |
| RD5 - Critical ICF, GCP and other protocol deviations                                                                   | 6 (1.8)                  | 2 (1.2)                  | 8 (1.6)                  |

Abbreviations: CSR = clinical study report; GCP = Good Clinical Practice; ICF = Informed Consent Form; MRD = major reportable deviation; RD = reportable deviation; RECIST = Response Evaluation Criteria in Solid Tumours

<div style=\"page-break-after: always\"></div>

## Baseline data

The demographic and other baseline characteristics for the ITT population are shown below in Table 8.

Table 8. Demographic and other baseline characteristics (ITT population)

|                                       | TAS-102        | Placebo        | Total          |
|---------------------------------------|----------------|----------------|----------------|
| Parameter                             | (N=337)        | (N=170)        | (N=507)        |
| Gender, n (%)                         |                |                |                |
| Male                                  | 252 (74.8%)    | 117 (68.8%)    | 369 (72.8%)    |
| Female                                | 85 (25.2%)     | 53 (31.2%)     | 138 (27.2%)    |
| Age (years)                           |                |                |                |
| Mean (SD)                             | 62.8 (10.78)   | 62.0 (10.04)   | 62.5 (10.53)   |
| Median                                | 64.0           | 62.5           | 63.0           |
| Min, Max                              | 24, 89         | 32,82          | 24, 89         |
| Age group (years), n (%)              |                |                |                |
| <65                                   | 183 (54.3%)    | 96 (56.5%)     | 279 (55.0%)    |
| ≥65                                   | 154 (45.7%)    | 74 (43.5%)     | 228 (45.0%)    |
| ≥65 -<75                              | 103 (30.6%)    | 56 (32.9%)     | 159 (31.4%)    |
| ≥75                                   | 51 (15.1%)     | 18 (10.6%)     | 69 (13.6%)     |
| Race, n (%)                           |                |                |                |
| White                                 | 244 (72.4%)    | 113 (66.5%)    | 357 (70.4%)    |
| Black or African American             | 1 (0.3%)       | 2 (1.2%)       | 3 (0.6%)       |
| Asian                                 | 51 (15.1%)     | 29 (17.1%)     | 80 (15.8%)     |
| Not Collectable                       | 38 (11.3%)     | 24 (14.1%)     | 62 (12.2%)     |
| Other                                 | 3 (0.9%)       | 2 (1.2%)       | 5 (1.0%)       |
| Body Surface Area (in?)               |                |                |                |
| Mean (SD)                             | 1.747 (0.2131) | 1.754 (0.1998) | 1.749 (0.2086) |
| Median                                | 1.750          | 1.740          | 1.740          |
| Min, Max                              | 1.20, 2.37     | 1.29,2.52      | 1.20, 2.52     |
| ECoG Performance Status,n (%)         |                |                |                |
| 0                                     | 123 (36.5%)    | 68 (40.0%)     | 191 (37.7%)    |
| 1                                     | 214 (63.5%)    | 102 (60.0%)    | 316 (62.3%)    |
| Region 1, n (%)                       |                |                |                |
| Japan                                 | 46 (13.6%)     | 27 (15.9%)     | 73 (14.4%)     |
| ROW1                                  | 291 (86.4%)    | 143 (84.1%)    | 434 (85.6%)    |
| Region 2, n (%)                       |                |                |                |
| Europe - EU*                          | 180 (53.4%)    | 97 (57.1%)     | 277 (54.6%)    |
| ROW2                                  | 157 (46.6%)    | 73 (42.9%)     | 230 (45.4%)    |
| Region 3, n (%)                       |                |                |                |
| USA                                   | 21 (6.2%)      | 5 (2.9%)       | 26 (5.1%)      |
| ROW3                                  | 316 (93.8%)    | 165 (97.1%)    | 481 (94.9%)    |
| Baseline Renal function, n (%) b      |                |                |                |
| Normal (CLcr >= 90 mL/min)            | 134 (39.8%)    | 68 (40.0%)     | 202 (39.8%)    |
| Mild Impairment (CLcr 60-89 mL/min)   | 141 (41.8%)    | 71 (41.8%)     | 212 (41.8%)    |
| ModerateImpairment (CLcr 30-59mL/min) | 58 (17.2%)     | 28 (16.5%)     | 86 (17.0%)     |
| Severe Impairment (CLcr <30 mL/min)   | 2 (0.6%)       | 1 (0.6%)       | 3 (0.6%)       |
| Missing                               | 2 (0.6%)       | 2 (1.2%)       | 4 (0.8%)       |

Abbreviations: CrCl = creatinine clearance; ECOG = European Cooperative Oncology Group; a Europe - EU refers to countries members of the European Union. b CrCl based on Cockcroft-Gault using baseline creatinine.

<div style=\"page-break-after: always\"></div>

The baseline disease characteristics for the ITT population are shown below in Table 9.

Table 9. Baseline disease characteristics (ITT population)

|                                                          | TAS-102 (N=337)   | Placebo (N=170)   | Total (N=507)   |
|----------------------------------------------------------|-------------------|-------------------|-----------------|
| Primary cancer type                                      |                   |                   |                 |
| Gastnic, n (%)                                           | 239 (70.9)        | 121 (71.2)        | 360 (71.0)      |
| Gastroesophageal jumction, n (%)                         | 98 (29.1)         | 47 (27.6)         | 145 (28.6)      |
| Both, n (%)                                              | 0                 | 2 (1.2)           | 2 (0.4)         |
| Tumor grade                                              |                   |                   |                 |
| Well differentiated, n (%)                               | 32 (9.5)          | 14 (8.2)          | 46 (9.1)        |
| Moderately differentiated, n (%)                         | 109 (32.3)        | 45 (26.5)         | 154 (30.4)      |
| Poorly differentiated, n (%)                             | 113 (33.5)        | 72 (42.4)         | 185 (36.5)      |
| Unknowm or missing, n (%)                                | 83 (24.6)         | 39 (22.9)         | 122 (24.1)      |
| Histology subtype                                        |                   |                   |                 |
| Intestinal, n (%)                                        | 103 (30.6)        | 52 (30.6)         | 155 (30.6)      |
| Diffused, n (%)                                          | 53 (15.7)         | 21 (12.4)         | 74 (14.6)       |
| Mixed, n (%)                                             | 14 (4.2)          | 8 (4.7)           | 22 (4.3)        |
| Unknown, n (%)                                           | 132 (39.2)        | 69 (40.6)         | 201 (39.6)      |
| Not applicable, n (%)                                    | 35 (10.4)         | 20 (11.8)         | 55 (10.8)       |
| Time from initial diagnosis to randomization (months)    |                   |                   |                 |
| Mean (standard deviation)                                | 26.98 (24.812)    | 25.63 (20.832)    | 26.53 (23.541)  |
| Median                                                   | 20.90             | 20.00             | 20.70           |
| xem 'mn                                                  | 3.6, 302.5        | 4.0, 190.4        | 3.6, 302.5      |
| Time from confirmed metastasis to randomization (months) |                   |                   |                 |
| Mean (standard deviation)                                | 19.44 (13.122)    | 19.12 (17.575)    | 19.33 (14.749)  |
| Median                                                   | 16.30             | 14.65             | 15.80           |
| Min, max                                                 | 0.6, 87.7         | 2.6, 189.7        | 0.6, 189.7      |
| Had measurable disease, n (%6)                           | 306 (90.8)        | 150 (88.2)        | 456 (89.9)      |
| Number of metastatic sites                               |                   |                   |                 |
| 1-2, n (%)                                               | 155 (46.0)        | 72 (42.4)         | 227 (44.8)      |
| 3 or more, n (%)                                         | 182 (54.0)        | 98 (57.6)         | 280 (55.2)      |
| Presence of liver metastases                             | 195 (57.9)        | 89 (52.4)         | 284 (56.0)      |
| Presence of lung metastases                              | 108 (32.0)        | 44 (25.9)         | 152 (30.0)      |
| Presence of peritoneal metastases                        | 87 (25.8)         | 53 (31.2)         | 140 (27.6)      |
| HER 2 status                                             |                   |                   |                 |
| Positive, n (%)                                          | 67 (19.9)         | 27 (15.9)         | 94 (18.5)       |
| Negative, n (%)                                          | 207 (61.4)        | 106 (62.4)        | 313 (61.7)      |
| Not done, n (%)                                          | 62 (18.4)         | 37 (21.8)         | 99 (19.5)       |

Abbreviations: HER 2 =human epidermal growthfactor receptor 2

## Prior anti-cancer treatment

Prior anti-cancer treatment for the ITT population is shown below in Table 10.

<div style=\"page-break-after: always\"></div>

Table 10. Prior anti-cancer treatment (ITT population)

Abbreviations:HER 2=human epidermal growthfactorreceptor 2;PD=programmed cell death(receptor)

|                                                         | TAS-102 (N=337)    | Placebo (N=170)     | Total (N=507)      |
|---------------------------------------------------------|--------------------|---------------------|--------------------|
| Had prior surgery related to gastric cancer, n (%)      | 271 (80.4)         | 133 (78.2)          | 404 (79.7)         |
| Had previous gastrectomy, n (%)                         | 147 (43.6)         | 74 (43.5)           | 221 (43.6)         |
| Type of surgery related to gastric cancer               |                    |                     |                    |
| Biopsy, n (%)                                           | 191 (56.7)         | 100 (58.8)          | 291 (57.4)         |
| Resection of primary lesion, n (%)                      | 136 (40.4)         | 63 (37.1)           | 199 (39.3)         |
| Other, n (%)                                            | 75 (22.3)          | 35 (20.6)           | 110 (21.7)         |
| Had prior radiotherapy related to gastric cancer, n (%) | 71 (21.1)          | 26 (15.3)           | 97 (19.1)          |
| Number of prior treatment regimens, n (%)               |                    |                     |                    |
| 2                                                       | 126 (37.4)         | 64 (37.6)           | 190 (37.5)         |
| 3                                                       | 134 (39.8)         | 60 (35.3)           | 194 (38.3)         |
| 4 or more                                               | 77 (22.8)          | 46 (27.1)           | 123 (24.3)         |
| Prior systemic therapeutic agentsab, n (%):             |                    |                     |                    |
| Fluoropyrimidine                                        | 336 (99.7)         | 170 (100)           | 506 (99.8)         |
| Platinumd                                               | 337 (100)          | 170 (100)           | 507 (100)          |
| Taxane                                                  | 311 (92.3)         | 148 (87.1)          | 459 (90.5)         |
| Ramucirumabf                                            | 114 (33.8)         | 55 (32.4)           | 169 (33.3)         |
| Irinotecan\"                                             | 183 (54.3)         | 98 (57.6)           | 281 (55.4)         |
| HER2i                                                   | 60 (17.8)          | 24 (14.1)           | 84 (16.6)          |
| Immunotherapy (PD1/PDL1)                                | 25 (7.4)           | 7 (4.1)             | 32 (6.3)           |
| Other                                                   | 77 (22.8)          | 41 (24.1)           | 118 (23.3)         |
| Intent of prior systemic cancer therapy*, n (%)         |                    |                     |                    |
| Neoadjuvant                                             | 37 (11.0)          | 15 (8.8)            | 52 (10.3)          |
| Adjuvant                                                | 56 (16.6)          | 35 (20.6)           | 91 (17.9)          |
| Advanced/metastatic                                     | 337 (100.0) 11(2.u | 170 (100.0) TV(1.1) | 507 (100.0) 12JZT. |

Patients with multiple levels were counted in each applicable category.

Fluoropyrimidine includes 5-FU (fluorouracil), capecitabine, doxifluridine, S-1, tegafiur, tegafur-uracil (UFT), and additional agents that were collected as 'Other' and later re-mapped to fluoropyrimidine.

b Includes all prior systemic therapies (neoadjuvant, adjuvant, metastatic)

d Platimum includes oxaliplatin, cisplation, carboplatin, and additional agents that were collected as 'Other' and later remapped to platinum.

Taxane includes docetaxel, paclitaxel, nab-paclitaxel (abraxane), and additional agents that were collected as *Other and later remapped to taxane.

f Ramucirumab as monotherapy or in combination with other agent(s)

Irinotecan includes irinotecan and CPT-11 and additional agents that were collected as *Other and later remapped to irinotecan

h HER2i includes trastuzumab, pertuzumab and TDM-1.

Immunotherapy includes all PD1/PDL1 agents.

See Table 11 for the number of prior regimens and the therapeutic agents that were given for metastatic disease only.

<div style=\"page-break-after: always\"></div>

Table 11 . Prior anti-cancer treatment for metastatic disease (ITT population)

| Parameter                                                                       | TAS-102 (N=337)   | Placebo (N=170)   | Total (N=507)   |
|---------------------------------------------------------------------------------|-------------------|-------------------|-----------------|
| Number of Prior Regimens for Metastatic Cancer n (%)                            |                   |                   |                 |
| 1                                                                               | 13 (3.9)          | 2 (1.2)           | 15 (3.0)        |
| 2                                                                               | 151 (44.8)        | 81 (47.6)         | 232 (45.8)      |
| 3                                                                               | 120 (35.6)        | 62 (36.5)         | 182 (35.9)      |
| ≥4                                                                              | 53 (15.7)         | 25 (14.7)         | 78 (15.4)       |
| Prior Systemic Cancer Therapeutic Agents to Treat Metastatic Cancer [1l , n (%) |                   |                   |                 |
| Yes                                                                             | 337 (100.0)       | 170 (100.0)       | 507 (100.0)     |
| Fluoropyrimidine [3]                                                            | 327 (97.0)        | 163 (95.9)        | 490 (96.6)      |
| Platinum [4]                                                                    | 317 (94.1)        | 160 (94.1)        | 477 (94.1)      |
| Taxane [5]                                                                      | 306 (90.8)        | 146 (85.9)        | 452 (89.2)      |
| Irinotecan [6]                                                                  | 183 (54.3)        | 98 (57.6)         | 281 (55.4)      |
| HER2i [8]                                                                       | 59 (17.5)         | 23 (13.5)         | 82 (16.2)       |
| Immunotherapy (PD1/PDL1) [7]                                                    | 25 (7.4)          | 7 (4.1)           | 32 (6.3)        |
| Other                                                                           | 76 (22.6)         | 38 (22.4)         | 114 (22.5)      |

[1]Patientswithmultiplelevelsarecountedineach applicablecategory.[2]Includesall priorsystemictherapies(Neoadjuvant,Adjuvant,Metastatic).

[3]Fluoropyrimidine includes5-FU(Fluorouracil),Capecitabine,Doxifluridine,S-1,Tegafur and UFT andsome agents that werecollected as'Other' andre-mapped latertoFluoropyrimidine.

[4]PlatinumincludesOxaliplatin,Cisplation,Carboplatinandsomeagentsthatwerecollectedas'Other'andre-mappedlatertoPlatinum.

[5]Taxane includes Docetaxel, Paxlitaxel, Nub-Paclitaxel (abraxane), and same agents that were collected as =Other| and re-mapped later to Taxane.

[6]Irinotecan includesIrinotecan and CPT-11, and same agents that were collected as=Other| andre-mapped latertoIrinotecan.

[7] Immunotherapy includes all PD1/PDL1 agents.[8] HER2i includes Trastuzumab,Pertuzumab and TDM-1. Data Source: ADSL, ADCM

All patients in both treatment arms had received ≥2 prior systemic treatment regimens. The percentage of patients that had received ≥2 prior treatment regimens for metastatic disease was 96.1% in the TAS-102 arm vs. 98.8% in the placebo arm. The median number of prior treatment regimens for metastatic disease was 3 (range 1-9) vs. 3 (range 1-5), respectively. Nearly all patients in both circumstances had received prior fluoropyrimidine and prior platinum, and approximately 90% had received prior taxane therapy. Over half of patients (in both circumstances) had received prior irinotecan.

The most frequently reported most recent regimens prior to randomization for the ITT population were taxane (48.7%), fluoropyrimidine (32.3%), irinotecan (32.9%), and platinum (20.3%). Most patients were refractory to their last regimen prior to randomization, i.e. 85.4% - 98.2% across these regimens.

## Prior and concomitant other medication

Other prior medication use was reported by 85.1% of patients in the TAS-102 group and 86.9% in the placebo group. The most frequently reported prior medications (≥20%) were in the WHO ATC Level III categories of drugs for peptic ulcer and gastroesophageal reflux disease (49.3%), opioids (25.2%), and antithrombotic agents (21.1%).

Concomitant medication use was reported by 90.1% of patients in the TAS-102 group and 84.5% in the placebo group. The most frequently reported concomitant medications (≥20%) were in the WHO ATC Level III categories of opioids (31.0%), drugs for peptic ulcer and gastroesophageal reflux disease (28.8%), other analgesics and antipyretics (21.1%), and propulsives (20.1%)

The use of any supportive blood product and/or growth factor was reported for 30.7% of patients in the TAS-102 and 7.1% in the placebo group. In the TAS-102 and placebo groups, respectively, supportive products  for  neutropenia  were  reported  for  17.3%  and  1.8%  of  patients,  supportive  products  for thrombocytopenia were reported for 0.9% and 0%, and supportive products for anaemia were reported for 18.2% and 5.4%.

<div style=\"page-break-after: always\"></div>

## Post-discontinuation anti-cancer treatment

Per protocol, there was no unblinding at the time of disease progression. The use of post-discontinuation anti-cancer therapy (PDT) was not specified per protocol. PDT for the ITT population is shown below in Table 12. PDT included amongst others ramucirumab, immunotherapy (including nivolumab), irinotecan, and paclitaxel. The proportion of patients receiving systemic PDT was similar between arms (24.6% vs. 26.5%), as  were  the  proportions  of  patients  for  whom  PDT  included  ramucirumab  (3.3%  vs.  2.4%)  or immunotherapy (4.5% vs. 4.7%).

Table 12. Post-discontinuation anti-cancer treatment (ITT population)

| Treatment, n (%)                     | TAS-102 N = 337   | Placebo N = 170   |
|--------------------------------------|-------------------|-------------------|
| Surgery                              | 47 (13.9)         | 28 (16.5)         |
| Radiotherapy                         | 8 (2.4)           | 5 (2.9)           |
| Any systemic Therapy                 | 83 (24.6)         | 45 (26.5)         |
| Number of regimens:                  |                   |                   |
| 1                                    | 53 (15.7)         | 25 (14.7)         |
| 2                                    | 16 (4.7)          | 7 (4.1)           |
| ≥3                                   | 14 (4.2)          | 13 (7.6)          |
| Any regimen containing ramucirumab   | 11 (3.3)          | 4 (2.4)           |
| Any regimen containing immunotherapy | 15 (4.5)          | 8 (4.7)           |

Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = number of patients in arm; n = number of patients in group

## Numbers analysed

The analysis populations are shown below in Table 13. The ITT population, consisting of all randomized patients, was used for all primary and secondary analyses of efficacy except as otherwise specified.

Table 13 . Analysis populations

|                       | Number of patients/total number of patients randomized (%)   | Number of patients/total number of patients randomized (%)   | Number of patients/total number of patients randomized (%)   |
|-----------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Analysis population   | TAS-102                                                      | Placebo                                                      | Total                                                        |
| Intent-to-treat (ITT) | 337/337 (100)                                                | 170/170 (100)                                                | 507/507 (100)                                                |
| As-treated (AT)       | 335/337 (99.4)                                               | 168/170 (98.8)                                               | 503/507 (99.2)                                               |
| Tumour response (TR)  | 290/337 (86.1)                                               | 145/170 (85.3)                                               | 435/507 (85.8)                                               |

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

## Primary endpoint (overall survival [OS])

## Primary analysis

The planned interim analysis was performed at 220 death events (refer to section Ancillary analysis for results).  Neither  the  efficacy  nor  futility  boundaries  were  met  for  any  of  the  analyses  and  the  DMC recommended to continue the study until completion, per protocol.

Treatment with TAS-102 resulted in a statistically significant improvement in OS compared to placebo (Table 14 and Figure 3), with a HR of 0.69 (95% CI: 0.560, 0.855; 1-sided p=0.0003 (boundary for final analysis 1-sided alpha=0.0215); stratified log-rank test) corresponding to a 31% reduction in the risk of death in the TAS-102 group. The mOS was 5.7 months (95% CI: 4.8, 6.2) for the TAS-102 group vs. 3.6 months (95% CI: 3.1, 4.1) for the placebo group (∆ +2.1 months). The median duration of survival follow-up was 10.6 months for the TAS-102 group and 10.7 months for the placebo group.

Table 14. Summary of overall survival endpoint (ITT population)

|                                  | TAS-102 N = 337     | Placebo N = 170     |
|----------------------------------|---------------------|---------------------|
| Number of events (deaths), n (%) | 244 (72.4)          | 140 (82.4)          |
| Censored                         | 93 (27.6)           | 30 (17.6)           |
| Overall survival                 |                     |                     |
| Median, months                   | 5.7                 | 3.6                 |
| 95% CI, months                   | 4.8, 6.2            | 3.1, 4.1            |
| Hazard ratio                     | 0.69 (0.560, 0.855) | 0.69 (0.560, 0.855) |
| 1-sided p-value a                | 0.0003              | 0.0003              |
| 2-sided p-value                  | 0.0006              | 0.0006              |
| Survival at 3 months, %(95% CI)  | 72.4 (67.3, 76.9]   | 60.3 (52.4, 67.2)   |
| Survival at 6 months, %(95% CI)  | 46.7 (41.1, 52.2)   | 33.1 (25.9, 40.3)   |
| Survival at 9 months, %(95% CI)  | 30.3 (24.9, 35.8)   | 23.3 (16.8, 30.3)   |
| Survival at 12 months,% (95% CI) | 21.2 (16.1, 26.7)   | 13.0 (7.7, 19.8)    |

Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = number of patients in arm; n = number of patients in group a  boundary for final analysis 1-sided alpha = 0.0215

<div style=\"page-break-after: always\"></div>

Figure 3. Kaplan-Meier curve of overall survival (ITT population)

<!-- image -->

## Sensitivity analyses

The following sensitivity analyses were performed for OS:

- -Analysis 1: Non-stratified log-rank test (that is, only treatment effect in the model) for the ITT population.
- -Analysis 2: ITT population excluding patients not meeting inclusion criteria #2 or #3 (see section Study participants above).
- -Analysis 3: ITT population excluding patients with major protocol deviations.
- -Analysis 4: Based on CRF-designated stratification factors for the AT population.
- -Analysis 5: By treatment group for the AT population.
- -Analysis 6: Excluding sites with high accrual.
- -Analysis 7: Using the date of all collected events (deaths) and survival status as of 30-Apr-2018.

An overview of the results of these analyses is provided below in Table 15.

Table 15. Sensitivity analyses of overall survival

| Analysis   | TAS-102   | TAS-102   | Placebo   | Placebo   | HR (95% CI)         | p-value a   |
|------------|-----------|-----------|-----------|-----------|---------------------|-------------|
| Analysis   | N         | mOS (m)   | N         | mOS (m)   | HR (95% CI)         | p-value a   |
| Analysis 1 | 337       | 5.7       | 170       | 3.6       | 0.71 (0.580, 0.880) | 0.0007      |
| Analysis 2 | 333       | 5.7       | 169       | 3.6       | 0.70 (0.567, 0.867) | 0.0005      |
| Analysis 3 | 330       | 5.7       | 169       | 3.6       | 0.70 (0.566, 0.866) | 0.0005      |
| Analysis 4 | 335       | 5.7       | 168       | 3.6       | 0.68 (0.554, 0.847) | 0.0002      |
| Analysis 5 | 335       | 5.7       | 168       | 3.6       | 0.69 (0.560, 0.856) | 0.0003      |
| Analysis 6 | 304       | 5.7       | 149       | 3.4       | 0.60 (0.475, 0.748) | <0.0001     |
| Analysis 7 | 337       | 5.6       | 170       | 3.6       | 0.71 (0.575, 0.873) | 0.0006      |

Abbreviations: CI = confidence interval; HR = hazard ratio; m = months; mOS = median overall survival; N = number of patients in arm

a  one-sided p-value

<div style=\"page-break-after: always\"></div>

Multivariate  analyses of potential prognostic factors for OS were performed. The factors included the stratification factors region, ECOG status at baseline, and prior treatment with ramucirumab, as well as age group (&lt;65 vs. ≥65 years), race, gender, number of prior regimens, prior treatment with a taxane, prior treatment with irinotecan, previous gastrectomy, gastroesophageal junction involvement, metastatic site (peritoneal, liver,  lung),  number of metastatic sites, measurable disease, histology subtype, and HER2 status at baseline. Stepwise selection was performed to identify the final subset of prognostic/predictive factors: treatment, region, ECOG status at baseline, prior treatment with ramucirumab, age group (&lt;65 vs. ≥65 years), number of prior regimens, number of metastatic sites, histology subtype, and HER2 status at baseline. In the resulting final Cox proportional hazard model, none of the listed factors were shown to modify the effect of treatment (all interaction p-values were &gt;0.24). The multivariate model estimate for the HR for  TAS-102  relative  to  placebo  remained  at  0.69  (95%  CI:  0.560,  0.851;  p  =  0.0005),  which  is consistent with the primary (bivariate and stratified) analysis of OS.

## Subgroup analyses

A forest plot summarizing the stratified subgroup analyses for OS in the ITT population is presented in Figure 1. The only subgroup analysis that is not included in this figure is the one for prior immunotherapy:

- -Yes: events/patients = 18/25 vs. 6/7; HR=0.22 (95% CI: 0.06, 0.86); mOS 6.0 vs. 3.5 months.
- -No: events/patients = 226/312 vs. 134/163; HR=0.71 (95% CI: 0.57, 0.88); mOS 5.7 vs. 3.6 months.

<div style=\"page-break-after: always\"></div>

Figure 4. Forest plot summarizing subgroup analyses of overall survival (ITT population)

| Subaroup                                                                                                                           | Events/Patients                                               | Events/Patients   | HR(95%IC)                                                                                                                             | Median (months) FTD/TPI Placebo   | Median (months) FTD/TPI Placebo   |
|------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|
| Sex Male                                                                                                                           | 282/369 102/138                                               |                   | 0.65 (0.50-0.83) 0.82 (0.53-1.27)                                                                                                     | 5.4 6.6                           | 3.5 3.8                           |
| Female Age (years) <65 65-<75                                                                                                      | 222/279 114/159 48/69 222/279                                 |                   | 0.67 (0.51-0.89) 0.75 0.50-1.13 0.67 0.33-1.37                                                                                        | 5.1 5.8 6.6 5.1 6.2               | 3.2 5.4 5.4 3.2 5.4               |
| >= 75                                                                                                                              |                                                               |                   |                                                                                                                                       |                                   |                                   |
| <65 >=65                                                                                                                           | 162/228                                                       |                   | 0.67(0.51-0.89) 0.73 (0.52-1.02)                                                                                                      |                                   |                                   |
| Ethnic origin White                                                                                                                | 265/357 69/80                                                 |                   | 0.77 (0.60->0.99) 0.77 (0.46-1.28)                                                                                                    | 5.3                               | 3.6 5.6                           |
| Asian                                                                                                                              | 50/70                                                         |                   | 0.37 (0.20-0.69)                                                                                                                      | 6.3 5.7                           | 2.5                               |
| Other                                                                                                                              | 63/73 211/277                                                 |                   | 0.77 (0.46-1.30) 0.68 0.54-0.85                                                                                                       |                                   | 5.9 3.3 3.2                       |
| Region Japan ROW1 Europe-EU[1] ROW2 USA ROW3 ECOGStatus atBaseline 0 1 PriortoRamucirumab                                          | 321/434 173/230 21/26 363/481 124/191 260/316 136/169 248/338 |                   | 0.59 0.44-0.78 0.83 0.60-1.14 0.73 (0.22-2.42                                                                                         | 6.3 5.4 5.5 6.0 4.4 5.7           | 4.9 3.4 3.6                       |
| Yes No Priorto lrinotecan Yes 224/281 No 160/226 Prior to Taxane Yes 351/459 No NumberofPriorRegimens 23 >=4 <24months >=24 months | 33/48 138/190 148/194 98/123 283/378 101/129 166/221          |                   | 0.68(0.55-0.85) 0.67 (0.47-0.97) 0.69 (0.53-0.89)                                                                                     | 7.4 4.6 5.0                       | 5.4 3.1 3.8 3.3                   |
| Timesincemetastasisdiagnosis                                                                                                       | 218/286                                                       |                   | 0.76 (0.53-1.09) 0.66 (0.51-0.85) 0.87 (0.66-1.15) 0.55 (0.39-0.76) 0.70 (0.45-1.09)                                                  | 6.0 5.1 6.1 5.7 7.8 6.8 4.3 6.0   | 3.6 3.3 3.6 5.4 3.2 3.4 3.8       |
| Previous gastrectomy Yes No Primary site [2] Gastroesophagealjunction Gastric Welldifferentiated Moderatelydifferentiated          | 117/145 265/360                                               |                   | 0.64 (0.51-0.80) 1.14 (0.55-2.35) 0.68 (0.47-0.97) 0.73(0.50-1.05) 0.69(0.54-0.89) 0.79 (0.50-1.25) 0.57 (0.41-0.79) 0.80 (0.60-1.06) | 5.5 6.0 6.0 5.6 4.8 6.0 5.7 6.2   | 3.4 4.8 3.4 3.8                   |
| TumorGrade Poorlydifferentiated                                                                                                    | 38/46 110/154 143/185                                         |                   | 0.75 (0.50-1.11) 0.67 (0.52-0.87) 1.20 (0.55-2.63) 0.54(0.36-0.81)                                                                    | 5.1 5.2                           | 3.5 3.6 5.8 3.6 4.0               |
| Unknown ormissing Peritonealmetastases Yes No                                                                                      | 93/122 111/140                                                |                   | 0.79 (0.56-1.13) 0.57 (0.36-0.89) 0.77 (0.51-1.15) 0.66 (0.51-0.86)                                                                   | 4.6 5.9 5.4                       | 2.1 3.1 3.6                       |
| Yes No 267/355                                                                                                                     | 273/367 215/284 169/223                                       |                   | 0.74 (0.59-0.93) 0.21 (0.09-0.52) 0.69 (0.36-1.31) 0.58 (0.39-0.87                                                                    | 6.2 4.9                           |                                   |
|                                                                                                                                    | 117/152                                                       |                   | 0.19 (0.05-0.77 0.78 (0.58-1.04)                                                                                                      | 5.5                               | 3.7                               |
| Yes No Numberofmetastaticsites 1-2                                                                                                 | 347/456 37/51 59/74 116/155                                   |                   |                                                                                                                                       | 7.2                               | 3.7                               |
| >=3 MeasurableDisease Yes No                                                                                                       | 18/22                                                         |                   |                                                                                                                                       |                                   |                                   |
| Histology type Diffused Intestinal Mixed                                                                                           | 191/256                                                       |                   |                                                                                                                                       | 4.4 7.1 6.0 5.2                   | 3.1 3.9 1.9                       |
| HER2Status                                                                                                                         |                                                               |                   |                                                                                                                                       |                                   |                                   |
| Positive                                                                                                                           | 70/94 245/313                                                 |                   | 0.76 (0.44-1.31) 0.62(0.48-0.82)                                                                                                      |                                   | 3.6                               |
| Negative                                                                                                                           | 68/99                                                         |                   | 0.73 (0.44-1.23)                                                                                                                      | 6.3                               |                                   |
| Notassessed                                                                                                                        |                                                               |                   |                                                                                                                                       | 5.2 5.6                           | 5.4 3.5 3.5                       |
| UnknownorN/A                                                                                                                       |                                                               |                   |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    |                                                               |                   | 3                                                                                                                                     |                                   |                                   |
| Lungmetastases                                                                                                                     |                                                               |                   |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    |                                                               |                   | 2                                                                                                                                     | 2                                 | 2                                 |
| Liver metastases                                                                                                                   |                                                               |                   |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    | 0 Favors TAS-102                                              |                   |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    | 0.5 1                                                         |                   |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    |                                                               | 1.5 HR (95%CI)    |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    |                                                               | FavorsPlacebo     |                                                                                                                                       |                                   |                                   |
|                                                                                                                                    |                                                               | 2.5               |                                                                                                                                       |                                   |                                   |
| 224/280                                                                                                                            |                                                               |                   | 0.71 (0.54-0.94)                                                                                                                      | 5.0                               | 4.8 3.4                           |
|                                                                                                                                    |                                                               |                   |                                                                                                                                       |                                   | 2.8                               |
| 160/227                                                                                                                            |                                                               |                   | 0.68 (0.49-0.96)                                                                                                                      |                                   | 3.8                               |
|                                                                                                                                    |                                                               |                   | 0.70 (0.53-0.94) 0.71(0.51-0.99) 0.62 (0.41-0.93) 0.70 (0.54-0.90)                                                                    | 5.9 7.0                           | 3.4                               |
|                                                                                                                                    |                                                               |                   |                                                                                                                                       |                                   | 3.4                               |

[1]Europe-EUreferstocountriesmembersof theEuropeanUnion.

[2]Twopatientshadprimarylesionsatbothsites;thissubgroupwasnot analyzed for Osdue toinsufficientsize.

Abbreviations: ECOG PS = Eastern Cooperative Oncology Group Performance Status; FTD/TPI = TAS-102; HER 2 = human epidermal growth factor receptor 2; HR = hazard ratio; ROW = rest of world; USA = United States of America

<div style=\"page-break-after: always\"></div>

## Secondary endpoints

## Progression-free survival (PFS)

Treatment with TAS-102 resulted in a statistically significant improvement in PFS compared to placebo (Table 16 and Figure 5), with a HR of 0.57 (95% CI: 0.467, 0.701; p&lt;0.0001 [2-sided]; stratified log-rank test), corresponding to a 43% reduction in the risk of disease progression in the TAS-102 group. The mPFS was 2.0 months (95% CI: 1.9, 2.3) for the TAS-102 group vs. 1.8 months (95% CI: 1.7, 1.9) for the placebo group (∆ +0.2 months).

Table 16. Summary of progression-free survival endpoint (ITT population)

|                                            | TAS-102 N = 337     | Placebo N = 170     |
|--------------------------------------------|---------------------|---------------------|
| Number of events, n (%)                    |                     |                     |
| Progression                                | 209 (62.0)          | 113 (66.5)          |
| Death                                      | 78 (23.1)           | 43 (25.3)           |
| Censored                                   | 50 (14.8)           | 14 (8.2)            |
| Discontinued follow-up                     | 12 (3.6)            | 1 (0.6)             |
| Initiated antitumor therapy                | 8 (2.4)             | 6 (3.5)             |
| Missed visit (>91 days since last contact) | 10 (3.0)            | 3 (1.8)             |
| Follow-up ongoing                          | 20 (5.9)            | 4 (2.4)             |
| Progression-free survival                  |                     |                     |
| Median, months                             | 2.0                 | 1.8                 |
| 95% CI, months                             | 1.9, 2.3            | 1.7, 1.9            |
| Hazard ratio (95% CI)                      | 0.57 (0.467, 0.701) | 0.57 (0.467, 0.701) |
| 2-sided p-value                            | <0.0001             |                     |
| PFS at 2 months, %(95% CI)                 | 49.7 (44.1, 55.1)   | 25.3 (18.9, 32.1)   |
| PFS at 4 months, %(95% CI)                 | 26.8 (21.9, 31.9)   | 7.7 (4.2, 12.5)     |
| PFS at 6 months, %(95% CI)                 | 14.6 (10.7, 19.0)   | 6.4 (3.2, 10.9)     |
| PFS at 8 months, %(95% CI)                 | 9.4 (6.2, 13.3)     | 2.8 (0.8, 6.8)      |

Abbreviations:  ITT  =  intent-to-treat;  CI  =  confidence  interval;  N  =  number  of  patients  in  arm; n = number of patients in group; PFS = progression-free survival

<div style=\"page-break-after: always\"></div>

Figure 5. Kaplan-Meier curve of progression-free survival (ITT population)

<!-- image -->

The following sensitivity analyses were performed for PFS:

- -Analysis 1: Including clinical progression as a progression event.
- -Analysis 2: Including clinical progression and initiation of new antitumor therapy as progression events.
- -Analysis  3: Including  clinical  progression,  initiation  of  new  antitumor  therapy,  and  all  deaths without censoring missed visits.
- -Analysis 4: Excluding sites with high accrual.
- -Analysis 5: Analysis of time to first, second and third radiological tumour assessments from the date of randomization.

An overview of the results of the first four of these analyses is provided below in Table 17. The results of Analysis 5 are not shown, but these confirmed that the assessments were performed to schedule and that timing was similar among the two arms.

Table 17. Sensitivity analyses of progression-free survival

| Analysis   | TAS-102 arm   | TAS-102 arm   | Control arm   | Control arm   | HR (95% CI)         | p-value a   |
|------------|---------------|---------------|---------------|---------------|---------------------|-------------|
|            | N             | mPFS (m)      | N             | mPFS (m)      |                     |             |
| Analysis 1 | 337           | 1.9           | 170           | 1.8           | 0.55 (0.452, 0.674) | <0.0001     |
| Analysis 2 | 337           | 1.9           | 170           | 1.8           | 0.55 (0.454, 0.675) | <0.0001     |
| Analysis 3 | 337           | 1.9           | 170           | 1.8           | 0.56 (0.460, 0.681) | <0.0001     |
| Analysis 4 | 304           | 1.9           | 149           | 1.8           | 0.48 (0.382, 0.593) | <0.0001     |

Abbreviations: CI = confidence interval; HR = hazard ratio; m = months; mPFS = median progression-free survival; N = number of patients in arm

a  two-sided p-value

A forest plot summarizing the stratified subgroup analyses for PFS in the ITT population is presented in Figure 6 (alternatively see page 11 of Supplementary appendix of Shitara, 2018). Again, the only subgroup analysis that is not included in this figure is the one for prior immunotherapy:

<div style=\"page-break-after: always\"></div>

- -Yes: events/patients = 22/25 vs. 7/7; HR= 0.4782 ( (95% CI: 0.1413, 1.6184); mPFS 2.4 vs. 1.9 months.
- -No: events/patients = 265/312 vs. 149/163 ; HR= 0.5774 (95% CI: 0.4690, 0.7110); mPFS 2.0 vs. 1.8 months.

Figure 6. Forest  plot  summarizing  subgroup  analyses  of  progression-free  survival  (ITT population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Subgroup Hitology subtype   | Favors TAS-102 Favors Placebo   | Subjects with Events,Total Subjects, Hazard Ratio[95%CI], Median(TAS-102/PBO)   |
|-----------------------------|---------------------------------|---------------------------------------------------------------------------------|
| Diffved                     |                                 | 64,74,0.3147[0.1574,0.6292] 2.1/1.7                                             |
| Intestinal                  | 137,155,0.4490                  | [0.3007,0.6702] 2.1/1.8                                                         |
| Mixed                       | 18, 22, 0.3927                  | [0.1221,1.2631] 2.1/1.8                                                         |
| UnknownorN/A                | 224,256,0.7236                  | [0.5478,0.9559] 1.9/1.8                                                         |
| HER2status                  |                                 |                                                                                 |
| Positive                    | 84,94,0.4695                    | [0.2764,0.7975] 2.3/1.7                                                         |
| Negative                    |                                 | 273,313,0.5353 [0.4107,0.6975] 1.9/1.8                                          |
| NotDone                     |                                 | 85,99,0.9099 [0.5712,1.4493] 3.7/1.9                                            |

[1] Europe - EU refers to countries members of the European Union.

## Tumour response (ORR and DCR)

As shown is Table 18, the ORR (CR + PR) was numerically higher for the TAS-102 arm when compared to the placebo arm (4.5% vs. 2.1%, respectively; ∆ +2.4% [95% CI: -0.9, 5.7]; p=0.2833). The median duration of response (DoR) was 3.7 months for the 13 responders in the TAS-102 group vs. 3.8 months for the 3 responders in the placebo group (p=0.4506 [1-sided]).

A statistically significant improvement was observed in the DCR (CR + PR + SD) for the TAS-102 arm when compared to the placebo arm (44.1% vs. 14.5%, respectively; ∆ +29.7% [95% CI: 21.6, 37.7], p&lt;0.0001).

## Table 18. Summary of tumour response (TR Population)

|                              | TAS-102 N = 290   | Placebo N = 145   |
|------------------------------|-------------------|-------------------|
| Best overall response, n (%) |                   |                   |
| Complete response (CR)       | 1 (0.3)           | 0                 |
| Partial response (PR)        | 12 (4.1)          | 3 (2.1)           |
| Stable disease (SD)          | 115 (39.7)        | 18 (12.4)         |
| Progressive disease (PD)     | 120 (41.4)        | 90 (62.1)         |
| Not evaluable                | 42 (14.5)         | 34 (23.4)         |
| Objective response rate,%    | 4.5               | 2.1               |
| 95% CI                       | 2.4, 7.5          | 0.4, 5.9          |
| p-value c                    | 0.2833            | 0.2833            |
| Disease control rate,%       | 44.1              | 14.5              |
| 95% CI                       | 38.3, 50.1        | 9.2, 21.3         |
| p-value c                    | <0.0001           | <0.0001           |

<div style=\"page-break-after: always\"></div>

Placebo

N = 145

Abbreviations: CI = confidence interval; N = number of patients in arm; n = number of patients in group; TR = tumour response c Fisher's exact test (2-sided)

## Time to deterioration to ECOG PS ≥2

In the ITT population, treatment with TAS-102 resulted in a statistically significant increase in the median time to deterioration to ECOG PS ≥2 compared to placebo (HR=0.69; 95% CI: 0.562, 0.854; p=0.0005 [2-sided]). The median time to deterioration to ECOG PS ≥2 was 4.3 months (95% CI: 3.7, 4.7) in the TAS-102 arm vs. 2.3 months (95% CI: 2.0, 2.8) in the placebo arm.

A sensitivity analysis was performed, using only on therapy ECOG assessments for analysis, i.e. excluding deaths during the survival follow-up period. For this analysis, 214/337 patients (63.5%) in the TAS-102 arm were censored and 90/170 patients (52.9%) in the placebo arm. The median time to ECOG PS ≥2 was 5.5 months in the TAS-102 arm (95% CI: 4.4, 6.9) vs. 2.2 months (95% CI: 1.9, 3.0) in the placebo arm (HR=0.54; 95% CI: 0.404, 0.721; p&lt;0.0001 [2-sided]).

## Time to deterioration of quality of life

Quality of life ( QoL ) was assessed using the EORTC QLQ-C30 and QLQ-STO22. Table 19 shows a summary of the absolute values and change from baseline in QoL scales for the ITT population. It can be seen that QoL was balanced at baseline, and that there were no (mean/median) changes ≥10 points in overall QoL from baseline up to cycle 3 in either treatment group. The number (and percentage) of patients completing the questionnaires decreased with each cycle, as the compliance (for the EORTC QLQ-C30 - global health status) was at cycle 1, 84.9% in the TAS-102 arm vs. 78.7% in the placebo arm, at cycle 2, 57.8% vs. 36%, and at cycle 3, 37.3% vs. 14%, respectively. Conversely, at cycle 3, in the TAS-102 arm 209/330 (63.3%) of EORTC QLQ-C30 - global health status values was missing vs. 140/163 (85.9%) in the placebo arm, and these percentages increased further thereafter.

<div style=\"page-break-after: always\"></div>

Table 19. Summary  of  absolute  values  and  change  from  baseline  in  QoL  scales  (ITT population)

| Parameter                     | TAS-102      | Placebo (N=170)   | Total        |
|-------------------------------|--------------|-------------------|--------------|
| Cycle/Day                     | (N=337)      |                   | (N=507)      |
| Statistics                    | n (%)        | n (%)             | n (%)        |
| QLQ-C30 -Global Health Status |              |                   |              |
| Baseline                      |              |                   |              |
| n                             | 330          | 163               | 493          |
| Mean (SD)                     | 58.4 (20.23) | 58.4 (19.72)      | 58.4 (20.04) |
| Median                        | 58.3         | 58.3              | 58.3         |
| Min, Max                      | 0,100        | 17,100            | 0,100        |
| Cycle 1                       |              |                   |              |
| n                             | 279          | 127               | 406          |
| Mean (SD)                     | 56.0 (20.67) | 54.3 (23.54)      | 55.5 (21.59) |
| Median                        | 58.3         | 50.0              | 50.0         |
| Min, Max                      | 0,100        | 0,100             | 0,100        |
| Cycle 1 Change from Baseline  |              |                   |              |
|                               | 279          | 127               | 406          |
| Mean (SD)                     | -2.7 (17.56) | -5.9 (22.20)      | -3.7 (19.17) |
| Median                        | 0.0          | 0.0               | 0.0          |
| Min, Max                      | -100,42      | -67,42            | -100, 42     |
| Cycle 2                       |              |                   |              |
| n                             | 187          | 58                | 245          |
| Mean (SD)                     | 54.1 (21.16) | 54.9 (21.06)      | 54.3 (21.09) |
| Median                        | 50.0         | 50.0              | 50.0         |
| Min, Max                      | 0,100        | 17,100            | 0,100        |
| Cycle 2 Change from Baseline  |              |                   |              |
| n                             | 187          | 58                | 245          |
| Mean (SD)                     | -5.9 (20.51) | -7.3 (25.80)      | -6.3 (21.83) |
| Median                        | 0.0          | 0.0               | 0.0          |
| Min, Max                      | -83, 58      | -83,50            | -83, 58      |
| Cycle 3                       |              |                   |              |
| n                             | 121          | 23                | 144          |
| Mean (SD)                     | 57.1 (20.74) | 59.8 (18.74)      | 57.5 (20.40) |
| Median                        | 50.0         | 66.7              | 58.3         |
| Min, Max                      | 0,100        | 17,100            | 0,100        |
| Cycle 3 Change from Baseline  |              |                   |              |
| n                             | 121          | 23                | 144          |
| Mean (SD)                     | -4.1 (18.26) | -1.4 (22.00)      | -3.6 (18.85) |
| Median                        | 0.0          | 0.0               | 0.0          |
| Min, Max                      | -67, 58      | -50, 42           | -67, 58      |

No statistically significant differences in the time to deterioration of QoL scores between TAS-102 and placebo groups were observed. Treatment with TAS-102 resulted in a numerically longer median time to deterioration by ≥5 points in global health status using the QoL questionnaires compared to placebo. The median time to deterioration was 2.6 months (95% CI: 2.3, 3.3) in the TAS-102 arm (N=288 for this analysis) vs. 2.3 months (95% CI: 1.4, not available [NA]) in the placebo arm (N=130) (HR=1.27; 95% CI: 0.854, 1.875; p=0.2350 [2-sided]). A sensitivity analysis using a decrease of ≥10 (and with the same patient numbers in both treatment arms) showed similar results, as the median time to deterioration was 5.6 months (95% CI: 3.8, NA) in the TAS-102 arm (N=288) vs. 4.6 months (95% CI: 2.2, NA) in the placebo arm (N=130; HR=0.97; 95% CI: 0.635, 1.470; p=0.8709 [2-sided]).

## Ancillary analyses

The interim analysis (see section Statistical methods above) was performed based on 220 events (deaths) reported as of 31-Aug-2017 and the associated efficacy boundary suggested to the DMC was a 1-sided p-value of 0.0031 and the associated futility boundary was OS HR ≥0.95. The observed HR, based on 200 events, was 0.7321 (95% CI: 0.5540, 0.9676; 1-sided p-value 0.0138). The associated mOS was 5.7 months for the TAS-102 group and 3.8 months for the placebo group. An additional sensitivity analysis was presented based on all events (deaths) reported as of the date of the 192 nd  death (194 deaths were reported

<div style=\"page-break-after: always\"></div>

as of that date). The corresponding efficacy boundary for the sensitivity analysis was 1-sided p-value of 0.0016.  Neither  the  efficacy  nor  futility  boundaries  were  met  for  any  of  the  analyses  and  the  DMC recommended to continue the study until completion, per protocol. Considering the alpha-spending that took place for the interim analysis, the associated efficacy boundary for the final analysis (assuming 384 events as planned) is 1-sided p-value of 0.0215.

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit-risk assessment (see later sections).

Table 20. Summary of efficacy for study TAS-102-302 (TAGS)

| Title: Randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments   | Title: Randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments   | Title: Randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments   | Title: Randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                         | TAS-102-302; NCT02500043; EudraCT Number: 2015-002683-16                                                                                                                                                 | TAS-102-302; NCT02500043; EudraCT Number: 2015-002683-16                                                                                                                                                 | TAS-102-302; NCT02500043; EudraCT Number: 2015-002683-16                                                                                                                                                                                       |
| Design                                                                                                                                                                                                   | Global, multicentre, randomized (2;1), parallel, double-blind, placebo-controlled                                                                                                                        | Global, multicentre, randomized (2;1), parallel, double-blind, placebo-controlled                                                                                                                        | Global, multicentre, randomized (2;1), parallel, double-blind, placebo-controlled                                                                                                                                                              |
| Design                                                                                                                                                                                                   | Date first patient was randomized: Date last patient was randomized: Duration of treatment:                                                                                                              | Date first patient was randomized: Date last patient was randomized: Duration of treatment:                                                                                                              | 24-Feb-2016 05-Jan-2018 Patients were treated until there was evidence of disease progression, unacceptable toxicity, one of the other discontinuation criteria was met or until completion of the primary endpoint, whichever occurred first. |
| Hypothesis                                                                                                                                                                                               | Superiority                                                                                                                                                                                              | Superiority                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                        | TAS-102                                                                                                                                                                                                  | TAS-102                                                                                                                                                                                                  | TAS-102 35 mg/m2 twice daily per os on days 1-5 and 8-12 of 28-day cycles + best supportive care (BSC) N = 337 (intention-to-treat [ITT] population)                                                                                           |
| Treatments groups                                                                                                                                                                                        | Placebo                                                                                                                                                                                                  | Placebo                                                                                                                                                                                                  | Placebo tablets twice daily per os on days 1-5 and 8-12 of 28-day cycles + BSC N = 170 (intention-to-treat [ITT] population)                                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                | Primary endpoint                                                                                                                                                                                         | Overall survival ( OS )                                                                                                                                                                                  | Time from the date of randomization to the date of death due to any cause                                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                                | Key secondary endpoint                                                                                                                                                                                   | Progression-free survival ( PFS )                                                                                                                                                                        | Time from the date of randomization until the first date of investigator-assessed radiological disease progression or death due to any cause                                                                                                   |
| Endpoints and definitions                                                                                                                                                                                | Other secondary endpoint                                                                                                                                                                                 | Objective response rate ( ORR )                                                                                                                                                                          | Proportion of patients with an investigator-assessed complete response (CR) or partial response (PR)                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                                | Other secondary endpoint                                                                                                                                                                                 | Disease control rate ( DCR )                                                                                                                                                                             | Proportion of patients with an investigator-assessed CR, PR or stable disease (SD)                                                                                                                                                             |
| Endpoints and definitions                                                                                                                                                                                | Other secondary endpoint                                                                                                                                                                                 | Time to deterioration to Eastern cooperative oncology group performance status ( ECOG PS ) ≥2                                                                                                            | Time from randomization until the first date on which an ECOG PS ≥2 was observed                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                 | Other secondary endpoint                                                                                                                                                    | Time to deterioration of quality of life ( QoL by ≥5 points                                                                                                                 | Time from randomization until the first date on which a deterioration of QoL by ≥5 points in global health status was observed, as measured using the European organisation for research and treatment of cancer QoL questionnaire - core 30 (EORTC QLQ-C30) and QoL questionnaire - gastric cancer-specific module (QLQ-STO22)   |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Database lock                                   | The target number of events, i.e. 384 deaths, was reached on 27-Mar-2018, which is thus the OS data cut-off date. The cut-off date for all other (non-OS) clinical data was | The target number of events, i.e. 384 deaths, was reached on 27-Mar-2018, which is thus the OS data cut-off date. The cut-off date for all other (non-OS) clinical data was | The target number of events, i.e. 384 deaths, was reached on 27-Mar-2018, which is thus the OS data cut-off date. The cut-off date for all other (non-OS) clinical data was                                                                                                                                                       |
| Results and Analysis                            | Results and Analysis                                                                                                                                                        | Results and Analysis                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                                                                                                              |
| Analysis description                            | Primary Analysis                                                                                                                                                            | Primary Analysis                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                                                                                                                  |
| Analysis population and time point description  | ITT population Data cut-off date for OS 27-Mar-2018 Data cut-off date for all other (non-OS) clinical data 31-Mar-2018                                                      | ITT population Data cut-off date for OS 27-Mar-2018 Data cut-off date for all other (non-OS) clinical data 31-Mar-2018                                                      | ITT population Data cut-off date for OS 27-Mar-2018 Data cut-off date for all other (non-OS) clinical data 31-Mar-2018                                                                                                                                                                                                            |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                             | TAS-102                                                                                                                                                                     | Placebo                                                                                                                                                                                                                                                                                                                           |
| Descriptive statistics and estimate variability | Number of subject                                                                                                                                                           | 337                                                                                                                                                                         | 170                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Median OS (months) 95% confidence                                                                                                                                           | 5.7                                                                                                                                                                         | 3.6                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | interval (CI)                                                                                                                                                               | 4.8, 6.2                                                                                                                                                                    | 3.1, 4.1                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Median PFS (months)                                                                                                                                                         | 2.0                                                                                                                                                                         | 1.8                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                      | 1.9, 2.3                                                                                                                                                                    | 1.7, 1.9                                                                                                                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | ORR (%) 95% CI                                                                                                                                                              | 4.5 2.4, 7.5                                                                                                                                                                | 2.1 0.4, 5.9                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | DCR (%)                                                                                                                                                                     | 44.1                                                                                                                                                                        | 14.5                                                                                                                                                                                                                                                                                                                              |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                      | 38.3, 50.1                                                                                                                                                                  | 9.2, 21.3                                                                                                                                                                                                                                                                                                                         |
| Descriptive statistics and estimate variability | Median time to deterioration to ECOG PS ≥2 (months)                                                                                                                         | 4.3                                                                                                                                                                         | 2.3                                                                                                                                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                      |                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Median time to deterioration of QoL by ≥5 points (months)                                                                                                                   | 3.7, 4.7 2.6                                                                                                                                                                | 2.0, 2.8 2.3                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability | 95% CI                                                                                                                                                                      | 2.3, 3.3                                                                                                                                                                    | 1.4, NA                                                                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                  | OS                                                                                                                                                                          | Comparison groups Hazard ratio (HR) 95% CI                                                                                                                                  | TAS-102 vs. placebo 0.69 0.560, 0.855                                                                                                                                                                                                                                                                                             |
| Effect estimate per comparison                  | PFS                                                                                                                                                                         | P-value (1-sided) Comparison groups HR                                                                                                                                      | 0.0003 (efficacy boundary 0.0215) TAS-102 vs. placebo 0.57                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                  |                                                                                                                                                                             | 95% CI P-value (2-sided) Comparison groups                                                                                                                                  | 0.467, 0.701 <0.0001 TAS-102 vs. placebo +2.4 -0.9, 5.7                                                                                                                                                                                                                                                                           |
| Effect estimate per comparison                  | ORR                                                                                                                                                                         | Difference 95% CI                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                             | P-value (2-sided)                                                                                                                                                           | 0.2833                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                  | DCR                                                                                                                                                                         | Comparison groups Difference 95% CI                                                                                                                                         | TAS-102 vs. placebo +29.7 21.6, 37.7                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  | Time deterioration                                                                                                                                                          | P-value (2-sided)                                                                                                                                                           | <0.0001 TAS-102 vs. placebo                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                  |                                                                                                                                                                             | Comparison groups                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                             | HR                                                                                                                                                                          | 0.69                                                                                                                                                                                                                                                                                                                              |
| Effect estimate per comparison                  |                                                                                                                                                                             | to of                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                             |                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                   |
| Effect estimate per comparison                  |                                                                                                                                                                             |                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|       | ECOG PS ≥2                                                                                                                                                                                                                                                | 95% CI                                                                                                                                                                                                                                                    | 0.562, 0.854                                                                                                                                                                                                                                              |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       |                                                                                                                                                                                                                                                           | P-value (2-sided)                                                                                                                                                                                                                                         | 0.0005                                                                                                                                                                                                                                                    |
|       | Time to deterioration                                                                                                                                                                                                                                     | Comparison groups                                                                                                                                                                                                                                         | TAS-102 vs. placebo                                                                                                                                                                                                                                       |
|       | of                                                                                                                                                                                                                                                        | HR                                                                                                                                                                                                                                                        | 1.27                                                                                                                                                                                                                                                      |
|       | QoL by ≥5 points                                                                                                                                                                                                                                          | 95% CI                                                                                                                                                                                                                                                    | 0.854, 1.875                                                                                                                                                                                                                                              |
|       |                                                                                                                                                                                                                                                           | P-value (2-sided)                                                                                                                                                                                                                                         | 0.2350                                                                                                                                                                                                                                                    |
| Notes | For the other secondary endpoints ORR and DCR the tumour response (TR) population was used, comprised of 290 TAS-102-treated patients and 145 placebo-treated patients. For the other secondary endpoint time to deterioration of QoL the study arms were | For the other secondary endpoints ORR and DCR the tumour response (TR) population was used, comprised of 290 TAS-102-treated patients and 145 placebo-treated patients. For the other secondary endpoint time to deterioration of QoL the study arms were | For the other secondary endpoints ORR and DCR the tumour response (TR) population was used, comprised of 290 TAS-102-treated patients and 145 placebo-treated patients. For the other secondary endpoint time to deterioration of QoL the study arms were |

Abbreviations: NA = not available

## Clinical studies in special populations

The below table shows the number of elderly patients in the TAGS study, further specified per age category (i.e. age 65-74, age 75-84, and age 85+). Refer also to the forest plot of OS subgroup analyses (Figure 4).

|                       | Age 65-74 (older subjects number/total number)   | Age 75-84 (older subjects number/total number)   | Age 85+ (older subjects number/total number)   |
|-----------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------------------|
| Controlled trials     | 159 / 507 (31.4%)                                | 67 / 507 (13.2%)                                 | 2 / 507 (0.4%)                                 |
| Non-controlled trials | NA                                               | NA                                               | NA                                             |

Note: the only controlled trial was study TAS-102-302 (TAGS).

## Supportive study(ies)

No supportive study(ies) was/were submitted by the applicant.

## 2.4.3. Discussion on clinical efficacy

## Dose selection

The proposed TAS-102 starting dose in adult patients with mGC is 35 mg/m 2  administered BID PO on days 1 to 5 and days 8 to 12 of each 28-day cycle, which is to be continued as long as benefit is observed or until unacceptable toxicity occurs. This posology is identical to that previously accepted for treatment of adult patients with mCRC, in which the 35 mg/m 2  dose was selected based on tolerability in patients with mCRC and other solid tumours. Though the support of the dose in mGC patients is limited, especially with regard to efficacy, no apparent differences are observed with respect to safety between mCRC and mGC patients treated at the proposed dose.

## Design and conduct of clinical studies

Study design. The randomised, double-blind, placebo-controlled design that was used in the pivotal study TAS-102-302 is considered adequate to evaluate the benefits and risks of TAS-102 in patients with mGC refractory to standard treatments, i.e. in the third- and later-line treatment setting. The choice for OS as the primary  endpoint  of  the  pivotal  study  is  considered  appropriate.  Firstly,  as  convincingly  demonstrated favourable effects  on  OS  are  from  both  a  clinical  and  methodological  perspective  the  most  persuasive outcome of a clinical trial (EMA/CHMP/205/95 Rev.5). Secondly, it is considered appropriate specifically for this target patient population, considering the short life expectancy. The study design also included the key secondary endpoint PFS and the other secondary endpoints ORR and DCR. All these imaging endpoints were assessed by the investigators according to RECIST 1.1 criteria. No (blinded) central evaluation of imaging

<div style=\"page-break-after: always\"></div>

was performed. As OS  was the primary endpoint  and the effect  on  OS  will  be  most  important  in  the assessment of efficacy, this lack of central evaluation of imaging for the imaging endpoints is considered acceptable.

Various second-line treatment options are used sequentially in second- and third-line in clinical practice for the  small  proportion  of  GC  patients  that  is  eligible  for  third-line  treatment.  On  this  matter,  the  ESMO guidelines concur, but indicates caution that 'there is no clear evidence for a benefit beyond second-line treatment' (Smyth, 2016).

According to the study protocol, QoL assessments were performed prior to study treatment administration in each cycle. However, the applicant was not able to confirm that the QoL questionnaires were completed at the beginning of each visit, prior to any clinical activities (i.e. before any extensive contact and consultation with  study  site  personnel).  As  a  result,  the  patient  responses  may  have  been  biased,  as  e.g.  medical information could bias retrospective evaluation (EMA/CHMP/292464/2014).

Patient population. The inclusion and exclusion criteria for the pivotal study appear overall acceptable. The  patient  population  enrolled  in  study  TAS-102-302  appears  to  be  a  somewhat  selected  population compared to patients with mGC treated in clinical practice in the sense that patients had to have an ECOG PS ≤1.  Certainly  not  all  European  patients  with  mGC  after  first-line  systemic  treatment  are  expected  to demonstrate  a  score  ≤1,  whereas  over  one  third  of  enrolled  patients  even  had  a  score  of  0.  This  is adequately reflected by the current proposed text in the SmPC.

Statistical analysis. Analyses were performed as outlined in the SAP and were appropriate given the type of endpoints. The IA was performed at a slightly higher number of events than planned, but the efficacy boundary for the final analysis was adjusted accordingly.

It is noted that for the analysis of ORR and DCR the TR population was used instead of the ITT population. This  analysis  may  be  biased  as  it  only  included  patients  with  at  least  one  post-baseline  assessment. However, given the low number of responders (TAS-102: 13; placebo: 3) this issue is considered not worth pursuing.

For the endpoint time to deterioration of QoL, patients with no deterioration in the QoL scores were censored at death date. The applicant later provided the results of additional sensitivity analyses wherein death was included as an event, and the results of these analyses were consistent with the results of the original analyses.

## Efficacy data and additional analyses

The demographics and other baseline characteristics were in general reasonably well balanced between both treatment arms, and no particularities were observed. There were amongst others slightly more males, slightly more patients ≥75 years of age, slightly more white patients, and slightly more patients with an ECOG PS of 1 in the TAS-102 arm (n=337) when compared to the placebo arm (n=170). The number of enrolled patients from the EU was 277 (54.6% of the ITT population; 180 in the TAS-102 arm and 97 in the placebo arm). The region subgroup analyses for OS and PFS  were consistent.

The baseline disease characteristics were in general reasonably well balanced between both treatment arms as well. It is noted that over half of the enrolled patients' tumours had the histology subtype 'Unknown' or 'Not  applicable'.  Importantly,  the  efficacy  of  TAS-102  does  not  appear  to  differ  (much)  between  the histology subtypes 'Diffused', 'Intestinal', and 'Unknown or NA', see Figure 1 and Figure 6 above. The performed multivariate  sensitivity  analysis (for  OS)  in  which  adjustment  was  made  for  possible prognostic baseline factors, showed a result (HR) fully in line with the primary OS analysis. Therefore, the slight imbalances in possible prognostic baseline factors apparently did not have a relevant impact on the primary efficacy analysis.

<div style=\"page-break-after: always\"></div>

Of  the  ITT  population,  43.6%  had  undergone  a  prior  gastrectomy.  This  percentage  is  similar  to  the percentages reported in other recent studies in mGC that enrolled a mostly non-Asian patient population (Cyramza EPAR: 26.8% and 37.1%; Shitara, 2018: 36.8%).

Ramucirumab, an approved second-line treatment, had been used by only 33.3% of patients in the ITT population. However, ramucirumab treatment was a stratification factor, and similar proportions of patients in each treatment group had received it. Moreover, efficacy did not differ much between patients that did and patients that did not receive prior ramucirumab treatment.

Remarkably, the HER2 status at baseline was not known/available for almost one in five patients in the pivotal study (i.e. 19.5%). Furthermore, in spite of inclusion criterion #3 (sub. a.) not all patients with HER2+ tumours had received previous anti-HER2 therapy. Use of previous anti-HER2 therapy might not have been available to all patients or possible in some patients because of comorbid conditions (e.g., cardiac disease). Reasons for withholding anti-HER2 therapy were not gathered. The abovementioned multivariate sensitivity analysis did identify baseline HER2 status as a prognostic/predictive factor. As HER2+ status in GC may be associated with a worse prognosis (van Cutsem, 2016), and more patients in the TAS-102 arm than in the placebo arm were baseline HER2+, this factor  is unlikely to have positively influenced the TAS-102 efficacy results. Not surprisingly, prior anti-HER2 therapy was also more frequent in the TAS-102 arm, but efficacy did not seem to be dependent on baseline HER2 status.

Considering the demographics and other baseline (disease) characteristics, there are overall no critical issues  regarding  the  enrolled  patient  population,  which  appears  reasonably  representative  of  the to-be-treated patient population in clinical practice, apart from the remark made above on ECOG PS.

Primary endpoint - OS. The effect of TAS-102 on OS relative to placebo resulted a HR of 0.69 (95% CI: 0.560, 0.855,; p=0.0003), with mOS of 5.7 months for TAS-102 versus 3.6 months for placebo, reflecting an increase in mOS of 2.1 months. The results of all sensitivity analyses were consistent with this primary analysis of OS. Moreover, there were no notable differences between arms in terms of the proportion of patients receiving PDT and/or the type(s) of PDT received, which adds robustness to the study results.

In the subgroup analyses the OS HRs almost consistently favoured the TAS-102 group, e.g. the number of prior (systemic) treatment regimens and the primary tumour site (GEJ vs. gastric) had little effect on the HR point estimate.

The only two exceptions (of the 49 subgroups examined) were the subgroups of patients who had not received prior  taxane  therapy  and  the  subgroup  of  patients  with  well  differentiated  tumours.  For  both subgroups the number of patients was limited (&lt;10% of the ITT population) and the PFS HR did favour the TAS-102  arm,  which  speaks  in  favour  of  these  exceptions  likely  being  chance  findings.  Moreover,  an additional unstratified sensitivity analysis showed an OS HR of 0.99 (95% CI: 0.50, 1.97) in the subgroup of patients with no prior taxane use, and 0.98 (95% CI: 0.49, 1.95) in the patients with well differentiated tumours.

A (prior) gastrectomy could alter the PK and pharmacodynamics of orally administered chemotherapeutic agents such as TAS-102 (Shitara, 2018). Unfortunately, PK data were not recorded in this study. The PK of TAS-102 were assessed in the phase 2 EPOC1201 study and moreover compared between patients who had undergone a gastrectomy and those who had not (Bando, 2016). There were no significant differences in the peak serum drug concentration (Cmax), area under the plasma drug concentration-time curve (AUC), and/or time of peak serum drug concentration (Tmax) values for FTD and TPI at the 35 mg/m 2  BID dosage when three patients with and three patients without a prior gastrectomy were compared, and in another six patients (two with, four without prior gastrectomy) at the 40 mg/m 2  dose. Despite the fact that this PK data is obtained from a relatively small number of patients, data do not point at the existence of major differences in FTD and/or TPI PK between patients with or without a prior gastrectomy. The fact that no relevant pH dependence of FTD and/or TPI PK is known intuitively supports this assumption. Reassuring is that both in

<div style=\"page-break-after: always\"></div>

patients that did undergo a prior gastrectomy (HR=0.57; 95% CI: 0.41, 0.79) as well as in patients that did not (HR=0.80; 95% CI: 0.60, 1.06), the OS HR favoured the TAS-102 group. Also, the above-mentioned multivariate sensitivity analysis did not identify (no) prior gastrectomy as a prognostic/predictive factor, and the PFS HR in the 'no prior gastrectomy' subgroup did statistically significantly favour the TAS-102 arm.

Numerically a 2.1-month mOS benefit may seem rather limited, especially because the enrolled patient population appears to be a somewhat selected population compared to patients with mGC treated in clinical practice (which e.g. may be more frail with a higher ECOG PS and possibly with more comorbidity). On the other hand, in Europe there is currently no therapy with proven OS or other clinical benefit. Therefore, in combination with the overall  poor prognosis of mGC patients, the observed gain in mOS  is considered clinically relevant.

Key secondary endpoint - PFS. A statistically significant benefit was also shown for the key secondary endpoint PFS. Treatment with TAS-102 when compared to placebo resulted in a HR of 0.57 (95% CI: 0.467, 0.701; p&lt;0.0001), with mPFS of 2.0 months for TAS-102 versus 1.8 months for placebo, reflecting an increase in mPFS of 0.2 months. The results of all relevant sensitivity analyses were consistent with this primary analysis of PFS. Of note, as is stated above, the primary analysis of PFS was not in accordance with EMA guidance, but one of the sensitivity analyses was and it showed consistent results.

In the subgroup analyses the PFS HRs favoured the TAS-102 group across all subgroups examined.

The observed PFS result does provide support for the observed OS result.

Other  secondary  endpoints  -  ORR  and  DCR. The  ORR  was  numerically  (but  not  statistically significantly) higher in patients in the TAS-102 arm as compared to the placebo arm (4.5% vs. 2.1%, respectively, p=0.2833). Due to the many patients with SD in the TAS-102 arm, there was a statistically significant improvement in the DCR when compared to the placebo arm (44.1% vs. 14.5%, respectively; p&lt;0.0001). These results are in line with the OS data.

Other secondary endpoint - time to deterioration to ECOG PS ≥2. Treatment with TAS-102 resulted in a statistically significant increase in the median time to deterioration to ECOG PS ≥2 compared to placebo (HR=0.69;  95%  CI:  0.562,  0.854;  p=0.0005;  4.3  vs.  2.3  months,  respectively).  This  is  considered  a relevant outcome from the clinical point of view, supportive of the overall good tolerability and acceptable safety profile of TAS-102 in this clinical context.

Other secondary endpoint - time to deterioration of QoL. No statistically significant differences in the time to deterioration of QoL scores (by ≥5 or ≥10 points) between TAS-102 and placebo groups were observed. More importantly however, the QoL assessment was severely hampered by the rapidly declining compliance and (as a result) many missing values in both treatment arms, even though this is in part a reflection of the high rate of progression and therefore not unexpected. Therefore, no clear conclusions can be made on the basis of the QoL data submitted.

Special  populations. Paediatric  patients: The  EMA  confirmed  the  applicability  of  the  class  waiver  for TAS-102 in GC. No data in paediatric patients have thus been submitted. Elderly patients: the pivotal study included 228 (45.0%) patients ≥65 and 69 (13.6%) patients ≥75 years of age. The OS subgroup analyses showed that efficacy (i.e. the HR) was similar regardless of age category, see Figure 4.

## 2.4.4. Conclusions on the clinical efficacy

In the single pivotal study, TAS-102 treatment (n=337) conferred a statistically significant, and clinically relevant mOS benefit of 2.1 months over placebo (n=170; HR=0.69; 5.7 vs. 3.6 months; p=0.0003) in the third- or later-line mGC setting. This OS result was robust and supported by a statistically significant benefit in PFS (HR=0.57; 2.0 vs. 1.8 months; p&lt;0.0001), a trend in ORR (4.5% vs. 2.1%; p=0.2833), and a statistically significant benefit in DCR (44.1% vs. 14.5%; p&lt;0.0001). Therefore, in spite of this being an

<div style=\"page-break-after: always\"></div>

application based on a single pivotal study, the efficacy results are considered quite convincing. In addition, considering that there is currently no approved third- or later-line therapy for patients with mGC, and the non-approved therapies currently used in clinical practice are given without proof of OS benefit, the observed gain in mOS of 2.1 months is considered clinically relevant.

## 2.5. Clinical safety

## Introduction

The known adverse drug reactions (ADRs) observed for Lonsurf (TAS-102) at rates ≥1/10 are neutropenia, leukopenia, anaemia, thrombocytopenia, decreased appetite, diarrhoea, nausea, vomiting, and fatigue.

The safety data in the current application of TAS-102 for the treatment of mGC are derived from the pivotal study TAGS only. The respective study concerns a randomized, controlled, double-blind Phase 3 study in which the effects of TAS-102 plus best supportive care (hereafter: TAS-102) were compared with those of placebo plus best supportive care (hereafter: placebo) in patients with mGC who had received at least 2 prior regimens for advanced disease and who were refractory to or unable to tolerate their last prior therapy.

Standard safety monitoring was performed, and adverse events (AEs) were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Safety assessments also included the evaluation of laboratory test results, vital signs measurements, physical examination findings, and changes in ECOG PS score.

Below, collected safety data on TAS-102 in the TAGS study in mGC will be compared with the known safety profile of TAS-102 in the RECOURSE study in mCRC (Lonsurf mCRC EPAR). The safety data cut-off for TAGS was 31-Mar-2018 and for RECOURSE 31-Jan-2014.

## Patient exposure

Study data from TAGS are presented for the as-treated (AT) population, consisting of all patients who received at least one dose of study therapy. The AT population comprised of 503 patients, including 335 patients who received TAS-102 and 168 who received placebo.

The patient disposition at the safety data cut-off date is summarised below in Table 21. The majority of patients in both arms had discontinued treatment, as only 19 (5.7%) patients in the TAS-102 arm and 3 (1.8%) patients in the placebo arm were still on treatment. The most important reason for treatment discontinuation in both treatment groups was progression of disease (TAS-102 (73.0%), placebo (85.3%)). A  total  of  44  patients  (including  33  (9.9%)  in  the  TAS-102  arm  and  11  (6.5%)  in  the  placebo  arm) discontinued study treatment due to AEs.

Table 21 . Summary of patient disposition (ITT population)

| Parameter, n (%)              | TAS-102 N = 337   | Placebo N = 170   |
|-------------------------------|-------------------|-------------------|
| Patients Randomized           | 337 (100)         | 170 (100)         |
| Patients Treated              | 335 (99.4)        | 168 (98.8)        |
| On Treatment                  | 19 (5.7)          | 3 (1.8)           |
| Off Treatment                 | 316 (94.3)        | 165 (98.2)        |
| Due to Progression of Disease | 246 (73.0)        | 145 (85.3)        |
| Due to an Adverse Event       | 33 (9.9)          | 11 (6.5)          |
| Due to Withdrawal of Consent  | 14 (4.2)          | 4 (2.4)           |
| Due to Patient Death          | 11 (3.3)          | 2 (1.2)           |

<div style=\"page-break-after: always\"></div>

| Parameter, n (%)             | TAS-102 N = 337   | Placebo N = 170   |
|------------------------------|-------------------|-------------------|
| Due to Investigator Decision | 11 (3.3)          | 3 (1.8)           |
| Due to Protocol Violation    | 1 (0.3)           | 0                 |

Abbreviations: ITT = intent-to-treat; N = number of patients in arm; n = number of patients in group

a  Of the deaths in the TAS-102 arm, 2 were due to AEs and 9 to disease progression; in the control arm, both deaths were due to disease progression.

Overall, exposure to study treatment tended to be higher in the TAS-102 study arm (median: 6.71 weeks) compared to the placebo study arm (median: 5.71 weeks), see Table 22. The number of initiated cycles per study patient tended to be higher in TAS-102-treated study patients compared to placebo-treated study patients (mean 3.3 vs. 2.3 respectively).

Table 22. Summary of exposure by treatment group (AT Population)

|                                     | TAS-102 N = 335   | Placebo N = 168   |
|-------------------------------------|-------------------|-------------------|
| Total number of weeks of exposure a | 4038              | 1191              |
| Mean (SD)                           | 12.05 (11.47)     | 7.09 (7.84)       |
| Median                              | 6.71              | 5.71              |
| Min, Max                            | 0.4, 62.7         | 0.1, 63.0         |
| Cycles initiated per patient b      |                   |                   |
| Total cycles initiated              | 1108              | 394               |
| Mean (SD)                           | 3.3 (2.50)        | 2.3 (1.92)        |
| Median                              | 2.0               | 2.0               |
| Min, Max                            | 1,14              | 1,16              |
| Cycle initiated, n (%) b            |                   |                   |
| 1                                   | 335 (100)         | 168 (100)         |
| 2                                   | 282 (84.2)        | 125 (74.4)        |
| 3                                   | 145 (43.3)        | 33 (19.6)         |
| 4                                   | 116 (34.6)        | 18 (10.7)         |
| >4                                  | 65 (19.4)         | 15 (8.9)          |

Abbreviations: AT = as-treated; N = number of patients in arm; n = number of patients in group; SD = standard deviation

a  (Date of last dose of study medication - date of first dose of study medication +1) / 7

b  Patients counted in each cycle initiated (at least 1 dose administered)

Median  dose  intensity  was  156.72  mg/m 2 /week  for  TAS-102-treated  study  patients  and  166.15 mg/m 2 /week for placebo-treated study patients, see Table 23. Dose intensities of provided study treatments were close to the planned dose intensities (median relative dose intensity: 0.90 for TAS-102 vs. 0.95 for placebo). Over the entire treatment period, 95.8% (320/334) of patients in the TAS-102 group and 92.3% (155/168) of patients in the placebo group received ≥90% of their target cycle dose.

Table 23. Summary  of  cumulative  dose  and  dose  intensity  by  treatment  group  (AT Population)

|                                 | TAS-102 N = 335   | Placebo N = 168   |
|---------------------------------|-------------------|-------------------|
| Total dose administered, mg/m 2 |                   |                   |
| N                               | 334               | 168               |

<div style=\"page-break-after: always\"></div>

|                              | TAS-102 N = 335   | Placebo N = 168   |
|------------------------------|-------------------|-------------------|
| Mean (SD)                    | 2127.3 (1651.7)   | 1512.05 (1325.3)  |
| Median                       | 1387.5            | 1341.1            |
| Min, Max                     | 104.8, 9367.9     | 68.3, 10802.3     |
| Dose intensity, mg/m 2 /week |                   |                   |
| N                            | 334               | 168               |
| Mean (SD)                    | 148.2 (26.8)      | 155.0 (27.9)      |
| Median                       | 156.7             | 166.2             |
| Min, Max                     | 26.2, 177.5       | 17.1, 191.9       |
| Relative dose intensity a    |                   |                   |
| N                            | 334               | 168               |
| Mean (SD)                    | 0.85 (0.15)       | 0.89 (0.16)       |
| Median                       | 0.90              | 0.95              |
| Min, Max                     | 0.15, 1.01        | 0.10, 1.10        |

Abbreviations: AT = as-treated; Max = maximum; Min = minimum; N = number of patients in arm; n = number of patients in group; SD = standard deviation a  Ratio of actual dose intensity divided by planned dose intensity

The patients in the TAS-102 arm in the TAGS study had a similar exposure to TAS-102 when compared to the patients in the TAS-102 arm in the RECOURSE study. The median total number of weeks exposure was 6.71 weeks in both studies, and the median relative dose intensity was 0.90 in the TAGS study and 0.91 in the RECOURSE study.

## Demographic and other characteristics of the study population

Overall, baseline characteristics were balanced across different treatment groups in the TAGS study, see for ITT population Table 8. Similar baseline characteristics were observed for the AT population. For example, the majority of included study patients in respective study were men (TAS-102: 74.6%, placebo: 69%). Median age was 64 years in TAS-102 treated study patients and 62 years in placebo-treated study patients. More than 50% of study patients were included in Europe. Most included study patients in the TAGS study were Caucasians (TAS-102: 72.2%, placebo: 66.7%).

Overall, baseline disease characteristics of the TAS-102 and placebo treatment groups were comparable in the TAGS study (Table 9). Performance status at baseline according to the Eastern Cooperative Oncology Group (ECOG) was 1 in 63.3% of TAS-102-treated patients and 59.5% of placebo-treated patients. All other study patients in both treatment groups had an ECOG performance status of 0.

Hepatic function was normal in 74.3% of patients treated with TAS-102 and 78.6% of patients treated with placebo. However, a slightly higher proportion of patients in the TAS-102 arm had mild hepatic impairment at baseline compared to the control arm (25.1% vs. 19.6%).

Renal function at baseline was normal (i.e. creatinine clearance ≥90 ml/min) in 40.0% of patients treated with TAS-102 and in 40.5% of patients treated with placebo. Similar proportions of patients in the TAS-102 and placebo treatment groups had mild renal impairment (i.e. creatinine clearance 60-89 ml/min)(respectively 42.1% and 42.3%), and more severe renal impairment (moderate impairment (i.e. creatinine  clearance  30-59  ml/min)  respectively  17.3%  and  16.7%,  severe  impairment  (i.e.  creatinine clearance &lt;30 ml/min) 0.6% in both treatment groups).

<div style=\"page-break-after: always\"></div>

## Adverse events

## Definitions

Per protocol, treatment-emergent adverse events (TEAEs) are defined as AEs with onset following the first dose of study therapy (TAS-102 or placebo) and no more than 30 days after the last dose of study therapy. TEAE do not necessarily have a causal relationship to the use of study treatment. Any event considered 'possibly,'  'probably,'  or  'definitely'  related  to  study  therapy  by  the  investigator  will  be  collectively described as 'related'.

A  distinction  is  made  between  'AEs  with  an  outcome  of  death  /  discontinuation'  and  'deaths  / discontinuations due to AEs', specifically:

- 'AEs with an outcome of death / discontinuation' includes all AEs where the investigator-assigned outcome is 'death / discontinuation.' This may include events that were simply ongoing at the time of death, even if the event was not a cause of death and/or discontinuation. Note: 'AEs with an outcome of death' are synonymous with 'Grade 5 (fatal) events.'
- 'Deaths / discontinuations due to AEs' include all deaths / discontinuation where the primary cause of death or discontinuation was an AE according to the investigator.

## Overview of adverse events

In the TAGS study, 97.3% of patients in the TAS-102 arm experienced TEAEs compared to 93.5% of patients in the placebo arm (Table 24). Numerical proportions of treatment-related AEs were higher in the TAS-102 treatment arm (80.9%) than in the placebo treatment arm (56.6%) as well. Overall occurrence of serious adverse  events  (SAEs)  was  similar  for  respective  treatment  groups  (42.7%  vs.  41.7%).  However, occurrence of treatment-related SAEs tended to be higher among study patients treated with TAS-102 (11.6%) compared to those treated with placebo (3.6%).

Study treatment doses tended to be adjusted more frequently among TAS-102 treated patients (58.2%) compared to placebo treated patients (22.0%). AEs with outcome death were observed at similar rates in both treatment groups (TAS-102: 13.4%, placebo: 11.3%).

Table 24. Overview AEs in the TAGS and RECOURSE study (AT population)

|                                                  | TAGS (mGC) (N=503)   | TAGS (mGC) (N=503)   | RECOURSE (mCRC) (N= 798)   | RECOURSE (mCRC) (N= 798)   |
|--------------------------------------------------|----------------------|----------------------|----------------------------|----------------------------|
| Parameter, n (%)                                 | TAS-102 N = 335      | Placebo N = 168      | TAS-102 N = 533            | Placebo N = 265            |
| Any TEAE                                         | 326 (97.3)           | 157 (93.5)           | 524 (98.3)                 | 247 (93.2)                 |
| Any treatment-related a event                    | 271 (80.9)           | 95 (56.6)            | 457 (85.7)                 | 145 (54.7)                 |
| Any Grade ≥3 event                               | 267 (79.7)           | 97 (57.7)            | 370 (69.4)                 | 137 (51.7)                 |
| Any SAE                                          | 143 (42.7)           | 70 (41.7)            | 158 (29.6)                 | 89 (33.6)                  |
| Any treatment-related a SAE                      | 39 (11.6)            | 6 (3.6)              | 52 (9.8)                   | 2 (0.6)                    |
| Any event with outcome treatment discontinuation | 43 (12.8)            | 28 (16.7)            | 55 (10.3)                  | 36 (13.6)                  |
| Any event with outcome dose modification b       | 195 (58.2)           | 37 (22.0)            | 73 (54.2)                  | 36 (13.6)                  |
| Any event leading to any dose reduction          | 36 (10.7)            | 2 (1.2)              | 72 (13.5)                  | 2 (0.8)                    |
| Any event with outcome death                     | 45 (13.4)            | 19 (11.3)            | 17 (3.2)                   | 30 (11.3)                  |

<div style=\"page-break-after: always\"></div>

|                  | TAGS (mGC) (N=503)   | TAGS (mGC) (N=503)   | RECOURSE (mCRC) (N= 798)   | RECOURSE (mCRC) (N= 798)   |
|------------------|----------------------|----------------------|----------------------------|----------------------------|
| Parameter, n (%) | TAS-102 N = 335      | Placebo N = 168      | TAS-102 N = 533            | Placebo N = 265            |

Abbreviations: AT = as treated; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group; SAE = serious adverse event; TEAE = treatment-emergent adverse event a  Relatedness per investigator assessment.

b  'Dose modification' comprises both dose delay and dose reduction.

Overall occurrence of TEAEs and treatment-related TEAEs was comparable in the TAGS and RECOURSE study for both TAS-102 and placebo treatment (Table 24). However, occurrence of Grade ≥3 AEs, and SAEs for both treatment groups tended to occur more frequently in the TAGS study compared to the RECOURSE study. This also applies to the occurrence of AEs with outcome death during TAS-102 treatment (13.4% vs. 3.2%), but not to the occurrence of AEs with outcome death during placebo treatment (11.3% in both studies).

## Common adverse events

Nearly all of the events reported with an incidence of ≥10% were reported more often in the TAS-102 arm than in the placebo arm (Table 25). Among the most frequently reported events, the largest differences between  arms  were  observed  for  myelosuppressive  AEs  (specifically,  neutropenia  /  neutrophil  count decreased,  anaemia,  and  leukopenia).  Modest  differences  were  observed  between  arms  (with  higher incidence  in  the  TAS-102  arm)  for  some  gastrointestinal  disorders  including  nausea,  vomiting,  and diarrhoea, and fatigue.

Grade  ≥3  events  reported  with  the  highest  incidence  in  the  TAS-102  arm  of  TAGS  were  neutropenia (23.3%), anaemia (18.8%), and neutrophil count decreased (11.3%). In each of these cases, the incidence of Grade ≥3 events was higher in the TAS-102 than the placebo arm. The only preferred term with an incidence of Grade ≥3 events greater than 5% in the TAS-102 arm of TAGS that is not already shown in Table 25 was general physical health deterioration (incidence of Grade ≥3 events 6.6% in the TAS-102 arm vs. 8.9% in the placebo arm).

Table 25. Treatment-emergent adverse events with incidence ≥ 10% in TAGS and RECOURSE study (AT population)

|                    | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   |
|--------------------|-----------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------------|-------------------|
|                    | TAS-102 N = 335 | TAS-102 N = 335 | Placebo N = 168 | Placebo N = 168 | TAS-102 N = 533   | TAS-102 N = 533   | Placebo N = 265   | Placebo N = 265   |
| Preferred Term,%   | All             | Gr ≥3           | All             | Gr ≥3           | All               | Gr ≥3             | All               | Gr ≥3             |
| All Adverse Events | 97.3            | 79.7            | 93.5            | 57.7            | 98.3              | 69.4              | 93.2              | 51.7              |
| Anaemia            | 44.5            | 18.8            | 19.0            | 7.7             | 40.2              | 16.1              | 8.3               | 2.6               |
| Neutropenia        | 38.5            | 23.3            | 3.6             | 0               | 29.3              | 20.1              | 0                 | 0                 |
| Nausea             | 37.0            | 3.0             | 31.5            | 3.0             | 48.4              | 1.9               | 23.8              | 1.1               |
| Decreased Appetite | 34.3            | 8.7             | 31.0            | 6.5             | 39.0              | 3.6               | 29.4              | 4.9               |
| Fatigue            | 26.6            | 6.9             | 20.8            | 6.0             | 35.3              | 3.9               | 23.4              | 5.7               |
| Vomiting           | 24.8            | 3.6             | 20.2            | 1.8             | 27.8              | 2.1               | 14.3              | 0.4               |

<div style=\"page-break-after: always\"></div>

|                            | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   |
|----------------------------|-----------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------------|-------------------|
| Preferred Term,%           | TAS-102 N = 335 | TAS-102 N = 335 | Placebo N = 168 | Placebo N = 168 | TAS-102 N = 533   | TAS-102 N = 533   | Placebo N = 265   | Placebo N = 265   |
|                            | All             | Gr ≥3           | All             | Gr ≥3           | All               | Gr ≥3             | All               | Gr ≥3             |
| Diarrhoea                  | 22.7            | 2.7             | 14.3            | 1.8             | 31.9              | 3.0               | 12.5              | 0.4               |
| Asthenia                   | 19.4            | 4.8             | 23.8            | 6.5             | 18.2              | 3.4               | 11.3              | 3.0               |
| Leukopenia                 | 17.0            | 6.9             | 1.8             | 0               | 5.4               | 2.4               | 0                 | 0                 |
| Abdominal Pain             | 16.4            | 4.2             | 18.5            | 8.9             | 14.8              | 2.1               | 13.6              | 3.8               |
| Neutrophil Count Decreased | 15.2            | 11.3            | 0.6             | 0               | 27.8              | 15.9              | 0.4               | 0                 |
| Constipation               | 13.4            | 1.2             | 14.9            | 2.4             | 15.2              | 0.2               | 15.1              | 1.1               |

Abbreviations: AT = as treated; Gr = Grade; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm

In both the TAGS and RECOURSE study, TEAEs tended to be reported more frequently in study patients treated with TAS-102 compared to those treated with placebo. More specifically, myelosuppressive AEs (anaemia (44.5% vs. 40.5%), neutropenia/ neutrophil count decreased (38.5/15.2% vs. 29.3/27.8%), and leukopenia (17.0 vs. 5.4%)) were reported more frequently in patients treated with TAS-102 in the TAGS study compared to the RECOURSE study.

## Treatment-related adverse events

Table 26. Treatment-related treatment-emergent adverse events with incidence ≥ 5% in TAS-102 arm of TAGS and RECOURSE study (AT population)

|                            | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   |
|----------------------------|-----------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------------|-------------------|
|                            | TAS-102 N = 335 | TAS-102 N = 335 | Placebo N = 168 | Placebo N = 168 | TAS-102 N = 533   | TAS-102 N = 533   | Placebo N = 265   | Placebo N = 265   |
| Preferred Term,%           | All             | Gr ≥3           | All             | Gr ≥3           | All               | Gr ≥3             | All               | Gr ≥3             |
| All Related Events         | 80.9            | 52.5            | 56.5            | 13.1            | 85.7              | 49.0              | 54.7              | 9.8               |
| Neutropenia                | 37.6            | 23.0            | 3.6             | 0               | 28.7              | 20.1              | 0                 | 0                 |
| Anaemia                    | 31.0            | 11.0            | 8.9             | 3.0             | 31.5              | 12.2              | 4.5               | 1.9               |
| Nausea                     | 25.4            | 2.1             | 15.5            | 1.2             | 39.4              | 0.9               | 10.9              | 0                 |
| Fatigue                    | 18.8            | 3.0             | 10.1            | 1.2             | 24.8              | 2.1               | 10.2              | 1.9               |
| Decreased Appetite         | 18.2            | 3.0             | 11.3            | 1.8             | 26.5              | 1.7               | 11.3              | 0                 |
| Diarrhoea                  | 16.1            | 2.7             | 9.5             | 1.2             | 23.6              | 2.3               | 9.1               | 0                 |
| Leukopenia                 | 15.5            | 6.9             | 1.8             | 0               | 4.7               | 2.1               | 0                 | 0                 |
| Neutrophil count decreased | 14.9            | 11.0            | 0.6             | 0               | 27.2              | 15.6              | 0.4               | 0                 |
| Vomiting                   | 10.7            | 0.6             | 7.1             | 1.2             | 20.1              | 0.6               | 4.5               | 0                 |
| Asthenia                   | 9.3             | 0.9             | 7.7             | 1.2             | 10.9              | 1.7               | 4.5               | 0.8               |
| Thrombocytopenia           | 8.4             | 1.8             | 0.6             | 0               | 5.6               | 1.7               | 0.4               | 0.4               |
| Platelet Count Decreased   | 7.2             | 1.2             | 3.0             | 0               | 14.4              | 2.4               | 1.5               | 0                 |
| WBC Count Decreased        | 6.9             | 2.7             | 0               | 0               | 26.3              | 9.8               | 0.4               | 0                 |

<div style=\"page-break-after: always\"></div>

|                  | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | TAGS (mGC)      | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   | RECOURSE (mCRC)   |
|------------------|-----------------|-----------------|-----------------|-----------------|-------------------|-------------------|-------------------|-------------------|
|                  | TAS-102 N = 335 | TAS-102 N = 335 | Placebo N = 168 | Placebo N = 168 | TAS-102 N = 533   | TAS-102 N = 533   | Placebo N = 265   | Placebo N = 265   |
| Preferred Term,% | All             | Gr ≥3           | All             | Gr ≥3           | All               | Gr ≥3             | All               | Gr ≥3             |
| Lymphopenia      | 5.4             | 1.2             | 3.6             | 1.8             | 0.6               | 0.2               | 0.4               | 0.4               |

Abbreviations: AT = as treated; Gr = Grade; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group

Consistent  with  known  safety  profile  of  TAS-102,  treatment-related  AEs  in  the  TAS-102  arm  were predominantly myelosuppressive and gastrointestinal in nature.

(Severe)  treatment-related  AEs  tended  to  be  reported  more  frequently  in  study  patients  treated  with TAS-102  compared  to  placebo-treated  patients,  both  in  the  TAGS  and  RECOURSE  study.  In  general, treatment-related  AEs  were  reported  less  frequently  in  TAS-102  treated  patients  in  the  TAGS  study compared to the RECOURSE study (80.9% vs. 85.7%). Leukopenia (15.5% vs. 4.7%), thrombocytopenia (8.4% vs. 5.6%), and lymphopenia (5.4% vs. 0.6%) however were reported more frequently in the TAGS study compared to the RECOURSE study.

## Deaths/serious adverse event/other significant events

Two analyses of death on study are presented in this section. The first summarises all deaths that occurred on study or within 30 days after the last dose of study therapy, with the primary cause of death as identified by the investigator. The second summarizes all AEs with an outcome of death, whether or not those AEs were the primary cause of death.

## Summary of deaths with primary cause per investigator assessment

As  of  31-Mar-2018,  a  total  of  395  deaths  were  reported.  A  total  of  104  patients  died  while  on  study treatment or within 30 days after the last dose of study treatment (Table 27). As shown in this table, the majority of on-study deaths in both arms were due to disease progression.

In total, there were 16 deaths on study treatment or within 30 days after last dose for which an AE was identified by the investigator as the primary cause of death (14 in the TAS-102 arm (4.2%); 2 in the control arm (1.2%)). Of these 16 events, 1 was considered at least possibly related to study therapy in the opinion of the investigator (1 event of toxic hepatitis in the control arm).

In addition, there was 1 death in the TAS-102 arm for which the cause of death was identified by the investigator  as  'Other.'  In  this  case,  the  patient  died  at  home  due  to  cardio-respiratory  arrest.  The investigator considered that the most probable cause of death was progressive disease; however a possible relationship to the study medication cannot be excluded. Upon review of the case, the applicant assessed that the underlying cause of death was most likely progression of GC and not the study medication. In view of the applicant, no safety signal was identified upon review of these cases.

<div style=\"page-break-after: always\"></div>

Table 27. Summary of deaths with cause of death per investigator assessment - TAGS study (ITT population)

|                                                              | TAS-102 N = 337   | Placebo N = 170   |
|--------------------------------------------------------------|-------------------|-------------------|
| Deaths on treatment or within 30 days after last dose, n (%) | 62 (18.4)         | 42 (24.7)         |
| Due to disease progression                                   | 47 (13.9)         | 40 (23.5)         |
| Due to an adverse event                                      | 14 (4.2)          | 2 (1.2)           |
| Due to a related adverse event                               | 0                 | 1 (0.6)           |
| Due to other reason                                          | 1 (0.3)           | 0                 |

Abbreviations: ITT = intent-to-treat; N = number of patients in arm; n = number of patients in group

## Summary of adverse events with outcome death

AEs with an outcome of death reported for more than 0.5% of patients in the TAS-102 arm of TAGS (that is, for more than 1 patient) are summarized in Table 28. Respective AEs were observed in 13.4% of study patients treated with TAS-102 and in 11.3% of study patients treated with placebo. General physical health deterioration was the most common AEs with outcome death in both study treatment groups (TAS-102 5.1%, placebo 11.3%).

There were 3 patients who experienced pulmonary embolism with an outcome of death in the TAS-102 arm of TAGS (0.9%), versus 0 in the placebo arm. In all three cases, the investigator assessed the events of pulmonary embolism to be related to patient's  underlying  disease  and  not  to  TAS-102.  In  addition,  3 different patients experienced septic shock with an outcome of death in the TAS-102 arm of TAGS versus 0 in the placebo arm. None of these 3 events were assessed as related to TAS-102 by the investigator. In 1 of these cases (case 961-003), the patient developed pancytopenia post initiation of TAS-102. Though the investigator did not assess this case to be related to TAS-102, the applicant assessed that a causal role of TAS-102 for the event of septic shock cannot be excluded, since pancytopenia could be a risk factor for developing infections.

Table 28. Adverse  events  with  outcome  death,  incidence  &gt;0.5%  in  the  TAGS  study  (AT population)

|                                       |   TAS-102 N = 335 |   Placebo N = 168 |
|---------------------------------------|-------------------|-------------------|
| All events with outcome death (%)     |              13.4 |              11.3 |
| General physical health deterioration |               5.1 |               6.5 |
| Pulmonary embolism                    |               0.9 |               0   |
| Septic shock                          |               0.9 |               0   |
| Acute coronary syndrome               |               0.6 |               0   |
| Failure to thrive                     |               0.6 |               0.6 |
| Hepatic failure                       |               0.6 |               0   |
| Pleural effusion                      |               0.6 |               0.6 |
| Shock haemorrhagic                    |               0.6 |               0   |

The occurrence of AEs with outcome death upon TAS-102 treatment tended to be higher in the TAGS study (13.4%) compared to the RECOURSE study (3.2%). Occurrence of AEs with outcome death upon placebo treatment was however similar in both studies (11.3%).

<div style=\"page-break-after: always\"></div>

## Other serious adverse events

SAEs reported for &gt;1% of patients in the TAS-102 arm of TAGS are summarized in Table 29. The incidence of SAEs was similar between arms (42.7% vs. 41.7% for the TAS-102 and control arms, respectively). The most  common  SAE  in  both  arms  was  general  physical  health  deterioration,  generally  secondary  to progression of disease; this preferred term was reported for 6.3% of patients in the TAS-102 arm and 8.9% of patients in the control arm. SAEs at an incidence of &gt;1% in the TAS-102 treatment group that were reported more than 1% more frequently in the TAS-102 treatment group compared to the placebo treatment group in the TAGS study were anaemia (3.9% vs. 2.4%), pancytopenia (2.1% vs. 0%), (febrile) neutropenia (1.2% vs. 0%), neutropenic sepsis (1.2% vs. 0%), vomiting (2.7% vs. 0.6%), and diarrhoea (1.8% vs. 0%),  i.e.  myelosuppressive  and  gastro-intestinal  AEs.  These  AEs  also  tended  to  be  observed  more frequently in the TAS-102 arm compared to the placebo arm in previous RECOURSE study.

Table 29. Serious adverse events, incidence &gt;1% in the TAS-102 arm of the TAGS study (AT population)

| Parameter,%                           |   TAS-102 N = 335 |   Placebo N = 168 |
|---------------------------------------|-------------------|-------------------|
| All Serious Adverse Events            |              42.7 |              41.7 |
| General Physical Health Deterioration |               6.3 |               8.9 |
| Anaemia                               |               3.9 |               2.4 |
| Decreased Appetite                    |               3.3 |               2.4 |
| Vomiting                              |               2.7 |               0.6 |
| Abdominal Pain                        |               2.4 |               3.6 |
| Pancytopenia                          |               2.1 |               0   |
| Diarrhoea                             |               1.8 |               0   |
| Dysphagia                             |               1.8 |               1.2 |
| Pleural Effusion                      |               1.5 |               0.6 |
| Pulmonary Embolism                    |               1.5 |               1.2 |
| Dyspnoea                              |               1.2 |               1.2 |
| Febrile Neutropenia                   |               1.2 |               0   |
| Gastrointestinal Haemorrhage          |               1.2 |               0.6 |
| Intestinal Obstruction                |               1.2 |               1.8 |
| Neutropenia                           |               1.2 |               0   |
| Neutropenic Sepsis                    |               1.2 |               0   |
| Pneumonia                             |               1.2 |               1.2 |

Abbreviations: AT = as treated; Gr = Grade; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group

Er or! Reference source not found.

( Cont'd)

Er or! Reference source not found.

Treatment-related SAEs were reported for 11.6% of patients in the TAS-102 treatment group and 3.6% in the placebo group (Table 30). The only treatment-related SAE occurring at an incidence of ≥2.0% in either treatment group was pancytopenia (2.1% in the TAS-102 arm vs. 0% in the control arm; all Grade 3 or higher). Related SAEs affecting more than 1 patient (≥0.6%) in the TAS-102 arm of TAGS were almost entirely myelosuppressive or gastrointestinal in nature. Similar trends were observed in previous RECOURSE study.

<div style=\"page-break-after: always\"></div>

Table 30. Treatment-related serious adverse events in the TAS-102 treatment arm in the TAGS study (AT population)

| Parameter,%                           |   TAS-102 N = 335 |   Placebo N = 168 |
|---------------------------------------|-------------------|-------------------|
| All Related SAEs                      |              11.6 |               3.6 |
| Pancytopenia                          |               2.1 |               0   |
| Anaemia                               |               1.8 |               1.2 |
| Diarrhoea                             |               1.8 |               0   |
| Febrile Neutropenia                   |               1.2 |               0   |
| Neutropenia                           |               1.2 |               0   |
| Neutropenic Sepsis                    |               1.2 |               0   |
| Decreased Appetite                    |               0.6 |               0   |
| Ileus                                 |               0.6 |               0   |
| Pyrexia                               |               0.6 |               0   |
| Vomiting                              |               0.6 |               0   |
| Acute Kidney Injury                   |               0.3 |               0   |
| Alkalosis Hypochloraemic              |               0.3 |               0   |
| Cardiorespiratory Arrest              |               0.3 |               0   |
| Cerebrovascular Accident              |               0.3 |               0   |
| Clostridium Difficile Colitis         |               0.3 |               0   |
| Gastric Haemorrhage                   |               0.3 |               0   |
| Gastrointestinal Haemorrhage          |               0.3 |               0   |
| General Physical Health Deterioration |               0.3 |               0   |
| Infection                             |               0.3 |               0   |
| Myocardial Infarction                 |               0.3 |               0   |
| Neutrophil Count Decreased            |               0.3 |               0   |
| Nausea                                |               0.3 |               0   |
| White Blood Cell Count Decreased      |               0.3 |               0   |

Abbreviations: AT = as treated; Gr = Grade; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group; SAE = serious adverse event

## Other significant events

## Adverse events of special interest

AEs of special interest include myelosuppressive (neutropenia, anaemia, thrombocytopenia, leukopenia) and gastrointestinal AEs (nausea, vomiting, diarrhoea), which are known adverse reactions of TAS-102.

## Myelosuppression

An overview of myelosuppressive AEs and laboratory abnormalities is provided in Table 31. Haematologic  AEs/  laboratory  abnormalities  were  generally  manageable  when  they  occurred.  Patients affected by neutropenia Grade 3 or 4 had a median time to recovery (i.e. to Grade &lt;2 or ≤ baseline Grade) of 8 days. In TAGS, haematologic AEs with an outcome of treatment discontinuation were reported for only 4 patients (1.2%) in the TAS-102 arm: 1 patient with Grade 4 thrombocytopenia, 1 patient with Grade 3

<div style=\"page-break-after: always\"></div>

thrombocytopenia, 1 patient with Grade 3 anaemia, and 1 patient with both Grade 4 neutropenia and Grade 4 thrombocytopenia.

The incidence of febrile neutropenia was low (n=6 [1.8%] in the TAS-102 arm, vs. 0 in the placebo arm). All cases of febrile neutropenia resolved with supportive treatment and none necessitated discontinuation of study therapy.

A total of 4 additional patients (1.2%) experienced events of neutropenic sepsis (Grade 3 in all cases). While all of these patients resolved/recovered with supportive treatment, the event of neutropenic sepsis had an outcome of treatment discontinuation for 2 patients (0.6%).

Supportive treatment (mainly granulocyte-colony stimulating factor [G-CSF]) for neutropenia was required for 58 patients in the TAS-102 arm (17.3%) and 3 patients in the placebo arm (1.8%).

Table 31. Overview of myelosuppressive events in the TAGS study

|                         | TAS-102 N = 335   |       | Placebo N = 168   | Gr ≥3   |
|-------------------------|-------------------|-------|-------------------|---------|
| Parameter,%             | All               | Gr ≥3 | All               |         |
| SOC: Blood / Lymphatic  | 63.6              | 40.9  | 25.0              | 9.5     |
| CT: Neutropenia         | 52.5              | 34.0  | 4.2               | 0       |
| PT: Neutropenia         | 38.5              | 23.3  | 3.6               | 0       |
| PT: Neutrophil Ct. Dec. | 15.2              | 11.3  | 0.6               | 0       |
| CT: Anaemia             | 44.8              | 19.1  | 19.0              | 7.7     |
| PT: Anaemia             | 44.5              | 18.8  | 19.0              | 7.7     |
| PT: Haemoglobin Dec.    | 0.6               | 0.3   | 0                 | 0       |
| CT: Thrombocytopenia    | 17.9              | 3.3   | 4.8               | 0       |
| PT: Thrombocytopenia    | 9.9               | 2.1   | 1.2               | 0       |
| PT: Platelet Ct. Dec.   | 8.4               | 1.2   | 3.6               | 0       |
| CT: Leukopenia          | 23.3              | 9.3   | 1.8               | 0       |
| PT: Leukopenia          | 17                | 6.9   | 1.8               | 0       |
| PT: WBC Ct. Dec.        | 6.9               | 2.7   | 0                 | 0       |
| Parameter,%             | Gr 3              | Gr 4  | Gr 3              | Gr 4    |
| Neutrophils (Low)       | 26.8              | 11.3  | 0                 | 0       |
| Haemoglobin (Low)       | 18.6              | 0     | 7.4               | 0       |
| Platelets (Low)         | 4.3               | 1.5   | 0                 | 0       |
| Leukocytes (Low)        | 18.6              | 2.4   | 0                 | 0       |

Abbreviations: AT = as treated; CT = consolidated term; Ct. Dec. = count decreased; Gr = Grade; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group; SAE = serious adverse event; SOC = system organ class; WBC = white blood cell

Overall incidences of all event types with respect to myelosuppression were higher in the TAS-102 arm than in the placebo arm and similar in trend compared to RECOURSE study. Reported AE rates tended to be lower in the TAGS study compared to the RECOURSE study. Moreover, differences between TAS-102 and placebo treatment  tended  to  be  smaller  in  the  TAGS  study  compared  to  the  RECOURSE  study  (e.g.  difference TAS-102 and placebo for leukopenia: 21.3% (23.3 vs. 1.9%) in TAGS study, 32.2% (32.6 vs. 0.4%) in RECOURSE study). Granulocyte-colony stimulating factor during TAS-102 treatment was required in 17.3%

<div style=\"page-break-after: always\"></div>

of study patients in the TAGS study compared to 9.4% of study patients in the RECOURSE study (Lonsurf mCRC EPAR).

To further assess the significance of neutropenia in TAGS, AEs in the System Organ Class (SOC) of Infections and Infestations are summarised in Table 32. As shown, the absolute occurrence of events of this type (included related events) was higher in the TAS-102 arm than in the placebo arm. The most common events reported in the TAS-102 arm of TAGS were upper respiratory tract infections (2.7%), urinary tract infections (2.7%),  pneumonia  (2.4%),  oral  Candidasis  (1.8%),  nasopharyngitis  (1.5%),  and  neutropenic  sepsis (1.2%).

Occurrence  of  severe  (Grade  ≥3)  events  (both  4.8%),  or  events  with  an  outcome  of  treatment discontinuation (both 1.2%) was however similar in both treatment arms. The overall incidence of events with an outcome of death was low in both arms, and the difference between arms with respect to  this outcome was &lt;1%.

Table 32. Summary of events in the system organ class: Infections and Infestations - TAGS (AT population)

|                                                  |   TAS-102 N = 335 |   Placebo N = 168 |
|--------------------------------------------------|-------------------|-------------------|
| SOC: Infections and Infestations (Any TEAE)      |              23.3 |              15.5 |
| Any treatment-related event                      |               4.5 |               1.2 |
| Any Grade ≥3 event                               |               4.8 |               4.8 |
| Any related Grade ≥3 event                       |               1.5 |               0   |
| Any treatment-related SAE                        |               1.8 |               0   |
| Any event with outcome treatment discontinuation |               1.2 |               1.2 |
| Any event with outcome dose modification a       |               3.3 |               2.4 |
| Any event with outcome death                     |               1.5 |               0.6 |

Abbreviations: AT = as treated; mCRC = metastatic colorectal cancer; mGC = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group; SAE = serious adverse event; SOC = System Organ Class; TEAE = treatment-emergent adverse event

a  'Dose modification' comprises both dose delay and dose reduction.

Error! Reference source not found.

(Cont'd)

Error! Reference source not found.

Occurrence of infections and infestations during TAS-102 treatment tended to be lower in the TAGS study (23.3%) compared to the RECOURSE study (28.0%).

## Gastrointestinal toxicity

Events in the SOC of gastrointestinal disorders are summarised in Table 33. The overall incidence of events in this SOC tended to be higher in the TAS-102 than in the placebo arm of TAGS (72.8% vs. 67.3%). Severe (Grade ≥3) AEs (20.9% vs. 28.6%) and treatment discontinuation due to AEs (4.5 vs. 6.5%) did not tend to be higher in the TAS-102 arm compared to the placebo arm.

<div style=\"page-break-after: always\"></div>

Table 33. Summary of events in the system organ class gastrointestinal disorders - TAGS study (AT Population)

|                                                  |   TAS-102 N= 335 |   Placebo N= 168 |
|--------------------------------------------------|------------------|------------------|
| SOC: Gastrointestinal Disorders (Any TEAE)       |             72.8 |             67.3 |
| Any serious event                                |             16.4 |             18.5 |
| Any treatment-related SAE                        |              3.3 |              0.6 |
| Any Grade ≥3 event                               |             20.9 |             28.6 |
| Any treatment-related event                      |             41.2 |             29.8 |
| Any related Grade ≥3 event                       |              5.4 |              3.6 |
| Any event with outcome treatment discontinuation |              4.5 |              6.5 |
| Any event with outcome dose modification a       |             14.3 |             10.7 |
| Any event with outcome death                     |              0.6 |              1.8 |

a  'Dose modification' comprises both dose delay and dose reduction.

Events of nausea, vomiting, and diarrhoea are summarised in Table 34. A total of 54.9% of patients in the TAS-102 arm and 45.8% of patients in the placebo arm reported nausea, diarrhoea, and/or vomiting. The difference between arms in the incidence of Grade ≥3 events was much smaller (7.2% vs. 6.0%). Incidence of nausea, vomiting, or diarrhoea with an outcome of treatment discontinuation was similar between arms (1.5% vs. 1.8%). Overall, increases in the occurrence of diarrhoea, nausea, and vomiting in the TAS-102 arm in comparison to placebo arm is less pronounced compared to what was observed in the previous RECOURSE study (Lonsurf mCRC EPAR).

Table 34. Treatment-emergent adverse events of nausea, vomiting, and diarrhoea - TAGS study (AT Population)

|               | TAS-102 N = 335   | TAS-102 N = 335   | Placebo N = 168   | Placebo N = 168   |
|---------------|-------------------|-------------------|-------------------|-------------------|
| Parameter,%   | All               | Gr ≥3             | All               | Gr ≥3             |
| Any Event     | 54.9              | 7.2               | 45.8              | 6.0               |
| PT: Diarrhoea | 22.7              | 2.7               | 14.3              | 1.8               |
| PT: Nausea    | 37.0              | 3.0               | 31.5              | 3.0               |
| PT: Vomiting  | 24.8              | 3.6               | 20.2              | 1.8               |

Abbreviations: CT = consolidated term; Gr = Grade; mCRC = metastatic colorectal cancer;  mGC  =  metastatic  gastric  cancer;  N  =  number  of  patients  in  arm;  PT  = preferred term; SOC = system organ class

## Analysis of adverse events by organ system or syndrome

## Liver impairment-related adverse events

Events in the SOC of hepatobiliary disorders are summarized in Table 35. AEs related to liver impairment were reported in &lt;10% of study patients and rarely resulted in an outcome of death (0.6% in both arms) or treatment discontinuation (0.6% in both arms). Similar trends had been observed in the RECOURSE study.

<div style=\"page-break-after: always\"></div>

Table 35. Overview of hepatobiliary disorders - TAGS and RECOURSE study (AT population)

|                               | TAGS (mGC)      | TAGS (mGC)      | RECOURSE (mCRC)   | RECOURSE (mCRC)   |
|-------------------------------|-----------------|-----------------|-------------------|-------------------|
| Preferred term,%              | TAS-102 N = 335 | Placebo N = 168 | TAS-102 N = 533   | Placebo N = 265   |
| All Events in SOC             | 7.5             | 6.0             | 10.3              | 10.6              |
| Events with Outcome Death     | 0.6             | 0.6             | 0.4               | 3.0               |
| PT: Hepatic Failure           | 0.6             | 0               | 0.4               | 2.3               |
| PT: Hepatitis Toxic           | 0               | 0.6             | 0                 | 0                 |
| Events with Outcome Treatment | 0.6             | 0.6             | 0.9               | 3.0               |
| Discontinuation               |                 |                 |                   |                   |
| PT: Hepatic Failure           | 0.3             | 0               | 0                 | 1.1               |
| PT: Hyperbilirubinaemia       | 0.3             | 0               | 0.4               | 0.4               |
| PT: Jaundice                  | 0               | 0.6             | 0.4               | 0.8               |

Abbreviations:  AT  =  as  treated;  Gr  =  Grade;  mCRC  =  metastatic  colorectal  cancer;  mGC  = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group; PT = preferred term; SOC = system organ class

## Renal impairment-related adverse events

Events in the SOC of renal and urinary disorders occurred slightly more frequently in the placebo arm (6.0%) than in the TAS-102 arm (5.4%). Grade ≥3 events were very rare (incidence 0.3% and 1.2% in the TAS-102 and placebo arms, respectively), and no events leading to outcomes of death or treatment discontinuation were reported.

In the TAGS study, proteinuria occurred in 2 patients (0.6%) in TAS-102 arm and none in placebo arm. All were Grade 1 or 2. Treatment-related proteinuria occurred only in 1 patient (0.3%) in TAS-102 arm and was limited to a Grade 1, and none occurred in the placebo arm.

In Table 41 the occurrence of AEs by creatinine clearance at baseline is presented.

## Laboratory findings

## Haematology

Table  36  summarises  Grade  3  (severe)  or  4  (potentially  life  threatening)  haematologic  laboratory abnormalities for selected parameters, including all instances where a parameter worsened by at least one Grade from baseline. As shown, the overall incidences of these event types were generally higher in the TAS-102 arm than in the placebo arm.

<div style=\"page-break-after: always\"></div>

Table 36. Grade 3-4 haematologic laboratory abnormalities worsening by at least 1 grade from baseline - TAGS study (AT population)

|                                  | TAS-102 N = 335   | TAS-102 N = 335   | Placebo N = 168   | Placebo N = 168   |
|----------------------------------|-------------------|-------------------|-------------------|-------------------|
| Laboratory Finding,%             | Gr 3              | Gr 4              | Gr 3              | Gr 4              |
| Neutropenia (neutrophils low)    | 26.8              | 11.3              | 0                 | 0                 |
| Anaemia (haemoglobin low)        | 18.6              | 0                 | 7.4               | 0                 |
| Leukopenia (leukocytes low)      | 18.6              | 2.4               | 0                 | 0                 |
| Lymphopenia (lymphocytes low)    | 16.8              | 2.1               | 8.0               | 0                 |
| Thrombocytopenia (platelets low) | 4.3               | 1.5               | 0                 | 0                 |

(Cont'd) Table 36. Grade 3-4 haematologic laboratory abnormalities worsening by at least 1 grade from baseline - TAGS study (AT population)

## Neutrophils

In  the  TAS-102  arm,  88  (26.8%)  patients  experienced  Grade  3  and  37 (11.3%)  experienced  Grade 4 neutrophil decreases, while no Grade 3 or 4 values were observed in the placebo arm.

Median neutrophil count at the end of each cycle (last value obtained in each cycle) was lower in the TAS-102 arm than in the placebo arm. In the TAS-102 arm, neutrophil count decreased from baseline, and remained relatively stable throughout the treatment period (figure 7). Of note, the number of study patients decreased with each subsequent study treatment cycle.

Figure 7. Median neutrophil count by cycle and treatment group TAGS study (AT population)

<!-- image -->

## Serum chemistry

<div style=\"page-break-after: always\"></div>

Table 37 summarises Grade 3 or 4 serum chemistry laboratory abnormalities for selected parameters, including all instances where a parameter worsened by at least one grade from baseline. There were no notable differences between arms for most parameters. The incidence of Grade 3 or 4 hypokalaemia that worsened from baseline was however higher in the TAS-102 arm (2.4%) than in the placebo arm (0.6%).

Table 37. Grade 3-4 serum chemistry abnormalities - TAGS study (AT population)

| Parameter Low/High Value                                                                       | TAS-102 N = 335                                                                                | TAS-102 N = 335                                                                                | Placebo N = 168                                                                                | Placebo N = 168                                                                                |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Cycle                                                                                          | N                                                                                              | Grades 3-4 n (%)                                                                               | N                                                                                              | Grades 3-4 n (%)                                                                               |
| Alanine aminotransferase (U/L) (high value)                                                    | Alanine aminotransferase (U/L) (high value)                                                    | Alanine aminotransferase (U/L) (high value)                                                    | Alanine aminotransferase (U/L) (high value)                                                    | Alanine aminotransferase (U/L) (high value)                                                    |
| Baseline                                                                                       | 335                                                                                            | 0                                                                                              | 168                                                                                            | 0                                                                                              |
| All Cycles                                                                                     | 327                                                                                            | 8 (2.4)                                                                                        | 161                                                                                            | 5 (3.1)                                                                                        |
| Albumin (g/L) (low value)                                                                      | Albumin (g/L) (low value)                                                                      | Albumin (g/L) (low value)                                                                      | Albumin (g/L) (low value)                                                                      | Albumin (g/L) (low value)                                                                      |
| Baseline                                                                                       | 329                                                                                            | 4 (1.2)                                                                                        | 167                                                                                            | 2 (1.2)                                                                                        |
| All Cycles                                                                                     | 327                                                                                            | 12 (3.7)                                                                                       | 161                                                                                            | 4 (2.5)                                                                                        |
| Alkaline Phosphatase (U/L) (high value)                                                        | Alkaline Phosphatase (U/L) (high value)                                                        | Alkaline Phosphatase (U/L) (high value)                                                        | Alkaline Phosphatase (U/L) (high value)                                                        | Alkaline Phosphatase (U/L) (high value)                                                        |
| Baseline                                                                                       | 333                                                                                            | 8 (2.4)                                                                                        | 167                                                                                            | 3 (1.8)                                                                                        |
| All Cycles                                                                                     | 327                                                                                            | 32 (9.8)                                                                                       | 162                                                                                            | 14 (8.6)                                                                                       |
| Aspartate Aminotransferase (U/L) (high value)                                                  | Aspartate Aminotransferase (U/L) (high value)                                                  | Aspartate Aminotransferase (U/L) (high value)                                                  | Aspartate Aminotransferase (U/L) (high value)                                                  | Aspartate Aminotransferase (U/L) (high value)                                                  |
| Baseline                                                                                       | 335                                                                                            | 0                                                                                              | 168                                                                                            | 0                                                                                              |
| All Cycles                                                                                     | 326                                                                                            | 13 (4.0)                                                                                       | 161                                                                                            | 8 (5.0)                                                                                        |
| Bilirubin (µmol/L) (high value)                                                                | Bilirubin (µmol/L) (high value)                                                                | Bilirubin (µmol/L) (high value)                                                                | Bilirubin (µmol/L) (high value)                                                                | Bilirubin (µmol/L) (high value)                                                                |
| Baseline                                                                                       | 335                                                                                            | 0                                                                                              | 167                                                                                            | 1 (0.6)                                                                                        |
| All Cycles                                                                                     | 327                                                                                            | 22 (6.7)                                                                                       | 162                                                                                            | 10 (6.2)                                                                                       |
| Calcium (mmol/L) (low value)                                                                   | Calcium (mmol/L) (low value)                                                                   | Calcium (mmol/L) (low value)                                                                   | Calcium (mmol/L) (low value)                                                                   | Calcium (mmol/L) (low value)                                                                   |
| Baseline                                                                                       | 330                                                                                            | 2 (0.6)                                                                                        | 165                                                                                            | 0                                                                                              |
| All Cycles                                                                                     | 323                                                                                            | 9 (2.8)                                                                                        | 160                                                                                            | 2 (1.3)                                                                                        |
| Creatinine (µmol/L) (high value)                                                               | Creatinine (µmol/L) (high value)                                                               | Creatinine (µmol/L) (high value)                                                               | Creatinine (µmol/L) (high value)                                                               | Creatinine (µmol/L) (high value)                                                               |
| Baseline                                                                                       | 335                                                                                            | 0                                                                                              | 168                                                                                            | 0                                                                                              |
| All Cycles                                                                                     | 328                                                                                            | 2 (0.6)                                                                                        | 162                                                                                            | 0                                                                                              |
| Glucose (mmol/L) (low value)                                                                   | Glucose (mmol/L) (low value)                                                                   | Glucose (mmol/L) (low value)                                                                   | Glucose (mmol/L) (low value)                                                                   | Glucose (mmol/L) (low value)                                                                   |
| Baseline                                                                                       | 333                                                                                            | 0                                                                                              | 167                                                                                            | 0                                                                                              |
| All Cycles                                                                                     | 326                                                                                            | 3 (0.9)                                                                                        | 160                                                                                            | 0                                                                                              |
| Glucose (mmol/L) (high value)                                                                  | Glucose (mmol/L) (high value)                                                                  | Glucose (mmol/L) (high value)                                                                  | Glucose (mmol/L) (high value)                                                                  | Glucose (mmol/L) (high value)                                                                  |
| Baseline                                                                                       | 333                                                                                            | 4 (1.2)                                                                                        | 167                                                                                            | 1 (0.6)                                                                                        |
| All Cycles                                                                                     | 326                                                                                            | 4 (1.2)                                                                                        | 160                                                                                            | 4 (2.5)                                                                                        |
| Potassium (mmol/L) (low value)                                                                 | Potassium (mmol/L) (low value)                                                                 | Potassium (mmol/L) (low value)                                                                 | Potassium (mmol/L) (low value)                                                                 | Potassium (mmol/L) (low value)                                                                 |
| Baseline                                                                                       | 334                                                                                            | 1 (0.3)                                                                                        | 168                                                                                            | 3 (1.8)                                                                                        |
| All Cycles                                                                                     | 328                                                                                            | 8 (2.4)                                                                                        | 162                                                                                            | 1 (0.6)                                                                                        |
| Potassium (mmol/L) (high value)                                                                | Potassium (mmol/L) (high value)                                                                | Potassium (mmol/L) (high value)                                                                | Potassium (mmol/L) (high value)                                                                | Potassium (mmol/L) (high value)                                                                |
| Baseline                                                                                       | 334                                                                                            | 1 (0.3)                                                                                        | 168                                                                                            | 0                                                                                              |
| All Cycles                                                                                     | 328                                                                                            | 4 (1.2)                                                                                        | 162                                                                                            | 1 (0.6)                                                                                        |
| Sodium (mmol/L) (low value)                                                                    | Sodium (mmol/L) (low value)                                                                    | Sodium (mmol/L) (low value)                                                                    | Sodium (mmol/L) (low value)                                                                    | Sodium (mmol/L) (low value)                                                                    |
| Baseline                                                                                       | 334                                                                                            | 6 (1.8)                                                                                        | 168                                                                                            | 2 (1.2)                                                                                        |
| All Cycles                                                                                     | 328                                                                                            | 21 (6.4)                                                                                       | 161                                                                                            | 18 (11.2)                                                                                      |
| Abbreviations: AT = as treated; N = number of patients in arm; n = number of patients in group | Abbreviations: AT = as treated; N = number of patients in arm; n = number of patients in group | Abbreviations: AT = as treated; N = number of patients in arm; n = number of patients in group | Abbreviations: AT = as treated; N = number of patients in arm; n = number of patients in group | Abbreviations: AT = as treated; N = number of patients in arm; n = number of patients in group |

In the TAS-102 arm, the percentage of patients with elevations of ALT, AST, or both was comparable to that of the placebo arm (Table 37). Bilirubin elevations tended to be higher in the TAS-102 arm, with elevations of 1.5 x ULN reported for 14.9% (vs. 11.9% in the placebo arm) and elevations of 2 x ULN reported for 11.6% (vs. 7.1% for the control arm). Elevation of alkaline phosphatase of 1.5 x ULN was reported for 45.1% of the TAS-102 arm and 41.7% of the placebo arm.

<div style=\"page-break-after: always\"></div>

Only in the TAS-102 arm, 2 patients met the laboratory criteria for Hy's Law (ALT or AST ≥3 x ULN; total bilirubin ≥2 x ULN; and alkaline phosphatase &lt;2 x ULN at the same visit) vs. no patient in the placebo arm. Of note, both patients had liver metastases at baseline.

## Vital signs, physical findings, and other observations related to safety

## Vital signs and body weight

No clinically relevant mean or median changes in body weight or vital signs were observed in either study treatment group. Median changes from baseline at the end of each cycle were relatively stable in both treatment groups over the first several treatment cycles.

## Safety in special populations and situations

## Overview

Occurrence of TEAEs by age (&lt;65 years, ≥65 years), gender, race, geographic region, ECOG PS, and baseline creatinine clearance in the TAGS and RECOURSE study are summarised in Table 38 (Integrated summary of safety). In the TAGS study, occurrence of AEs was in general higher in study patients treated with  TAS-102 compared to placebo treatment. Occurrence of TEAEs during TAS-102 treatment was in general comparable for different patient features in the TAGS and RECOURSE study. Occurrence of TEAEs during both TAS-102 (98.8% vs. 96.8%) and placebo treatment (96.2% vs. 92.2%) tended to be somewhat higher for female study patients compared to male study patients in the TAGS study.

Occurrence of TEAEs in both treatment groups varied among different levels of renal impairment. However, consistent trends were neither observed in the TAGS nor the RECOURSE study.

## Table 38. Subgroup analysis of treatment-emergent adverse events TAGS and RECOURSE study (Integrated summary of safety)

| AE Category                   | TAGS study (mGC)   | TAGS study (mGC)   | TAGS study (mGC)   | TAGS study (mGC)   | RECOURSE study (mCRC)   | RECOURSE study (mCRC)   | RECOURSE study (mCRC)   | RECOURSE study (mCRC)   |
|-------------------------------|--------------------|--------------------|--------------------|--------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                               | N                  | TAS-102 n (%)      | N                  | Placebo n (%)      | N                       | TAS-102 n (%)           | N                       | Placebo n (%)           |
| Age, years                    |                    |                    |                    |                    |                         |                         |                         |                         |
| <65                           | 182                | 179 (98.4)         | 96                 | 91 (94.8)          | 299                     | 293 (98.0)              | 147                     | 137 (93.2)              |
| ≥65                           | 153                | 147 (96.1)         | 72                 | 66 (91.7)          | 234                     | 231 (98.7)              | 118                     | 110 (93.2)              |
| Gender                        |                    |                    |                    |                    |                         |                         |                         |                         |
| Male                          | 250                | 242 (96.8)         | 116                | 107 (92.2)         | 326                     | 322 (98.8)              | 164                     | 152 (92.7)              |
| Female                        | 85                 | 84 (98.8)          | 52                 | 50 (96.2)          | 207                     | 202 (97.6)              | 101                     | 95 (94.1)               |
| Race                          |                    |                    |                    |                    |                         |                         |                         |                         |
| White                         | 242                | 233 (96.3)         | 112                | 107 (95.5)         | 305                     | 298 (97.7)              | 154                     | 144 (93.5)              |
| Asian                         | 51                 | 51 (100)           | 29                 | 24 (82.8)          | 184                     | 183 (99.5)              | 94                      | 87 (92.6)               |
| Other                         | 1                  | 1 (100)            | 2                  | 2 (100)            | 4                       | 4 (100)                 | 5                       | 5 (100)                 |
| Region                        |                    |                    |                    |                    |                         |                         |                         |                         |
| European Union                | 179                | 172 (96.1)         | 96                 | 92 (95.8)          | 270                     | 266 (98.5)              | 131                     | 120 (91.6)              |
| Rest of world                 | 156                | 154 (98.7)         | 72                 | 65 (90.3)          | 263                     | 258 (98.1)              | 134                     | 127 (94.8)              |
| ECOG performance status       |                    |                    |                    |                    |                         |                         |                         |                         |
| 0                             | 123                | 117 (95.1)         | 68                 | 60 (88.2)          | 301                     | 295 (98.0)              | 147                     | 132 (89.8)              |
| 1                             | 212                | 209 (98.6)         | 100                | 97 (97.0)          | 232                     | 229 (98.7)              | 118                     | 115 (97.5)              |
| Baseline creatinine clearance |                    |                    |                    |                    |                         |                         |                         |                         |
| ≥ 90 ml/min                   | 145                | 142 (97.9)         | 75                 | 71 (94.7)          | 306                     | 299 (97.7)              | 146                     | 134 (91.8)              |
| 60-89 ml/min                  | 136                | 132 (97.1)         | 70                 | 63 (90.0)          | 178                     | 177 (99.4)              | 90                      | 86 (95.6)               |

<div style=\"page-break-after: always\"></div>

| 30-59 ml/min                                                                                                                                                                                                                                           | 52                                                                                                                                                                                                                                                     | 50 (96.2)                                                                                                                                                                                                                                              | 23                                                                                                                                                                                                                                                     | 23 (100)                                                                                                                                                                                                                                               | 47                                                                                                                                                                                                                                                     | 46 (97.9)                                                                                                                                                                                                                                              | 26                                                                                                                                                                                                                                                     | 24 (92.3)                                                                                                                                                                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category | Abbreviations: AE = adverse event; ECOG= Eastern Cooperative Oncology Group; mGC= metastatic gastric cancer; mCRC= metastatic colorectal cancer; N = number of treated patients in the safety population; n = number of patients in specified category |
| Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 | Note: Patients may be counted in more than 1 category.                                                                                                                                                                                                 |

## Analysis of safety data by age

In TAGS, the overall incidence of AEs (regardless of Grade or relationship to study therapy) was &gt;89% in all age groups (Table 39). All age categories in the TAS-102 group of TAGS reported approximately 80% of patients with Grade 3 or higher AEs.

<div style=\"page-break-after: always\"></div>

Table 39. Summary of adverse events by age interval TAGS study

|                                                                      | TAS-102 N= 335       |                        |                     | Placebo N= 168      |                       |                     |
|----------------------------------------------------------------------|----------------------|------------------------|---------------------|---------------------|-----------------------|---------------------|
|                                                                      | Age <65 N= 182 n (%) | Age 65-74 N= 103 n (%) | Age ≥75 N= 50 n (%) | Age <65 N= 96 n (%) | Age 65-74 N= 55 n (%) | Age ≥75 N= 17 n (%) |
| Total adverse events                                                 | 179 (98.4)           | 97 (94.2)              | 50 (100)            | 91 (94.8)           | 49 (89.1)             | 17 (100)            |
| Treatment-related adverse events                                     | 149 (81.9)           | 103 (79.6)             | 40 (80.0)           | 59 (61.5)           | 27 (49.1)             | 9 (52.9)            |
| Grade ≥3 adverse events                                              | 145 (79.7)           | 82 (79.6)              | 40 (80.0)           | 60 (62.5)           | 28 (50.9)             | 9 (52.9)            |
| Treatment-related Grade ≥3 adverse events                            | 89 (48.9)            | 59 (57.3)              | 28 (56.0)           | 14 (14.6)           | 6 (10.9)              | 2 (11.8)            |
| System organ class AEs                                               |                      |                        |                     |                     |                       |                     |
| Blood and lymphatic system disorders                                 | 120 (65.9)           | 62 (60.2)              | 31 (62.0)           | 28 (29.2)           | 8 (14.5)              | 6 (35.3)            |
| Cardiac disorders                                                    | 13 (7.1)             | 4 (3.9)                | 2 (4.0)             | 7 (7.3)             | 1 (1.8)               | 1 (5.9)             |
| Congenital, familial and genetic disorders                           | 1 (0.5)              | 0 (0)                  | 0 (0)               | 0 (0)               | 0 (0)                 | 0 (0)               |
| Ear and labyrinth disorders                                          | 2 (1.1)              | 3 (2.9)                | 1 (2.0)             | 1 (1.0)             | 0 (0)                 | 0 (0)               |
| Eye disorders                                                        | 2 (1.1)              | 0                      | 4 (8.0)             | 0 (0)               | 0 (0)                 | 0 (0)               |
| Gastrointestinal disorders                                           | 148 (81.3)           | 63 (61.2)              | 33 (66.0)           | 71 (74.0)           | 32 (58.2)             | 10 (58.8)           |
| General disorders and administration site conditions                 | 108 (59.3)           | 60 (58.3)              | 30 (60.0)           | 54 (56.3)           | 30 (54.5)             | 14 (82.4)           |
| Hepatobiliary disorders                                              | 13 (7.1)             | 8 (7.8)                | 4 (8.0)             | 7 (7.3)             | 2 (3.6)               | 1 (5.9)             |
| Immune system disorders                                              | 0 (0)                | 1 (1.0)                | 0 (0)               | 1 (1.0)             | 0 (0)                 | 0 (0)               |
| Infections and infestations                                          | 43 (23.6)            | 19 (18.4)              | 16 (32.0)           | 16 (16.7)           | 8 (14.5)              | 2 (11.8)            |
| Injury, poisoning, and procedural complications                      | 3 (1.6)              | 4 (3.9)                | 1 (2.0)             | 3 (3.1)             | 3 (5.5)               | 0 (0)               |
| Investigations                                                       | 76 (41.8)            | 41 (39.8)              | 28 (56.0)           | 28 (29.2)           | 17 (30.9)             | 3 (17.6)            |
| Metabolism and nutrition disorders                                   | 77 (42.3)            | 49 (47.6)              | 27 (54.0)           | 43 (44.8)           | 18 (32.7)             | 7 (41.2)            |
| Musculoskeletal and connective tissue disorders                      | 32 (17.6)            | 12 (11.7)              | 5 (10.0)            | 13 (13.5)           | 5 (9.1)               | 3 (17.6)            |
| Neoplasms benign, malignant and unspecified (incl. cysts and polyps) | 7 (3.8)              | 7 (6.8)                | 2 (4.0)             | 5 (5.2)             | 1 (1.8)               | 0 (0)               |
| Nervous system disorders                                             | 27 (14.8)            | 17 (16.5)              | 10 (20.0)           | 14 (14.6)           | 5 (9.1)               | 0 (0)               |
| Psychiatric disorders                                                | 17 (9.3)             | 7 (6.8)                | 4 (8.0)             | 12 (12.5)           | 5 (9.1)               | 2 (11.8)            |
| Renal and urinary disorders                                          | 11 (6.0)             | 3 (2.9)                | 4 (8.0)             | 7 (7.3)             | 3 (5.5)               | 0 (0)               |
| Reproductive system and breast disorders                             | 2 (1.1)              | 0 (0)                  | 0 (0)               | 4 (4.2)             | 1 (1.8)               | 0 (0)               |
| Respiratory, thoracic and                                            | 37 (20.3)            | 24 (23.3)              | 10 (20.0)           | 22 (22.9)           | 8 (14.5)              | 3 (17.6)            |
| mediastinal disorders Skin and subcutaneous tissue                   | 25 (13.7)            | 11 (10.7)              | 10 (20.0)           | 4 (4.2)             | 3 (5.5)               | 1 (5.9)             |
| disorders Vascular disorders                                         | 11 (6.0)             | 4 (3.9)                | 6 (12.0)            | 3 (3.1)             | 0 (0)                 | 2 (11.8)            |

In the RECOURSE study in mCRC, occurrence of AEs upon TAS-102 treatment was comparable for patients aged under 65 years (98.0%), patients aged 65-74 years (98.5%), and patients aged 75 years and above (100%).

## Analysis of safety data by gender

<div style=\"page-break-after: always\"></div>

In TAGS, the overall incidence of AEs was &gt;92% in both male and female patients, across all treatment arms. In both men and women occurrence of AEs during TAS-102 treatment was higher than during placebo treatment (Table 40). Treatment-related AEs were reported for 79.2% of male and 85.9% of female patients in the TAS-102 arm, and 56.9% and 55.8%, respectively, in the placebo arm.

Table 40. Summary of adverse events by gender TAGS study

|                                                                      | TAS-102          |                   | Placebo          |                   |
|----------------------------------------------------------------------|------------------|-------------------|------------------|-------------------|
|                                                                      | Men N= 250 n (%) | Women N= 85 n (%) | Men N= 116 n (%) | Women N= 52 n (%) |
| Total adverse events                                                 | 242 (96.8)       | 84 (98.8)         | 107 (92.2)       | (96.2)            |
| Treatment-related adverse events                                     | 198 (79.2)       | 73 (85.9)         | 66 (56.9)        | 29 (55.8)         |
| Grade ≥3 adverse events                                              | 193 (77.2)       | 74 (87.1)         | 65 (56.0)        | 32 (61.5)         |
| Treatment-related Grade ≥3 adverse events                            | 123 (49.2)       | 53 (62.4)         | 13 (11.2)        | 9 (17.3)          |
| System organ class AEs                                               |                  |                   |                  |                   |
| Blood and lymphatic system disorders                                 | 151 (60.4)       | 62 (72.9)         | 23 (19.8)        | 19 (36.5)         |
| Cardiac disorders                                                    | 12 (4.8)         | 7 (8.2)           | 5 (4.3)          | 4 (7.7)           |
| Congenital, familial and genetic disorders                           | 1 (0.4)          | 0 (0)             | 0 (0)            | 0 (0)             |
| Ear and labyrinth disorders                                          | 6 (2.4)          | 0 (0)             | 0 (0)            | 1 (1.9)           |
| Eye disorders                                                        | 3 (1.2)          | 3 (3.5)           | 0 (0)            | 0 (0)             |
| Gastrointestinal disorders                                           | 175 (70.0)       | 69 (81.2)         | 78 (67.2)        | 35 (67.3)         |
| General disorders and administration site conditions                 | 144 (57.6)       | 54 (63.5)         | 64 (55.2)        | 34 (65.4)         |
| Hepatobiliary disorders                                              | 20 (8.0)         | 5 (5.9)           | 7 (6.0)          | 3 (5.8)           |
| Immune system disorders                                              | 1 (0.4)          | 0 (0)             | 1 (0.9)          | 0 (0)             |
| Infections and infestations                                          | 57 (22.8)        | 21 (24.7)         | 18 (15.5)        | 8 (15.4)          |
| Injury, poisoning, and procedural complications                      | 5 (2.0)          | 3 (3.5)           | 3 (2.6)          | 3 (5.8)           |
| Investigations                                                       | 112 (44.8)       | 33 (33.8)         | 24 (20.7)        | 24 (46.2)         |
| Metabolism and nutrition disorders                                   | 113 (45.2)       | 40 (47.1)         | 47 (40.5)        | 21 (40.4)         |
| Musculoskeletal and connective tissue disorders                      | 35 (14.0)        | 14 (16.5)         | 15 (12.9)        | 6 (11.5)          |
| Neoplasms benign, malignant and unspecified (incl. cysts and polyps) | 13 (5.2)         | 3 (3.5)           | 5 (4.3)          | 1 (1.9)           |
| Nervous system disorders                                             | 40 (16.0)        | 14 (16.5)         | 17 (14.7)        | 2 (3.8)           |
| Psychiatric disorders                                                | 18 (7.2)         | 10 (11.8)         | 15 (12.9)        | 4 (7.7)           |
| Renal and urinary disorders                                          | 12 (4.8)         | 6 (7.1)           | 3 (2.6)          | 7 (13.5)          |
| Reproductive system and breast disorders                             | 1 (0.4)          | 1 (1.2%)          | 1 (0.9)          | 4 (7.7)           |
| Respiratory, thoracic and mediastinal disorders                      | 54 (21.6)        | 17 (20.0)         | 21 (18.1)        | 12 (23.1)         |
| Skin and subcutaneous tissue disorders                               | 34 (13.6)        | 12 (14.1)         | 6 (5.2)          | 2 (3.8)           |
| Vascular disorders                                                   | 17 (6.8)         | 4 (4.7)           | 2 (1.7)          | 3 (5.8)           |

Occurrence of AEs (97.6% vs. 98.8%) and treatment-related AEs (85.5% vs. 85.9%) during TAS-102 treatment was similar for respectively women and men in the RECOURSE study in mCRC.

## Analysis of safety data by ECOG PS at baseline

<div style=\"page-break-after: always\"></div>

The rates of AEs by ECOG PS at baseline (0 vs. 1) were in alignment with those observed in the total AT population (Table 38). As expected, patients with an ECOG PS of 0 at baseline generally had lower rates of AEs than patients with a score of 1, with the exception of AEs of special interest in the TAS-102 group (ECOG 0: 76.4%; ECOG 1: 68.4%).

The overall incidence of AEs was &gt;88% in both ECOG PS categories and treatment groups. For the TAS-102 group, AEs were reported for 95.1% of patients with an ECOG PS of 0, and 98.6% of patients with a score of 1. For the placebo group, AEs were reported for 88.2% and 97.0%, respectively (Table 38).

Grade ≥3 AEs in the TAS-102 group were reported for 72.4% of patients with an ECOG PS of 0, and 84.0% of patients with a score of 1. For the placebo group, Grade ≥3 AEs were reported for 44.1% and 67.0%, respectively.

## Analysis of safety data by creatinine clearance at baseline

In TAGS, the overall incidence of AEs was &gt;90% for patients with normal renal function, mild, and moderate impairment in both treatment groups (Table 41; Integrated summary of safety). Overall occurrence of treatment-related AEs did not tend to increase during TAS-102 treatment with increasing rates of renal impairment at baseline (normal renal function: 97.9%; mild renal impairment: 97.1%; moderate renal impairment: 96.2%). However, AEs in the system organ classes blood and lymphatic system disorders (respectively 62.1%, 62.5%, 71.2%), metabolism and nutrition disorders (respectively 37.9%, 50.0%, 55.8%),  and  skin  and  subcutaneous  tissue  disorders  (respectively  13.1%,  14.0%,  15.4%)  tended  to increase with increasing renal impairment.

<div style=\"page-break-after: always\"></div>

Table 41. Summary  of  adverse  events  by  renal  function  in  TAGS  study  (Integrated summary of safety)

|                                                                      | TAS-102 N= 335                                         | TAS-102 N= 335                                                        | TAS-102 N= 335                                                           | Placebo N= 168                                        | Placebo N= 168                                                       | Placebo N= 168                                                            |
|----------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------------------|---------------------------------------------------------------------------|
| Baseline creatinine clearance                                        | Normal (creatinine clearance ≥ 90 mL/min) N= 145 n (%) | Mild renal impairment (creatinine clearance 60-89 mL/min N= 136 n (%) | Moderate renal impairment (creatinine clearance 30-59 mL/min N= 52 n (%) | Normal (creatinine clearance ≥ 90 mL/min) N= 75 n (%) | Mild renal impairment (creatinine clearance 60-89 mL/min N= 70 n (%) | Moderate renal impairmen t (creatinine clearance 30-59 mL/min N= 23 n (%) |
| Total adverse events                                                 | 142 (97.9)                                             | 132 (97.1)                                                            | 50 (96.2)                                                                | 91 (94.7)                                             | 63 (90.0)                                                            | 23 (100)                                                                  |
| Treatment-related adverse events                                     | 115 (79.3)                                             | 114 (83.8)                                                            | 40 (76.9)                                                                | 39 (52.0)                                             | 46 (65.7)                                                            | 10 (43.5)                                                                 |
| Grade ≥3 adverse events                                              | 107 (73.8)                                             | 116 (85.3)                                                            | 42 (80.8)                                                                | 47 (62.7)                                             | 36 (51.4)                                                            | 14 (60.9)                                                                 |
| Treatment-related Grade ≥3 adverse events                            | 63 (43.3)                                              | 79 (58.1)                                                             | 32 (61.5)                                                                | 11 (14.7)                                             | 10 (14.3)                                                            | 1 (4.3)                                                                   |
| System organ class AEs                                               |                                                        |                                                                       |                                                                          |                                                       |                                                                      |                                                                           |
| Blood and lymphatic system disorders                                 | 90 (62.1)                                              | 85 (62.5)                                                             | 37 (71.2)                                                                | 71 (94.7)                                             | 63 (90.0)                                                            | 23 (100)                                                                  |
| Cardiac disorders                                                    | 10 (6.9)                                               | 6 (4.4)                                                               | 3 (5.8)                                                                  | 5 (6.7)                                               | 1 (1.4)                                                              | 3 (13.0)                                                                  |
| Congenital, familial and genetic disorders                           | 1 (0.7)                                                | 0 (0)                                                                 | 0 (0)                                                                    | 0 (0)                                                 | 0 (0)                                                                | 0 (0)                                                                     |
| Ear and labyrinth disorders                                          | 1 (0.7)                                                | 5 (3.7)                                                               | 0 (0)                                                                    | 1 (1.3)                                               | 0 (0)                                                                | 0 (0)                                                                     |
| Eye disorders                                                        | 3 (2.1)                                                | 2 (1.5)                                                               | 0 (0)                                                                    | 0 (0)                                                 | 0 (0)                                                                | 0 (0)                                                                     |
| Gastrointestinal disorders                                           | 108 (74.5)                                             | 97 (71.3)                                                             | 37 (71.2)                                                                | 54 (72.0)                                             | 42 (60.0)                                                            | 17 (73.9)                                                                 |
| General disorders and administration site conditions                 | 86 (59.3)                                              | 77 (56.6)                                                             | 33 (63.5)                                                                | 45 (60.0)                                             | 37 (52.9)                                                            | 16 (69.6)                                                                 |
| Hepatobiliary disorders                                              | 10 (6.9)                                               | 11 (8.1)                                                              | 3 (5.8)                                                                  | 9 (12.0)                                              | 0 (0)                                                                | 1 (4.3)                                                                   |
| Immune system disorders                                              | 0 (0)                                                  | 1 (0.7)                                                               | 0 (0)                                                                    | 1 (1.3)                                               | 0 (0)                                                                | 0 (0)                                                                     |
| Infections and infestations                                          | 43 (29.7)                                              | 24 (17.6)                                                             | 10 (19.2)                                                                | 14 (18.7)                                             | 8 (11.4)                                                             | 4 (17.4)                                                                  |
| Injury, poisoning, and procedural complications                      | 5 (3.4)                                                | 2 (1.5)                                                               | 1 (1.9)                                                                  | 2 (2.7)                                               | 2 (2.9)                                                              | 2 (8.7)                                                                   |
| Investigations                                                       | 57 (39.3)                                              | 64 (47.1)                                                             | 22 (42.3)                                                                | 20 (26.7)                                             | 19 (27.1)                                                            | 9 (39.1)                                                                  |
| Metabolism and nutrition disorders                                   | 55 (37.9)                                              | 68 (50.0)                                                             | 29 (55.8)                                                                | 28 (37.3)                                             | 31 (44.3)                                                            | 9 (39.1)                                                                  |
| Musculoskeletal and connective tissue disorders                      | 24 (16.6)                                              | 16 (11.8)                                                             | 9 (17.3)                                                                 | 12 (16.0)                                             | 8 (11.4)                                                             | 1 (4.3)                                                                   |
| Neoplasms benign, malignant and unspecified (incl. cysts and polyps) | 7 (4.8)                                                | 8 (5.9)                                                               | 1 (1.9)                                                                  | 2 (2.7)                                               | 3 (4.3)                                                              | 1 (4.3)                                                                   |
| Nervous system disorders                                             | 19 (13.1)                                              | 25 (18.4)                                                             | 9 (17.3)                                                                 | 12 (16.0)                                             | 7 (10.0)                                                             | 0 (0)                                                                     |
| Psychiatric disorders                                                | 12 (8.3)                                               | 13 (9.6)                                                              | 3 (5.8)                                                                  | 11 (14.7)                                             | 6 (8.6)                                                              | 2 (8.7)                                                                   |
| Renal and urinary disorders                                          | 7 (4.8)                                                | 7 (5.1)                                                               | 3 (5.8)                                                                  | 5 (6.7)                                               | 2 (2.9)                                                              | 3 (13.0)                                                                  |
| Reproductive system and breast disorders                             | 2 (1.4)                                                | 0 (0)                                                                 | 0 (0)                                                                    | 3 (4.0)                                               | 1 (1.4)                                                              | 1 (4.3)                                                                   |
| Respiratory, thoracic and mediastinal disorders                      | 31 (21.4)                                              | 23 (16.9)                                                             | 16 (30.8)                                                                | 11 (14.7)                                             | 15 (21.4)                                                            | 7 (30.4)                                                                  |
| Skin and subcutaneous tissue disorders                               | 19 (13.1)                                              | 19 (14.0)                                                             | 8 (15.4)                                                                 | 4 (5.3)                                               | 4 (5.7)                                                              | 0 (0)                                                                     |
| Vascular disorders                                                   | 8 (5.5)                                                | 11 (8.1)                                                              | 2 (3.8)                                                                  | 2 (2.7)                                               | 2 (2.9)                                                              | 1 (4.3)                                                                   |

<div style=\"page-break-after: always\"></div>

In previous RECOURSE study in mCRC, ≥ Grade 3AEs (85.1% vs. 66.7% and 70.8% respectively), serious AEs  (42.6%  vs.  27.5%  and  30.3%  respectively),  and  dose  delays  (38.8%  vs.  28.7%  and  26.7% respectively) and reductions (23.9% vs. 11.2% and 17.6% respectively) tended to occur more frequently during TAS-102 treatment in study patients with moderate renal impairment (i.e. creatinine clearance 30-59 mL/min) compared to patients without or mild renal impairment (Lonsurf mCRC EPAR). This trend was not observed in the TAGS study.

## Overdose

An AE of accidental overdose was reported for 2 study patients in the TAS-102 arm of TAGS (0.6%).

-  One patient mistakenly received a total dose of 1900 mg during cycle 2, approximately 158% of the planned dose of 1200 mg. This event was recorded as a Grade 3 SAE of accidental overdose. The patient also experienced a treatment-related SAE of Grade 4 neutropenia on cycle 2, day 28, which led to  an  11-day  delay  in  the  initiation  of  cycle  3.  The  patient  also  experienced  non-serious treatment-related events of Grade 3 leukopenia and Grade 2 anaemia on the same day. The patient went on to receive a total of 6 cycles of treatment.
-  One patient mistakenly received a higher-than-prescribed single dose of TAS-102 during cycle 1; although the total dose administered during cycle 1 was 1100 mg as prescribed, this event was reported as a non-serious AE of accidental overdose (with no severity grade assigned).

## Discontinuation due to adverse events

## Adverse events with an outcome of treatment discontinuation

A total of 43 patients in the TAS-102 arm (12.8%) and 28 patients in the placebo arm (16.7%) experienced 1 or more AEs with an outcome of treatment discontinuation. Events with an outcome of discontinuation were most common in the MedDRA SOCs of gastrointestinal disorders (4.5% [TAS-102 arm] vs. 6.5% [placebo arm]) and general disorders and administration site conditions (2.4% vs. 6.0%). There was no particular pattern to these events; no individual preferred term had an outcome of discontinuation for 1% or more of patients in the TAS-102 arm with the exception of general physical health deterioration (1.2% in the TAS-102 arm vs. 2.4% in the placebo arm).

This is  in  line  with  what  was  observed  in  RECOURSE.  Events with an outcome of  discontinuation were reported in 10.3% in the TAS-102 group and 13.6% in the placebo group. The most frequent AE leading to discontinuation in the TAS-102 group was general physical health deterioration (2.3% vs. 1.9% in the placebo arm).

## Adverse events with outcome of treatment modification

Events with an outcome of treatment modification (i.e. treatment interruption, treatment delay, or dose reduction)  are  summarised  in  Table  42.  This  table  includes  any  AE  with  an  outcome  of  treatment interruption, treatment delay, or dose reduction (whether or not the AE caused the modification). Treatment modification due to AEs tended to occur more frequently during TAS-102 treatment (58.2%) compared to placebo treatment (22.0%) in the TAGS study. Neutropenia (25.7%) and anaemia (8.8%) were the most frequently  reported  AEs  leading  to  treatment  modification.  AEs  leading  to  treatment  modification (interruption, delay, or dose reduction) were mostly either myelosuppressive or gastrointestinal in nature, or related to underlying disease.

A total of 36 patients in the TAS-102 arm (10.7%) and 2 patients in the placebo arm (1.2%) experienced AEs with an outcome of dose reduction. The two most common events leading to dose reduction in the TAS-102 arm of TAGS were neutropenia (3.6%; n=12) and anaemia (2.1%; n=7). Events of febrile neutropenia, pancytopenia, diarrhoea, and neutrophil count decreased each had an outcome of dose reduction for a total of 3 patients (0.9%); no other individual preferred term had an outcome of dose reduction for more than 2 patients (0.6%).

<div style=\"page-break-after: always\"></div>

Table 42. Summary of events with an outcome of treatment modification, incidence ≥1% in the TAS-102 arm of TAGS and RECOURSE (AT population)

|                                                  | TAGS (mGC)      | TAGS (mGC)      | RECOURSE (mCRC)   | RECOURSE (mCRC)   |
|--------------------------------------------------|-----------------|-----------------|-------------------|-------------------|
| Preferred Term,%                                 | TAS-102 N = 335 | Placebo N = 168 | TAS-102 N = 533   | Placebo N = 265   |
| All events with outcome treatment modification a | 58.2            | 22.0            | 54.2              | 13.6              |
| Neutropenia                                      | 25.7            | 0               | 19.9              | 0                 |
| Anaemia                                          | 8.7             | 1.8             | 5.4               | 0.8               |
| Leukopenia                                       | 4.8             | 0               | 0.9               | 0                 |
| Nausea                                           | 4.5             | 2.4             | 1.9               | 0.4               |
| Fatigue                                          | 3.9             | 1.8             | 3.0               | 0.4               |
| Vomiting                                         | 3.3             | 0.6             | 1.9               | 0                 |
| Thrombocytopenia                                 | 2.4             | 0               | 0.6               | 0                 |
| Abdominal Pain                                   | 2.1             | 0.6             | 1.1               | 0.8               |
| Decreased Appetite                               | 2.1             | 1.8             | 1.7               | 1.9               |
| Diarrhoea                                        | 2.1             | 0.6             | 2.4               | 0                 |
| Asthenia                                         | 1.8             | 1.2             | 1.3               | 0.8               |
| Pancytopenia                                     | 1.5             | 0               | 0.2               | 0                 |
| Pyrexia                                          | 1.5             | 0.6             | 2.8               | 1.1               |
| Blood Bilirubin Increased                        | 1.2             | 0.6             | 0.9               | 0.4               |
| Dysphagia                                        | 1.2             | 0.6             | 0                 | 0                 |
| Gastrointestinal Haemorrhage                     | 1.2             | 0.6             | 0                 | 0                 |
| Platelet Count Decreased                         | 1.2             | 0               | 1.3               | 0                 |
| White Blood Cell Count Decreased                 | 1.2             | 0               | 1.5               | 0                 |

Abbreviations:  AT  =  as  treated;  Gr  =  Grade;  mCRC  =  metastatic  colorectal  cancer;  mGC  = metastatic gastric cancer; N = number of patients in arm; n = number of patients in group

a  Includes any AE with an outcome of treatment interruption, treatment delay, or dose reduction. Er or! Reference source not found. ( Cont'd) Table 42. Summary of events with an outcome of treatment modification, incidence ≥1% in the TAS-102 arm of TAGS and RECOURSE (AT population)

Occurrence of AEs with an outcome of treatment modification for both treatment groups tended to be higher in the TAGS study compared to the RECOURSE study. However, the difference in occurrence of AEs tended to be smaller in the TAGS study (36.0%) compared to the RECOURSE study (40.6%).

## Post-marketing experience

From post-marketing experience, myelosuppressive (anaemia, neutropenia, leukopenia, thrombocytopenia and febrile neutropenia) events, gastrointestinal events (nausea, vomiting and diarrhoea) and infections remain the primary safety concerns with Lonsurf according to post-marketing experience of Lonsurf for mCRC.

## 2.5.1. Discussion on clinical safety

As a result of the eligibility criteria for the TAGS study, all patients in the safety population had an ECOG PS of  0  or  1,  as  well  as  normal  or  mildly  abnormal  haematological  parameters.  The  to-be-treated patient population in clinical practice is expected to include more frail patients with e.g. ECOG PS of 2 and/or more

<div style=\"page-break-after: always\"></div>

impaired renal function. Currently available study data on the effects of TAS-102 do not allow a proper characterisation of the safety profile of TAS-102 in a more frail population with mGC. However, in the TAGS study, the overall incidence of TEAEs did not increase with advancing levels of renal or hepatic impairment. Moreover, in a Japanese post-marketing surveillance study with respect to TAS-102 treatment for mCRC the incidence of any grade and grade ≥3 adverse reactions in patients with a baseline ECOG PS 2 was similar to the incidence of respective adverse reactions in patients with an ECOG PS of 0 or 1. Aforementioned data allow safe use of TAS-102 in more frail patients with mGC in clinical practice.

Regarding patient exposure, the median duration of therapy was rather short but longer in the TAS-102 treatment group (median 6.7 weeks) compared to the placebo treatment group (median 5.7 weeks). The most important reason for  premature  treatment  discontinuation  was  progression  of  disease  (&gt;70%  of patients in both treatment groups). The rather short duration of therapy prevents assessment of long-term safety, but this is in accordance with the observed relatively short PFS in this disease setting. The patients in the TAS-102 arm in TAGS had a similar exposure to TAS-102 when compared to the patients in the TAS-102 arm in RECOURSE.

Most patients experienced at least one TEAE of any Grade in the TAGS study, and the majority experienced Grade ≥3 events. Severe, life-threatening, disabling or fatal AEs (i.e. Grade ≥3 AEs) and treatment-related AEs tended to be reported more frequently in the TAS-102 treatment group than in the placebo treatment group. This also applies to the occurrence of treatment-related SAEs.

The  pattern  of  TEAEs  in  general  and  treatment-related  emergent  (serious)  AEs  in  the  TAGS  study  is comparable to that observed in the previous placebo-controlled RECOURSE study on the effects of TAS-102 in mCRC. However, incidence of Grade ≥3 AEs (79.7% vs. 69.4%), SAEs (42.7% vs. 29.6%), AEs with outcome dose modification (58.2% vs. 54.2%), and AEs with outcome death (13.4% vs. 3.2%) tended to occur more frequently upon TAS-102 treatment in respectively the TAGS study compared to the RECOURSE study. Observed differences between TAS-102 and placebo for respective outcomes were not consistently larger in the TAGS study than in the RECOURSE study. This finding indicates that the higher incidence of AEs in the TAGS study as compared to the RECOURSE study is probably due to other factors than TAS-102 treatment itself. It is agreed with the applicant that the higher incidence of (serious) AEs in the TAGS study as compared to the RECOURSE study may be explained by the fact that the mGC patients tend to be frailer, sicker and have poorer prognosis than patients with mCRC.

Among the most frequently reported events (occurrence ≥10%), the largest differences between arms were observed for myelosuppressive AEs (specifically: neutropenia / neutrophil count decreased, anaemia, and leukopenia). For some gastrointestinal disorders including nausea, vomiting, and diarrhoea, and fatigue modest  differences  were  observed  between  study  arms  (with  higher  incidence  in  the  TAS-102  arm). Aforementioned AEs tended to be reported more frequently in patients treated with TAS-102 in the TAGS study compared to the RECOURSE study.

Treatment-related AEs tended to be reported more frequently in TAS-102 treated patients compared to placebo-treated study patients. Treatment-related AEs tended to occur less frequently in study patients treated with TAS-102 in the TAGS study compared to study patients treated with TAS-102 in the RECOURSE study, with the exception of leukopenia, thrombocytopenia, and lymphopenia.

Occurrence of death on treatment or within 30 days after the last treatment dose tended to be lower for TAS-102 treatment (18.4%) compared to placebo treatment (24.7%). It is difficult to determine the cause of death in patients with mGC in a poor condition due to previous treatment for this condition, comorbidities, and concomitant medication. Despite these limitations, disease progression appears to be the main cause of death in both patient groups. According to the investigators, no deaths due to AEs related to TAS-102 treatment were observed in the TAGS study.

Occurrence of AEs with outcome death was similar in study patients treated with TAS-102 (13.4%) and placebo  (11.3%).  This  is  remarkable  considering  the  more  extensive  patient  exposure  for  TAS-102 compared to placebo treatment. The most common AE with an outcome of death in both treatment groups was general physical health deterioration. There were 3 patients experiencing pulmonary embolism with an

<div style=\"page-break-after: always\"></div>

outcome of death in the TAS-102 arm vs. 0 in the placebo arm, considered not related to study treatment; and 3 different patients experienced septic shock with an outcome of death in the TAS-102 arm vs. 0 in the placebo arm. Only in 1 case of septic shock, the applicant assessed that a causal role of TAS-102 for the event  cannot  be  excluded,  whereas  the  investigator  did  not  consider  the  event  as  related  to  study medication. Though deaths due to pulmonary embolism or septic shock were (in most cases) not identified as ADRs in the TAGS study, it is noted that both AEs are listed as ADRs in the SmPC of Lonsurf. A contribution of TAS-102 to these events cannot be ruled out, but it is difficult to definitively conclude on this with the limited data available. In any case, it is indicated for both pulmonary embolism and septic shock in SmPC section 4.8 that fatal cases have been reported.

The occurrence of AEs with outcome death upon TAS-102 treatment tended to be higher in the TAGS study (13.4%) compared to the RECOURSE study (3.2%). According to the applicant, the difference in the number of  AEs  with  outcome  of  death  between  TAGS  and  RECOURSE  is  probably  due  to  the  different  patient populations and the increased morbidity of the patients in TAGS. In support of this, OS of TAS-102 treated patients with mGC in the TAGS study tends to be lower compared to TAS-102 treated patients with mCRC in the RECOURSE study (mOS 5.7 vs. 7.1 months; Lonsurf mCRC EPAR).

The incidence of SAEs was similar between the TAS-102 and placebo arms in the TAGS study (42.7 vs. 41.7%). However, treatment-related SAEs tended to be reported more often in study patients treated with TAS-102 (11.6%) compared to those treated with placebo (3.6%).

The most common SAE in both arms was general physical health deterioration, generally secondary to progression of disease. SAEs at an incidence of &gt;1% in the TAS-102 treatment group that were reported more than 1% more frequently in the TAS-102 treatment group compared to the placebo treatment group in the TAGS study were anaemia, pancytopenia, (febrile) neutropenia, neutropenic sepsis, vomiting, and diarrhoea,  i.e.  myelosuppressive  and  gastro-intestinal  AEs.  Similar  trends  for  SAEs  either  or  not treatment-related were observed in the RECOURSE study.

AEs of special interest included myelosuppressive and gastro-intestinal AEs. Overall incidence of AEs in the blood and lymphatic SOC tended to be higher in the TAS-102 arm (63.6%) than in the placebo arm (25%) in the TAGS study. Haematologic AEs / laboratory abnormalities were generally manageable when they occurred.

In the SOC infections and infestations the absolute incidence of events of this type included related events was higher in the TAS-102 arm than in the placebo arm. However, occurrence of serious and severe (Grade ≥ 3) AEs, and AEs with an outcome of treatment discontinuation in this SOC were comparable. The overall incidence of events with an outcome of death was low in both arms, and the difference between arms was &lt;1%. Reported AE rates with respect to myelosuppressive AEs tended to be lower in the TAGS study compared to the RECOURSE study. Hence, no new safety concerns with respect to infections and infestations emerged from the TAGS study.

The overall incidence of events in the SOC of gastrointestinal disorders tended to be slightly higher in the TAS-102 group than in the placebo arm of TAGS (72.8% vs. 67.3%). Occurrence of serious and severe (Grade ≥3) events was not higher in the TAS-102 arm compared to the placebo arm.

A total of 54.9% of patients in the TAS-102 arm and 45.8% of patients in the control arm reported nausea, diarrhoea, and/or vomiting. Occurrence of Grade ≥3 AEs was similar. Incidence of nausea, vomiting, or diarrhoea with an outcome of treatment discontinuation was similar between arms. Overall, increases in the occurrence of diarrhoea, nausea, and vomiting in the TAS-102 arm in comparison to placebo arm is less pronounced compared to what was observed in previous RECOURSE study. Hence, no new safety concerns with respect to gastrointestinal disorders emerged from the TAGS study.

AEs related to liver impairment were reported at similar rates upon TAS-102 and placebo treatment in the TAGS study.

Occurrence of AEs in both treatment groups varied among different levels of renal impairment. Consistent trends in the occurrence of AEs in patients with normal renal function, mild renal impairment and moderate renal impairment were however not observed for TAS-102 and placebo treatment in the TAGS study in mGC.

<div style=\"page-break-after: always\"></div>

In pooled safety data of the TAGS and RECOURSE study overall incidence of AEs upon TAS-102 treatment was similar for patients with normal renal function, mild and moderate renal impairment. However, the incidence of serious, severe treatment-emergent AEs and AEs leading to dose modification upon TAS-102 treatment tended to be higher in patients with moderate renal impairment compared to those without or mild renal impairment (defined as a difference of at least 5%). This information is reflected in section 4.4 of the SmPC.

Reported haematologic laboratory abnormalities were neutropenia, anaemia, leukopenia, lymphopenia, and thrombocytopenia. Overall, severe (4.3 - 26.8% vs. 7.4 - 8%) and potentially life-threatening (0 - 11.3% vs. 0%) haematologic laboratory abnormalities tended to occur more frequently during TAS-102 treatment compared to placebo treatment. Differences in occurrence were largest for neutropenia, leukopenia, and anaemia.

With respect to chemistry laboratory abnormalities, there were no notable differences between TAS-102 and placebo arms for most parameters. However, the incidence of Grade 3 or 4 hypokalaemia that worsened from baseline was higher in the TAS-102 arm (2.4%) than in the placebo arm (0.6%). This observation may be due to the higher incidence of gastrointestinal effects (e.g. diarrhoea, vomiting) observed with TAS-102 treatment compared to placebo treatment. For example, Grade ≥3 diarrhoea and vomiting were more frequently observed in the TAS-102 arm (2.7% and 3.6%, respectively) than the placebo arm (1.8% and 1.8%, respectively). The SmPC already includes a warning for clinical monitoring of gastrointestinal events and management as clinically indicated.

In addition, hepatobiliary abnormalities were commonly reported and were more frequently observed in the TAS-102 arm vs. the placebo arm, in particular elevations of bilirubin and alkaline phosphatase. In the TAS-102 arm 2 patients met the laboratory criteria for Hy's Law. The applicant acknowledged the absolute high incidence of hepatobiliary laboratory abnormalities reported in Lonsurf arm, in particular bilirubin and alkaline  phosphatase,  but  pointed  out  that  when  comparing  these  incidences  to  the  placebo  arm,  the difference  is  &lt;5%.  It  is  agreed  with  the  applicant  that  there  is  no  need  for  additional  precautionary statements with recommendations for monitoring of these events during treatment in the SmPC.

No clinically relevant mean or median changes in body weight or vital signs were observed in either study treatment group. Median changes from baseline at the end of each cycle were relatively stable in both treatment groups over the first several treatment cycles.

Though occurrence of AEs was higher among study patients treated with TAS-102 compared to those treated with placebo in the TAGS study, occurrence of AEs during TAS-102 treatment was overall comparable for patients of different age and race.

Patients with an ECOG PS of 0 at baseline generally had lower rates of adverse events than patients with a score of 1, with the exception of AEs of special interest in the TAS-102 group (ECOG 0: 76.4%; ECOG 1: 68.4%). The applicant additionally presented a comparative analysis (ECOG PS 1 vs. ECOG PS 0, and vs. placebo) of the frequency of overall AEs, treatment related AEs, SAEs, AEs leading to discontinuation and leading to death. This analysis did show that the absolute values of serious, severe AEs and AEs leading to death in the ECOG 1 subgroup were higher than in the ECOG 0 subgroup in the TAS-102 arm. When comparing the relative values vs. placebo of these events however, the differences appear similar or even lower in the ECOG 1 subgroup as compared to the ECOG 0 subgroup.

Occurrence of AEs during TAS-102 treatment was overall comparable for patients of different race. Also, occurrence of TEAEs in Asian patients and patients from Japan in the TAGS and RECOURSE study was similar with respect to TAS-102 treatment (Asian patients: 100% vs. 99.5%; Japanese patients: 100% vs. 99.4%) but tended to be lower during placebo treatment in the TAGS study compared to the RECOURSE study (Asian patients: 82.8 vs. 92.6%; Japanese patients: 81.5 vs. 92.0%).

Two patients (0.6%) mistakenly received a single overdose of TAS-102 in the TAGS study. No fatal AEs occurred upon respective accidental overdoses.

<div style=\"page-break-after: always\"></div>

AEs with an outcome of treatment discontinuation tended to be observed less frequently in the TAS-102 arm (12.8%) compared to the placebo arm (16.7%). Events with an outcome of discontinuation were most common in the SOCs of gastrointestinal disorders and general disorders and administration site conditions.

Treatment modification tended to occur more frequently during TAS-102 treatment (58.2%) compared to placebo treatment (22.0%) in the TAGS study. AEs leading to treatment modification (interruption, delay, or dose reduction) were mostly either myelosuppressive or gastrointestinal in nature, or related to underlying disease and were generally comparable with observations from RECOURSE, i.e. the established safety profile of TAS-102.

Observed post-marketing safety data are consistent with the current SmPC. At this time, there are no additional safety signals.

## 2.5.2. Conclusions on clinical safety

The safety profile of TAS-102 in the TAGS study in mGC is overall similar to that of TAS-102 in previous RECOURSE study in mCRC. No new safety signals emerged. TAS-102 was generally well tolerated and the identified risks are considered manageable in clinical practice. Most frequently reported TEAEs were myelosuppressive (e.g. neutropenia, anaemia, leukopenia) or gastrointestinal (e.g. nausea, decreased appetite, diarrhoea) by nature, for which close monitoring is already recommended in the SmPC.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 7.0 is acceptable.

The CHMP endorsed the Risk Management Plan version 7.0 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                  |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Bone marrow suppression Gastrointestinal symptoms (nausea, vomiting and diarrhoea) Infection Use in patients with moderate renal impairment |
| Important potential risks    | Developmental toxicity/Use in pregnant and breast-feeding women                                                                             |

<div style=\"page-break-after: always\"></div>

| Missing information   | Use in patients with severe renal impairment Use in patients with cardiac disorders Use in patients in worse condition than ECOG 0-1.   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

No changes to the list of safety concerns were made as a result of the new indication (metastatic gastric cancer).

## Pharmacovigilance plan

| Study Status                                                                                                                                                                                                      | Summary of objectives                                                                                                                                                                   | Safety concerns addressed                                     | Milestones                                                    | Due dates                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                     | Category 3 - Required additional pharmacovigilance activities                                                                                                                           | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| TO-TAS-102-107- A phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of trifluridine-tipiracil in patients with advanced solid tumours and varying degrees of renal impairment. | Compare PK profile and assess safety and tolerability of trifluridine-tipiracil in patients with advanced solid tumours (except breast cancer) and varying degrees of renal impairment. | Use in patients with severe renal impairment                  | Final report                                                  | June 2019                                                     |
| DIM-95005-001 (PROMETCO) - A Real World Evidence Prospective Cohort Study in the Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective On-going                                          | Provide real world data on treatment patterns, associated effectiveness and safety, and impact on patients with mCRC after two disease progressions.                                    | Use in patients in a worse condition than ECOG 0-1            | Final report                                                  | March 2023                                                    |

<div style=\"page-break-after: always\"></div>

The study DIM-95005-001 (PROMETCO), a non-interventional real world data study, as an additional pharmacovigilance activity (category 3 study) was added to the pharmacovigilance plan in order to further characterise the missing information 'Use in patients in worse condition than ECOG 0-1'.

## Risk minimisation measures

| Safety concern                                             | Risk minimisation measures                                                                                                                                                                                                          | Pharmacovigilance activities                                                                                                                     |
|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Bone marrow suppression                                    | Routine risk minimisation measures: SmPC sections 4.2 and 4.8 SmPC section 4.4 where advice is given on monitoring blood cells count. PL sections 2 and 4 Legal status Labelling Additional risk minimisation measures: None        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Gastrointestinal symptoms (nausea, vomiting and diarrhoea) | Routine risk minimisation measures: SmPC section 4.8 SmPC section 4.4 where advice is given on monitoring the occurrence of gastrointestinal symptoms. PL sections 2 and 4 Legal status Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Infection                                                  | Routine risk minimisation measures: SmPC sections 4.2 and 4.8 SmPC section 4.4 where advice is given on monitoring the patient's condition. PL sections 2 and 4 Legal status Additional risk minimisation                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                  | Risk minimisation measures                                                                                                 | Pharmacovigilance activities                                                                                                                                              |
|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                 | measures: None                                                                                                             |                                                                                                                                                                           |
| Use in patients with moderate renal impairment.                 | Routine risk minimisation measures: SmPC sections 4.2 , 4.4 Legal status Additional risk minimisation measures: None       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: TO-TAS-102-107 clinical study |
| Developmental toxicity/Use in pregnant and breast feeding women | Routine risk minimisation measures: SmPC section 4.6 PL section 2 Legal status Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                          |
| Use in patients with severe renal impairment                    | Routine risk minimisation measures: SmPC section 4.4 Legal status Additional risk minimisation measures:                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: TO-TAS-102-107 study          |
| Use in patients with cardiac disorders                          | Routine risk minimisation measures: None Additional risk minimisation measures: None                                       | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                          |
| Use in patients in a worse condition than ECOG 0-1              | Routine risk minimisation measures: None                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None                                                                        |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimisation measures                  | Pharmacovigilance activities                                            |
|------------------|---------------------------------------------|-------------------------------------------------------------------------|
|                  | Additional risk minimisation measures: None | Additional pharmacovigilance activities: Study DIM-95005-001 (PROMETCO) |

No changes to the risk minimisation measures were made as a result of the new indication (metastatic gastric cancer). Routine risk minimisation measures remain sufficient to manage the risks of Lonsurf.

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.7.1. User consultation

A justification for not performing a (full) user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable as the proposed changes introduced in the Package Leaflet (PL) as part of this variation application, are limited to:

- -the addition of the new indication for mGC (including adenocarcinoma of the gastroesophageal junction) in section 1. Patient friendly terms used to describe the new indication are already present in the PL of another approved product in the same indication  and;
- -the deletion or moving of some terms in the section 4.

It is agreed that the changes introduced by this variation do not substantially impact the readability of the package leaflet.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The agreed indication for Lonsurf in this procedure is: 'Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease'.

## 3.1.2. Available therapies and unmet medical need

For  advanced/metastatic GC in third- or later-line treatment, there are  neither approved nor standard therapies. Nevertheless, selected patients could be offered chemotherapy without proof of OS benefit. Then again, the ESMO guidelines note on this matter that second-line treatment options may be used sequentially in  second  and  third  line,  but  indicates  caution  that  'there  is  no  clear  evidence  for  a  benefit  beyond second-line treatment' (Smyth, 2016).

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The single pivotal study in this procedure is TAGS, a randomised, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of TAS-102 plus BSC vs. placebo plus BSC in patients with mGC refractory to standard treatments, i.e. patients who had received ≥2 prior regimens for advanced disease and were refractory to or unable to tolerate their last prior therapy. Importantly, these prior regimens were required to have included a fluoropyrimidine-, platinum-, and either a taxane- and/or irinotecan-containing regimen (plus patients with HER2+ tumours were required to have received prior anti-HER2 therapy). OS was the primary endpoint of this study, PFS was the key secondary efficacy endpoint, and ORR and DCR were among the other secondary endpoints. In total, 507 patients were randomized 2:1 to either TAS-102 (N=337) or placebo (N=170).

## 3.2. Favourable effects

On  OS,  the  effect  of  TAS-102  relative  to  placebo  resulted  in  a  HR  of  0.69  (95%  CI:  0.560,  0.855,; p=0.0003), with mOS of 5.7 months for TAS-102 versus 3.6 months for placebo, reflecting an increase in mOS of 2.1 months. The results of all sensitivity analyses were consistent with this primary analysis of OS. In the subgroup analyses the OS HRs in general favoured the TAS-102 group.

The results for all secondary (efficacy) endpoints are in line with the OS data.

For  the  key  secondary  endpoint  PFS,  a  statistically  significant  benefit  was  also  shown.  Treatment  with TAS-102 when compared to placebo resulted in a HR of 0.57 (95% CI: 0.467, 0.701; p&lt;0.0001), with mPFS of 2.0 months for TAS-102 versus 1.8 months for placebo, reflecting an increase in mPFS of 0.2 months. The results of all relevant sensitivity analyses were consistent with this primary analysis of PFS. The PFS HRs favoured the TAS-102 group across all subgroups examined.

The ORR was numerically higher for the TAS-102 arm when compared to the placebo arm (4.5% vs. 2.1%, respectively; ∆ +2.4% [95% CI: -0.9, 5.7]; p=0.2833).

A statistically significant improvement was observed in the DCR for the TAS-102 arm when compared to the placebo arm (44.1% vs. 14.5%, respectively; ∆ +29.7% [95% CI: 21.6, 37.7], p&lt;0.0001).

Treatment with TAS-102 resulted in a statistically significant reduction in the rate of deterioration to ECOG PS ≥2 compared to placebo. The median time to ECOG PS ≥2 was 4.3 months (95% CI: 3.7, 4.7) in the TAS-102 arm vs. 2.3 months (95% CI: 2.0, 2.8) in the placebo arm (HR=0.69; 95% CI: 0.562, 0.854; p=0.0005).

QoL as assessed using the EORTC QLQ-C30 and QLQ-STO22, was balanced between both treatments arms at baseline, and there were no (mean/median) changes ≥10 points in overall QoL from baseline up to cycle 3 in either treatment group. Treatment with TAS-102 resulted in a numerically longer median time to deterioration by ≥5 points in global health status using the above-mentioned QoL questionnaires compared to placebo. The median time to deterioration was 2.6 months (95% CI: 2.3, 3.3) in the TAS-102 arm vs. 2.3 months (95% CI: 1.4, NA) in the placebo arm (HR=1.27; 95% CI: 0.854, 1.875; p=0.2350).

## 3.3. Uncertainties and limitations about favourable effects

The efficacy of TAS-102 in mGC patients with an ECOG PS score &gt;1 is not known, as these patients were excluded from TAGS (which is adequately reflected in section 5.1 of the proposed amended SmPC).

The clinical relevance of the observed 0.2-month improvement in mPFS (i.e. approximately 6 days) is uncertain.

<div style=\"page-break-after: always\"></div>

The MAH was not able to confirm that the QoL questionnaires were completed at the beginning of each visit, prior to any clinical activities (i.e. before any extensive contact and consultation with study site personnel). As a result, the patient responses may have been biased, as e.g. medical information could bias retrospective evaluation. Also, there were a lot of missing data at later time-points. Therefore, no conclusions can be drawn on the basis of the QoL data submitted and these data have not been included in the SmPC.

## 3.4. Unfavourable effects

The incidence of AEs in the different AE categories for TAS-102 vs. placebo were any AE: 97.3% vs. 93.5%; any treatment-related AE: 80.9% vs. 56.6%; Grade ≥3 AEs: 79.7% vs. 57.7%; SAEs: 42.7% vs. 41.7%; treatment-related SAEs: 11.6% vs. 3.6%; discontinuation due to an AE: 12.8% vs. 16.7%; dose modification due to an AE: 58.2% vs. 22.0%; death due to an AE: 13.4% vs. 11.3%.

104 Study patients died while on study treatment or within 30 days after the last dose of study treatment. Most patients died due to disease progression (TAS-102 13.9% vs. placebo 23.5%). The proportion of patients who died due to an AE tended to be higher for TAS-102 (4.2%) than for placebo treatment (1.2%). However, according to the investigators none of the TAS-102-treated study patients died due to a treatment-related AE.

Occurrence of liver impairment-related AEs was similar for TAS-102 (7.5%) and placebo treatment (6.0%). The same applies to the occurrence of renal impairment-related AEs in these treatment groups (TAS-102: 5.4%, placebo: 6.0%).

In general, serum chemistry abnormalities occurred at similar frequencies during TAS-102 and placebo treatment. However, the incidence of Grade 3 or 4 hypokalaemia that worsened from baseline was higher in the TAS-102 arm (2.4%) than in the placebo arm (0.6%). Also, hepatobiliary abnormalities were more frequent in the TAS-102 arm, in particular bilirubin elevations of 1.5 x ULN were reported for 14.9% vs. 11.9% in the control arm, and elevations of 2 x ULN reported for 11.6% vs. 7.1% for the control arm; elevation of alkaline phosphatase of 1.5 x ULN was reported for 45.1% of the TAS-102 arm and 41.7% of the control arm. In the TAS-102 arm, 2 patients met the laboratory criteria for Hy's Law.

A total of 43 patients in the TAS-102 arm (12.8%) and 28 patients in the placebo arm (16.7%) experienced 1 or more AEs with an outcome of treatment discontinuation. Events with an outcome of discontinuation were most common in the SOCs of gastrointestinal disorders (4.5% [TAS-102 arm] vs. 6.5% [placebo arm]) and general disorders and administration site conditions (2.4% vs. 6.0%).

Treatment modification due to AEs tended to occur more frequently during TAS-102 treatment (58.2%) compared  to  placebo  treatment  (22.0%)  in  the  TAGS  study.  AEs  leading  to  treatment  modification (interruption, delay, or dose reduction) were mostly either myelosuppressive or gastrointestinal in nature, or related to underlying disease.

In conclusion, the safety profile of TAS-102 in the TAGS study in mGC is overall similar to that of TAS-102 in previous RECOURSE study in mCRC. No new safety signals emerged. TAS-102 was generally well tolerated and the identified risks (see RMP) are considered manageable in clinical practice. Most frequently reported TEAEs were myelosuppressive (e.g. neutropenia, anaemia, leukopenia) or gastrointestinal (e.g. nausea, decreased appetite, diarrhoea) by nature, for which close monitoring is already recommended in the SmPC.

## 3.5. Uncertainties and limitations about unfavourable effects

As a result of the eligibility criteria for the TAGS study, all patients in the safety population had an ECOG PS of 0 or 1, as well as normal or mildly abnormal haematological parameters and liver function tests. The

<div style=\"page-break-after: always\"></div>

to-be-treated patient population in clinical practice is expected to include more frail patients with e.g. ECOG PS of 2 and/or more impaired renal function. Currently available study data on the effects of TAS-102 therefore do not allow a proper characterization of the safety profile of TAS-102 in more frail subpopulations with mGC. However, limitations with respect to particular subpopulations are appropriately reflected in the SmPC.

Occurrence of TEAEs in Asian patients and patients from Japan in the TAGS and RECOURSE study was similar with respect to TAS-102 treatment (Asian patients: 100% vs. 99.5%; Japanese patients: 100% vs. 99.4%) but tended to be lower during placebo treatment in the TAGS study compared to the RECOURSE study (Asian patients: 82.8 vs. 92.6%; Japanese patients: 81.5 vs. 92.0%). Since differences in occurrence of AEs in the TAGS and RECOURSE study were only observed for placebo treatment but not for active TAS-102 treatment, this issue is not further pursued.

## 3.6. Effects Table

Table 43 . Effects table for Lonsurf (TAS-102) as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two systemic treatment regimens for advanced disease (data cut-off for OS data: 27-Mar-2018; for all other [non-OS] clinical data: 31-Mar-2018)

| Effect                                   | Short description                                                        | Unit   | TAS-102   | Placebo   | Uncertainties / Strength of evidence                        | References                                                           |
|------------------------------------------|--------------------------------------------------------------------------|--------|-----------|-----------|-------------------------------------------------------------|----------------------------------------------------------------------|
| Favourable effects                       | Favourable effects                                                       |        |           |           |                                                             |                                                                      |
| OS                                       | Median time from date of randomization to date of death due to any cause | Months | 5.7       | 3.6       | HR=0.69 (95% CI: 0.560, 0.855) p=0.0003 Clinically relevant | Section 2.4.2. Main study and 2.4.3. Discussion on clinical efficacy |
| Unfavourable effects                     | Unfavourable effects                                                     |        |           |           |                                                             |                                                                      |
| Grade  3 TEAEs                          | Patients with  1 treatment-emerge nt adverse event Grade  3            | %      | 79.7      | 57.7      |                                                             |                                                                      |
| Treatment-r elated SAEs                  | Patients with  1 treatment-related serious adverse event                | %      | 11.6      | 3.6       |                                                             |                                                                      |
| Anaemia                                  | Grade  3                                                                | %      | 18.8      | 7.7       |                                                             |                                                                      |
| Neutropenia + neutrophil count decreased | Grade  3                                                                | %      | 34.6      | 0         |                                                             |                                                                      |
| Nausea                                   | Grade  3                                                                | %      | 3.0       | 3.0       |                                                             |                                                                      |
| Decreased appetite                       | Grade  3                                                                | %      | 8.7       | 6.5       |                                                             |                                                                      |
| Diarrhoea                                | Grade  3                                                                | %      | 2.7       | 1.8       |                                                             |                                                                      |

Abbreviations; AEs = adverse events; CI = confidence interval; DCR = disease control rate; ECOG PS = Eastern cooperative oncology group performance score; EORTC = European organisation for research and treatment of cancer ; HR = ; ORR = OS = overall survival; PFS = progression-free survival; QLQ-C30 = QoL questionnaire - core 30; QLQ-STO22 = QoL questionnaire - gastric cancer-specific module; QoL = quality of life; SAEs = serious adverse events; TEAEs = treatment-emergent adverse events

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The prognosis of patients with mGC overall is poor, but even more so in the third- and later-line treatment setting, as shown by the ≤6-month mOS observed in several recent studies. In this disease setting, there are neither approved nor standard therapies and thus new treatment options are necessary.

The OS benefit observed for TAS-102 of 2.1 months in TAGS was statistically significant and clinically relevant. Moreover, the OS result was robust and supported by the key secondary efficacy endpoint PFS and most other secondary efficacy endpoints (e.g. DCR). Therefore, in spite of this being an application based on a single pivotal study, the efficacy results are considered quite convincing.

There were no unexpected findings in the assessment of TEAEs in the safety population, with the known myelosuppressive AEs (e.g. neutropenia, leukopenia, anaemia, and thrombocytopenia) and gastro-intestinal AEs (e.g. diarrhoea, nausea, vomiting), and fatigue. TAS-102 was generally well tolerated and the identified risks (see RMP) are considered manageable in clinical practice. When compared with the known safety profile of TAS-102 for the mCRC patient population, no new safety signals were identified.

Only study patients with a relatively good ECOG PS and normal or only mildly abnormal haematological and chemistry parameters were included in the TAGS study. Currently available study data on the effects of TAS-102 therefore do not allow a proper characterisation of the safety profile of TAS-102 in more frail subpopulations with mGC. However, limitations with respect to particular subpopulations are adequately reflected in the SmPC.

## 3.7.2. Balance of benefits and risks

Treatment with TAS-102 resulted in a clear OS benefit in a disease setting with a very poor prognosis, and wherein there are neither approved nor standard therapies.

The overall safety profile  of  TAS-102  in  patients  with  mGC  appears  to  be  similar  to  that  observed  for TAS-102 in patients with mCRC, and is considered acceptable in this disease setting.

The benefit-risk balance is therefore considered positive in the target population as represented by the above mentioned indication.

## 3.7.3. Additional considerations on the benefit-risk balance

The final proposed indication is:

Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease (see section 5.1) or are not considered candidates for, available therapies including fluoropyrimidine-, platinum-, and either a taxaneor irinotecan-based chemotherapy.

For brevity reasons the previous regimen followed by patients have been reflected in a more general way making then clear specification on them in section 5.1

## 3.8. Conclusions

The B/R of Lonsurf (trifluridine/tipiracil) is positive.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include the treatment, as monotherapy, of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two systemic treatment regimens for advanced disease for Lonsurf; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 7.0 has also been submitted and updated in accordance with Template Rev 2. For clarification, the term monotherapy has also been added to the existing indication in metastatic colorectal cancer.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include the treatment, as monotherapy, of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two systemic treatment regimens for advanced disease for Lonsurf; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 7.0 has also been submitted and updated in accordance with Template Rev 2. For clarification, the term monotherapy has also been added to the existing indication in metastatic colorectal cancer.

## Summary

Please refer to the published Assessment Report Lonsurf H-3897-II-0012.

## Attachments

1. Product information  (changes highlighted) of Lonsurf as adopted by the CHMP on 25 Juy 2019.

## Appendix

1. CHMP AR on additional 1 year of marketing exclusivity

<div style=\"page-break-after: always\"></div>

## Reminders to the MAH

1. In accordance with Article 13(3) of Regulation (EC) No 726/2004 the Agency makes available a European Public Assessment Report (EPAR) on the medicinal product assessed by the Committee for Medicinal Products for Human Use. The EPAR is first published after the granting of the initial marketing authorisation (MA) and is continuously updated during the lifecycle of the medicinal product. In particular, following a major change to the MA, the Agency further publishes the assessment report of the CHMP and the reasons for its opinion in favour of granting the change to the authorisation, after deletion of any information of a commercially confidential nature.

Should you consider that the CHMP assessment report contains commercially confidential information, please provide the EMA Procedure Assistant your proposal for deletion of commercially confidential information (CCI) in 'track changes' and with detailed justification within 15 days of receipt of the opinion documents. The principles to be applied for the deletion of CCI are published on the EMA website at https://www.ema.europa.eu/documents/regulatory-procedural-guideline/principles-be-applied-deleti on-commercially-confidential-information-disclosure-emea-documents\\_en.pdf.

2. The MAH is reminded that, within 30 calendar days of the receipt of the Opinion, an updated version of Annex I of the RMP template, reflecting the final RMP agreed at the time of the Opinion should be submitted to h-eurmp-evinterface@emea.europa.eu.
3. If the approved RMP is using Rev. 2 of the 'Guidance on the format of the RMP in the EU' and the RMP 'Part VI: Summary of the risk management plan' has been updated in the procedure, the MAH is reminded to provide to the EMA Procedure Assistant by Eudralink a PDF version of the 'Part VI: Summary of the risk management plan' as a standalone document, within 14 calendar days of the receipt of the CHMP Opinion. The PDF should contain only text and tables and be free of metadata, headers and footers.
4. The MAH is reminded to submit an eCTD closing sequence with the final documents provided by Eudralink during the procedure (including final PI translations, if applicable) within 15 days after the Commission Decision, or prior to the next regulatory activity, whichever is first.